Clinical validation of near-patient assessment of fluid status in dialysis patients by Tan, Boon Kay
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is protected by copyright and other intellectual property rights and 
duplication or sale of all or part is not permitted, except that material may be 
duplicated by you for research, private study, criticism/review or educational 
purposes. Electronic or print copies are for your own personal, non-
commercial use and shall not be passed to any other individual. No quotation 
may be published without proper acknowledgement. For any other use, or to 
quote extensively from the work, permission must be obtained from the 
copyright holder/s. 
 
  
 
Clinical validation of near-patient assessment of 
fluid status in dialysis patients 
 
Boon Kay Tan 
 
8 March 2017 
 
A thesis submitted in accordance with the 
requirements of the University of Keele for the 
degree of Doctor of Philosophy 
 
 
 I 
Abstract 
Dialysis patients have an extraordinarily high level of cardiovascular morbidity and 
mortality. Volume expansion is common among this cohort and this is linked to markers of 
cardiac dysfunction, inflammation and low plasma albumin, all of which predict worse 
survival. Fluid status deteriorates over time due to loss of residual renal function (RRF) 
and progressive muscle wasting and currently there is a lack of effective or validated 
clinical tools to detect such changes that can inform clinical decision making given that 
gold standard methods are not practical for routine use.  
 
This thesis first evaluates the role of albumin and fluid status of peritoneal dialysis (PD) 
patients and demonstrates that hypoalbuminaemia is an important determinant of tissue 
overhydration that is largely extravascular given the normal plasma volume. Attempts to 
‘dry out’ such patients may precipitate hypovolaemic episodes and loss of RRF. The 
cardiac sub-analysis suggests that cardiac dysfunction, in particular heart failure with 
normal ejection fraction (HFNEF) is prevalent and associated with higher intravascular 
volume.  
 
Next the potential of bioimpedance analysis (BIA) in the form of vector plots to detect the 
changing body composition in order to improve fluid management was investigated in a 
multi-centre randomised controlled trial. The clinical impact of this tool was small given 
the overall stability of fluid status in non-anuric PD patients but deterioration in anuric 
subject could be ameliorated; in the secondary cardiac analysis, patients in the intervention 
group seems to experience less damaged hearts. This study underlined the value of RRF in 
maintaining normal body composition and cardiac function. Lastly, the feasibility of 
 II 
measuring lung water volume using breath analysis of deuterium concentration by flowing 
afterglow mass spectrometer (FA-MS) following mouth inhalation and intravenous 
injection of deuterium was explored. The study data vastly overestimated the predicted 
volume and alternative approaches are needed in the future. (300 words) 
.  
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 Chapter 1 Introduction  
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1 Chapter 1 Introduction 
 
1.1 End stage renal disease (ESRD): A significant health burden 
1.1.1 The prevalence of ESRD 
The kidneys perform many vital functions to maintain a constant optimal internal 
homeostasis in order to sustain life, one of which is the salt and water regulation. This is 
achieved by highly selective and tightly regulated filtration, reabsorption and elimination 
of water, electrolytes and solutes. Approximately 180 litres of plasma are filtered through 
the glomeruli everyday resulting in the production of around 1.5 litres of urine per day, 
indicating the highly efficient tubular reabsorption capacity. Other functions include 
maintenance of acid base balance, the production of erythropoietin essential for 
erythropoiesis, renin angiotensin system in blood pressure regulation and the metabolism 
of calcium, phosphate and vitamin D (Kerr, Bray et al. 2012).  
 
Disruption of these important functions becomes evident as the glomerular filtration rate 
(GFR) falls below around 30ml/min/1.73m2. End stage renal disease (ESRD) or chronic 
kidney disease stage 5 (CKD 5) is defined by the estimated GFR of below 
15ml/min/1.73m2 by the current UK guidelines (NICE 2014). It is characterised by the 
varying degree of abnormal fluid status, grossly deranged metabolic state with toxin 
accumulation, metabolic acidosis, renal osteodystrophy, inflammation, anaemia and 
malnutrition.   
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Such undesirable physiological disturbance can be partially ameliorated by the 
commencement of renal replacement therapy (RRT), which consists of haemodialysis 
(HD), peritoneal dialysis (PD) and renal transplantation. According to the 2014 UK Renal 
Registry 17th report, 7,006 patients commenced on RRT in 2013, reflecting the incidence 
rate of 109 per million population (pmp). There were 56,940 adults patients receiving RRT 
in the UK and the prevalence rate of RRT has increased from 523 pmp in 2000 to 888 pmp 
over the past 14 years. Transplantation is the most common treatment modality (52%) 
while HD was the more popular dialysis treatment (41.6%) compared to PD (6.4%) but the 
distribution varies greatly with age with younger patients tend to have a functioning kidney 
transplant while the older population treated with dialysis in particular HD (Figure 1.1 and 
Figure 1.2)  
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Figure 1.1 Treatment modality in prevalent RRT patients in 2013 (UK Renal 
Registry report 2014) 
 
Figure 1.2 Treatment modality distribution by age in prevalent RRT population in 
2013 (UK Renal Registry report 2014) 
 
Although kidney transplantation confers better survival benefit and is considered preferred 
choice of RRT, the scarcity of donor kidneys and its prolonged waiting time coupled with 
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general frailty and multiple morbidities in the elderly CKD have compromised their 
eligibility. As the elderly is more susceptible to CKD, the incidence rate of CKD in this 
particular age group is forecasted to have the greatest increment given the overall increased 
survival of the general population (Figure 1.3). 
 
 
 
Figure 1.3 Adjusted odds ratios of eGFR<60 ml/min/1.73m2 in National Health 
and Nutrition Examination Survey (NHANES) participants by age, 1998-2012 
 
1.1.2 The health and financial cost of ESRD 
Despite the declining trend in the overall mortality rate in RRT population over the past ten 
years in particular the 65 years and over, the survival is markedly reduced compared to the 
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general population without ESRD with the estimated 5 year survival rate of around 50% 
(Figure 1.4). The reason for such high mortality rate is multifactorial and likely to be 
attributed to patient factors (advancing age, frailty, increasing cardiovascular morbidity) 
and dialysis technique (cardiac stunning in HD).  Cardiovascular disease was by far the 
commonest cause of death in the prevalent dialysis population that accounted for 27% of 
all reported deaths (Table 1.1) (Registry 2014). It was estimated that 7000 excess cerebral 
vascular disease events and 12,000 excess myocardial infarctions occurred in the CKD 
population, compared to the age and gender matched population without CKD at a cost of 
£174 to £178 millions to the NHS (Kerr, Bray et al. 2012). With the average annual cost of 
£23,287 per patient on RRT, this represented half of the £1.45 billions NHS spending on 
CKD care in 2009 to 2010, despite RRT only accounting for 2% of all CKD care 
(Baboolal, McEwan et al. 2008).  
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Figure 1.4 Death rate per 1,000 patient years in incident patients from 2003 to 
2012 (UK renal registry report 2014) 
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Table 1.1 Cause of death in RRT patients by modality in 2012 cohort 
 All modalities Dialysis Transplant 
Cause of death N % N % N % 
Cardiac disease 734 23 647 24 87 17 
Cerebrovascular 
disease 
136 4 111 4 25 5 
Infection 664 21 531 20 133 26 
Malignancy 311 10 186 7 125 24 
Treatment 
withdrawal 
525 16 517 19 8 2 
Other 660 21 543 20 117 23 
Uncertain 186 6 161 6 25 5 
Total 3,216  2,696  520  
No cause of 
death data 
1,353 30 1,130 30 223 30 
 
1.1.3 Dialysis principles and modalities 
The Scottish chemist Thomas Graham first described the concept of dialysis in 1854 and 
this would form the basis of treatment for kidney failure. The main principle of dialysis is 
through the process of diffusion where different solutes are removed down a concentration 
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gradient across a semi-permeable membrane. They are two main types of modalities: 
haemodialysis (HD) and peritoneal dialysis (PD). 
  
1.1.3.1 Haemodialysis 
The first HD treatment of a uraemic patient was performed in 1924 by Haas in Germany 
using a filtering device made of collodion tubes. Hirudin was initially used to prevent 
clotting but it was unpredictable and subsequently replaced by heparin. There was 
progressive improvement in the design of dialyser and equipment throughout the 1940 and 
1950 including the production of synthetic hollow fibre dialysers that greatly improved the 
efficiency of dialysis. In 1960 Quinton and Scribner invented an arterio-venous shunt made 
of silastic tubes with Teflon tips allowing continuous blood circulation during treatment. 
This was closely followed by the formation of native arterio-venous fistula first described 
by Cimino and Brecia, which remains to this day the safest and longest lasting vascular 
access.  
 
Significant and continued improvements have been made in the subsequent decades in 
areas such as membrane biocompatibility, dialyser design, isothermal dialysis, safety 
measures and high flux membrane. Patients were previously vulnerable to unpleasant 
symptoms such as hypotension and headache following the exposure to the non-
physiological acetate used as buffer. This issue is largely resolved with bicarbonate-based 
dialysis with dry bicarbonate concentrates. Further modification to the dialysis technique 
using convective process to increase solute clearance with high UF volume followed with 
fluid re-infusion called haemodiafiltration (HDF) and this is gaining popularity with the 
potential to offer greater haemodynamic stability during dialysis.  
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Despite the advancement of haemodialysis techniques over the recent decades, HD patients 
are still disadvantaged by very high rate of cardiovascular morbidity and mortality (Foley, 
Parfrey et al. 1998). Interventions to address conventional cardiac risk factors in this 
particular cohort have not produced the desirable results. This is perhaps not too surprising 
given atherosclerotic heart disease is not a predominant feature in HD patients. Alternative 
risk factors related to uraemia and dialysis technique have to be considered here. The 
pathogenesis of uraemic cardiomyopathy is complex involving structural remodelling at 
the macroscopic and cellular level culminating in measurable ventricular 
dysfunction (Gross and Ritz 2008). HD patients suffer from significant sudden cardiac 
death due to abnormal ventricle with arrhythmogenic potential. Apart from left ventricular 
systolic dysfunction, it is becoming more recognised that diastolic dysfunction occurs early 
in HD vintage (Silberberg, Barre et al. 1989, Levin, Singer et al. 1996). A combination of 
LVH and myocardial fibrosis results in reduced ventricular compliance and filling, giving 
rise to an increase in pulmonary pressure, predisposing patients to the development of 
pulmonary oedema.  
 
There is a developing body of evidence that HD induces myocardial ischaemia and that 
this is determined by the amount and rate of UF and its associated haemodynamic 
instability during dialysis treatment (Zuber, Steinmann et al. 1989). The nature of 
conventional short intermittent thrice-weekly HD demands relatively high UF rate in a 
short space of time. This predisposes to intradialytic hypotension (IDH) when the UF rate 
exceeds the plasma refilling rate. This could be observed in 20 to 30% of HD patients and 
it predicts mortality (Bos, Bruin et al. 2000, Shoji, Tsubakihara et al. 2004). Myocardial 
stunning describes the phenomenon of acute reversible segmental myocardial 
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hypoperfusion causing regional systolic contractile dysfunction. Such repetitive ischaemic 
injury can lead to permanent systolic dysfunction (Selby and McIntyre 2007, McIntyre 
2009). This can be studied using conventional intra-dialytic echocardiography to look for 
left ventricle regional wall motion abnormality (RWMA) which resolves upon termination 
of HD. Studies by Burton et al showed that up to 60% of HD patients developed 
myocardial stunning during dialysis treatment and it was independent predicted by IDH 
and UF volume in the multivariate analysis (Burton, Jefferies et al. 2009). In this 12 month 
follow up study, the 'non-stunners' were found to have only one significant cardiac event 
and 100% survival with no segmental shortening or reduction in LVEF. This was in stark 
contrast to 28% of the 'stunners' who died during the same period with the development of 
regional fixed systolic dysfunction and a significant 10% reduction in LVEF (Burton, 
Jefferies et al. 2009).  
  
Apart from myocardial stunning, there are other cardiac parameters to support the concept 
of HD induced myocardial ischaemia. Studies suggest the rate of asymptomatic or silent 
ST depression on electrocardiogram (ECG) during HD is between 15 and 40% (Abe, 
Yoshizawa et al. 1996, Conlon, Krucoff et al. 1998). Singh et al used sestamibi single 
photon emission computed tomography (SPECT) as an alternative technique to evaluate 
coronary perfusion defects in ten HD patients without coronary artery stenosis. Seven 
patients were found to have perfusion defect but only three patients showed concurrent ST 
depression, indicating ST abnormality could have underestimated cardiac ischaemia 
(Singh, Langer et al. 1994).  
In conclusion, HD treatment has undergone significant advancement and refinement over 
the years. This has enabled the achievement of desired solute clearance and ultrafiltration 
volume with relative ease. However, the detrimental effect of HD induced myocardial 
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ischaemia as a result of excess UF and IDH deserves careful consideration in order to limit 
long term irreversible cardiac damage and death. 
 
1.1.3.2 Peritoneal Dialysis 
In the early 1740s Christopher Warrick, an English surgeon presented his finding at the 
Royal Society meeting regarding the treatment of a 50 year old woman with ascites by 
instilling Bristol water and claret wine. This could be the first documented treatment 
involving the peritoneal membrane. This was followed by the first scientific description of 
the peritoneal cellular composition by Friedrich Daniel Von Recklinghaussen. In 1877 the 
German G. Wegner discovered the basis of peritoneal ultrafiltration in the peritoneal cavity 
following the introduction of glucose containing solution. 45 years later, Putnam described 
the osmotic equilibrium between plasma and peritoneal fluid was driven by the 
concentration gradient across a semipermeable membrane through the process of diffusion. 
 
George Ganter from Germany was critical of the extensive operation required by 
extracorporeal haemodialysis and he suggested that the peritoneal membrane could be 
exploited for the removal of uraemic toxins. Following some animal experiments he 
treated the first uraemic patient with PD in 1923 (Teschner, Heidland et al. 2004). Rhoads 
subsequently used lactate to correct acidosis and this became the standard buffer for PD.  
 
By 1950, PD was used to treat over 100 patients (Odel, Ferris et al. 1950) but early 
technique was hindered by high rate of infective complication and the need to replace 
catheter frequently. Arthur Grollman and Morton Maxwell advocated a system where fluid 
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was instilled and let dwelt for a period of time before being drained out. The process can 
be repeated and this forms the intermittent basis of PD we observe today. With the 
development of the Tenckhoff catheter, a flexible silicone catheter with Dacron cuffs 
which could be inserted percutaneously, the introduction of the light titanium connector 
that reduced peritonitis rate and the availability of commercially produced closed system 
for easy drainage, the PD technique experienced a tremendous growth in its utilisation in 
the late 1970s and formed an integral part of home therapies. 
 
It is estimated around 250,000 patients globally are currently on PD therapy, making it the 
commonest form of home dialysis (Jain, Blake et al. 2012). The technique’s inherent 
simplicity enables patient self care for chronic disease management and promotes patient 
autonomy and control. Over the past two decades the survival of PD patients has steadily 
improved both in absolute term and in comparison with haemodialysis patients (Davies 
2013). Most analyses have demonstrated equivalent medium term survival rate between 
three to five years between patients treated with PD and HD but early survival benefit is 
most apparent in patients with least comorbidity (Voges, Faict et al. 2004, Vonesh, Snyder 
et al. 2004, Kramer, Stel et al. 2009, Mehrotra, Chiu et al. 2009, Mehrotra, Chiu et al. 
2011, van de Luijtgaarden, Noordzij et al. 2011, Yeates, Zhu et al. 2012).  
 
Despite the wide application of PD as a viable dialysis modality there are still a number of 
limitations both the clinicians and patients face. Glucose of varying concentrations has 
been used as an effective osmotic agent in the peritoneal dialysate to facilitate 
ultrafiltration since the beginning and it is still the case today. However the negative 
impacts of prolonged exposure of hypertonic glucose solution which also contains glucose 
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degradation products (GDP) on peritoneal membrane function has been well described, 
including the finding of advanced glycosylation end products (AGE) within the peritoneal 
membrane (Honda, Nitta et al. 1999) and the diabetiform and sclerotic changes in the 
peritoneal membrane (Hendriks, Ho-dac-Pannekeet et al. 1997, Krediet, Zweers et al. 
1999). Such morphological changes play a significant role in the alteration of membrane 
function characterised by rapid rate of peritoneal solute transport which results in the rapid 
absorption of glucose with the loss of osmotic gradient and fluid reabsorption. Early 
exposure to hypertonic glucose solution has been showed to be associated with increase in 
solute transport status while the use of low glucose strength (1.36%) is associated with 
stable membrane function over 5 years (Davies, Phillips et al. 2001). 
 
There has been considerable work to develop a more biocompatible solution to address this 
issue and the introduction of Icodextrin (Extraneal®) in the 1980s represents a major 
improvement. Icodextrin consists of large molecular weight glucose polymer derived from 
starch that provides a more sustained osmotic gradient and ultrafiltration in the long dwell 
without the negative effect of glucose absorption. It is particular suited for patients with 
rapid peritoneal solute transport with reduced residual renal function and it has been 
showed to preserve peritoneal ultrafiltration and to improve fluid status with the reduction 
in ECW (Davies, Woodrow et al. 2003). However it is only licensed for once a day 
exchange and patients are still subjected to some degree of glucose exposure. Apart from 
the benefit of membrane preservation, it has been hypothesised that biocompatible solution 
may confer similar benefit in the maintenance of residual renal function (RRF). Anuric 
patients, both in HD and PD, tend to have more adverse cardiovascular, metabolic and 
volume status and more importantly the loss of RRF has been shown to be a power 
predictor of survival in two large randomised controlled trials (Bargman, Thorpe et al. 
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2001, Paniagua, Amato et al. 2002). Previous evidence did support the delayed onset of 
anuria with the use of neutral pH; lactate-buffered and low GDP solution compared with 
conventional solution but the decline in RRF did not reach statistical significance 
(Johnson, Brown et al. 2012). However, a more recent meta-analysis supports the idea of 
general use of biocompatible PD solution leading to greater urine output and higher RRF. 
Other clinical relevant benefits include better peritoneal ultrafiltration and avoid 
uncontrolled fluid overload (Cho, Johnson et al. 2014). 
   
Peritoneal infection, together with ultrafiltration failure, remains an important cause of 
technique failure. Despite improvements in connection technology, peritonitis continues to 
be a major source of morbidity and mortality in PD patients with up to 18% of PD catheter 
removed and less than 4% resulted in death (Mujais 2006). While majority of peritonitis 
response well to antimicrobial treatment, patients are at risk of medium and long term 
sequelae including loss of RRF, peritoneal membrane injury with increase in solute 
transport and reduced ultrafiltration and the risk of developing encapsulating peritoneal 
sclerosis (Davies, Bryan et al. 1996). There is considerable variation in the incidence, 
practice and outcome in different PD centres and more studies are needed to understand 
this better. The likely strategy to reduce PD catheter associated infections probably lies in 
the adoption of best practice and evidence based approach such as regular patient 
education on exit site care, the use of prophylactic antibiotic during catheter insertion and 
the decontamination of nasal Staphylococcus Aureus with Mupirocin. 
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1.2 Cardiovascular disease in dialysis patients 
Patients with ESRD treated with dialysis have disproportionately high morbidity and 
mortality rate and the leading cause of death is cardiovascular disease as previous alluded 
to (de Jager, Grootendorst et al. 2009, Collins, Foley et al. 2012, Registry 2014). The 
extent of the problem was best illustrated in a large epidemiological study comparing the 
cardiovascular mortality in dialysis patient and the general population across all age groups 
(Foley, Parfrey et al. 1998) (Figure 1.5) illustrated the overall major increase in death rate 
but the most dramatic relative increase was seen in the youngest population, hence patients 
who started dialysis in their 20s would have similar death rate as the over 80s without 
kidney failure.  
 
Figure 1.5 Cardiovascular death rate in the general population compared with 
patients on dialysis; USRDS data (Foley, Parfrey et al. 1998).  
 
Dialysis patients share many ‘traditional’ cardiovascular risk factors with the general 
population such as diabetes mellitus, hypertension, dyslipidaemia, smoking etc. While 
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interventions to these risk factors have produced positive outcomes in the general 
population, this is not observed in the dialysis cohort. The recent SHARP (Study of Heart 
and Renal Protection) trial was a randomised double-blind multinational study to assess the 
effect of lowering LDL cholesterol with Simvastatin plus Ezetimibe in more than 9000 
CKD patients of which over 3000 received dialysis therapy. Despite the reduction of LDL 
cholesterol and a significant 17% reduction in major atherosclerotic events, there was no 
impact on coronary or vascular mortality (Baigent, Landray et al. 2011).  
 
1.2.1 Uraemic toxin 
The cardiovascular death rate in dialysis population is therefore complex and multifactorial 
in nature and cannot be attributed entirely to the conventional cardiovascular risk factors. 
Hence the patients must be subjected to detrimental effects unique to uraemia and dialysis 
therapy in order to account for this increase in cardiovascular burden above and beyond 
than what is present in non-CKD patients. Uraemic compounds are toxic when they are 
biologically active but despite the identification of various toxins the mechanism as to how 
they contribute to the pathogenesis of cardiovascular disease is not well understood. More 
than 90 compounds have been compiled by the European uraemic toxin work group 
(EUTox) in 2003 based on their physicochemical characteristics that affect their removal 
by dialysis therapies (Vanholder, De Smet et al. 2003). 
• Small molecules: They represent the majority of identified retained uraemic 
solutes. With molecular weight (MW) of ≤500 Da they are readily removed by 
dialysis and generally exhibit limited toxicity.  
• Middle molecules: Characterised by MW of >500Da. They have very low 
concentrations in uraemic patients but are toxic to multiple organs. 
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• Protein-bound molecules: Similar toxicity to middle molecules except smaller 
compounds with low MW.  
 
Both middle and protein-bound molecules are not effectively removed by standard 
haemodialysis with small pores, low flux membranes compared with the water soluble 
small molecules (Locatelli, Mastrangelo et al. 1996). Peritoneal dialysis, on the other hand, 
offers better removal of the toxic compounds in part through the combination of semi-
porous peritoneal membrane and the better preservation of residual renal function (Dhondt, 
Vanholder et al. 2000, Lameire, Vanholder et al. 2001). This may possibly explain the 
early survival benefit of PD over HD. There are evidence to support the pathogenic role of 
uraemic toxins in increasing the risk of cardiac morbidity and mortality in dialysis 
population, primarily in the acceleration of atherosclerosis and vascular calcification but so 
far effective therapeutic intervention remains elusive (Barreto, Barreto et al. 2009, Liabeuf, 
Barreto et al. 2010, Wang, Lu et al. 2010). 
 
1.2.2 Inflammation and hypoalbuminaemia  
Kidney failure is a pro-inflammatory state and chronic inflammation has been associated 
with increased cardiac death in dialysis population. An observational study in 91 HD 
patients showed that patients with the highest serum albumin had the best survival whereas 
the lowest survivors had the greatest CRP level (Yeun, Levine et al. 2000). Elevated 
plasma CRP level was found in 58% of PD patients in a single centre study and it was a 
powerful predictor of myocardial infarction during the 3 year follow up period (Herzig, 
Purdie et al. 2001). Compared with patients with normal level of CRP, raised level was 
associated with hypoalbuminaemia, reduced total weekly creatinine clearance and 
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increased left ventricular wall thickness. The predictive power of all cause mortality of 
raised CRP and hypoalbuminaemia was also established in CKD stage 3 and 4 prior to the 
initiation of dialysis treatment. The relationship between hypoalbuminaemia, inflammation 
and malnutrition is complex and may play a significant role in the acceleration of 
atherosclerosis, thus in part explaining the high cardiovascular death in this population. 
  
1.2.3 Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) appears early in CKD 3 and 4 and could be found in 
60 to 80% of patients by the time of RRT commencement (Parfrey, Foley et al. 1996, 
Stack and Saran 2002). It is associated with patient’s survival with multiple causative 
factors sharing a complex interaction. Pressure overload from hypertension and vascular 
calcification is a common finding in ESRD and predisposes the development of LVH. 
Renin-angiotensin-aldosterone system overactivity coupled with salt and fluid overload 
plays an important role in the pathogenesis of LVH (Yamakawa, Imamura et al. 2000). 
Abnormal metabolic profile with hyperparathyroidism (Fujii, Kim et al. 2007) and anaemia 
(Parfrey, Lauve et al. 2009) has been implicated as well. The myocardial changes in LVH 
are characterised by the increase in size of the myocardial cells, accumulation of interstitial 
collagen and fibrosis and the reduction of myocardial capillaries (Amann, Breitbach et al. 
1998). Such pathological mismatch of hypertrophied myocyte and reduced capillary 
perfusion increased the risk of cell necrosis and this greatly enhanced the propagation of 
fatal cardiac arrhythmias (McLenachan, Henderson et al. 1987). This may partly explain 
up to 25% of all cardiac mortality is due to sudden cardiac death. LVH reduces left 
ventricle compliance that predisposes the development of pulmonary oedema when left 
ventricle filling pressure and left atrial pressure increase more readily in hypervolaemic 
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state. It also increases the risk of intradialytic hypotension in HD that has been identified as 
a strong predictor of cardiac death (Shoji, Tsubakihara et al. 2004).   
 
1.2.4 Relationship between cardiovascular disease and abnormal fluid 
status in dialysis patients 
Cardiovascular mortality in ESRD is strongly related to the presence of hypertension and 
LVH. There is cumulative evidence to implicate fluid overload as a significant driver of 
hypertension and LVH that accelerates cardiovascular disease that leads to reduced 
survival (London, Pannier et al. 2001, Zoccali, Benedetto et al. 2001). Overhydration as 
determined by multi-frequency BIA is an important independent predictor of mortality in 
maintenance HD patients (Wizemann, Wabel et al. 2009). The reduction of BP can be 
achieved with strict volume control without resorting to antihypertensive medication and 
this has led to the regression of LVH and improvement of arterial stiffness with possible 
survival benefit in HD patients  (Onofriescu, Hogas et al. 2014).  
 
Hypertension is extremely common in ESRD, affecting up to 80% of prevalent PD 
population with associated poor outcome (Cocchi, Degli Esposti et al. 1999, Koc, Toprak 
et al. 2002). However epidemiological study paints a complex picture regarding the 
relationship between hypertension and mortality with greater survival benefit in early stage 
of dialysis therapy and higher mortality in the longer term (Udayaraj, Steenkamp et al. 
2009). Systolic BP of less than 110 mmHg was associated with reduced survival in 
prevalent PD cohort in an observational study and patients were more likely to have a 
history of heart failure, diabetes mellitus or receiving antihypertensive medication 
(Goldfarb-Rumyantzev, Baird et al. 2005). The pathophysiology of hypertension in ESRD 
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is complex involving the dysregulation of salt and water handling and overhydration is 
increasingly established as a major driver for hypertension in PD patients (Wang, Axelsson 
et al. 2005). There were initial concerns that fluid balance in PD patients may be less well 
preserved compared to other treatment modalities. ECW of 37% of PD patients was found 
to be above the 90th percentile compared to those with stable renal transplantation 
(Konings, Kooman et al. 2002) and markers of volume expansion such as high plasma 
atrial natriuretic peptides (ANP), increased left atrial volume and severe LVF were more 
common in PD than HD patients (Enia, Mallamaci et al. 2001). More circumstantial 
evidence to support overhydration in PD was the disproportionate use of antihypertensive 
medications (Velasquez, Lew et al. 1997, Cocchi, Degli Esposti et al. 1999, Enia, 
Mallamaci et al. 2001). However, careful examination of the data in the first direct 
comparison, using the bioimpedance analysis (BIA) derived ECW:TBW ratio, suggested 
that the fluid status of PD patients was similar to HD patients predialysis (Plum, 
Schoenicke et al. 2001). Interestingly the plasma ANP levels in PD patients were the same 
as HD patients postdialysis, despite their improved ECW/TBW ratio, which may suggest 
that compartmentalization of excess fluid may differ by treatment modality. With the 
introduction of icodextrin and the more widespread use of automated peritoneal dialysis 
(APD), especially in patients with rapid transport membrane characteristics, subsequent 
studies have consistently found that fluid status is not so different by treatment modality 
(Boudville, Cordy et al. 2007, Devolder, Verleysen et al. 2010, Paniagua, Ventura et al. 
2010). It was estimated that as many as 25% (PD and HD) patients may have significant 
hypervolaemia (Devolder, Verleysen et al. 2010). 
 
It is commonly acknowledged that PD is a more gentle dialysis therapy given its 
continuous ultrafiltration and solute clearance that can be performed at home. Therefore, 
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one would expect PD to be more cardio-protective but similar rate of cardiovascular death 
has been found between PD and HD. Glucose is the main osmotic agent used in 
conventional PD solution to drive ultrafiltration but it can be absorbed systemically to 
create multiple metabolic disturbances including hyperglycaemia, hyperinsulinaemia and 
fat gain which have negative impact on the cardiovascular risk factors (Holmes 2007). PD 
patients are not spared entirely from haemodynamic interruption as PD fluid exchange has 
been shown to cause increments in both systolic and diastolic blood pressure and total 
peripheral resistance proportional to the glucose strengths (Boon, Bos et al. 2001). The 
rapid disappearance of glucose in patients with rapid solute transport status and reduced 
ultrafiltration increases the risk of tissue overhydration, hypertension and multiple organ 
dysfunctions.  
 
In view of such a unique profile the management of cardiovascular risk factors for PD 
patients differs from HD and requires careful consideration. First of all the loss of residual 
renal function is a strong predictor of all cause mortality including cardiovascular death 
(Wang, Wang et al. 2004). Increase in peritoneal small solute clearance was not associated 
with survival benefit suggesting peritoneal and renal clearance were not equivalent and 
qualitatively different (Paniagua, Amato et al. 2002). Therefore the preservation of RRF is 
considered an important strategy in PD patient care. The beneficial effect of angiotensin 
converting enzyme inhibitor and angiotensin receptor blockers on the rate of decline of 
renal function has been demonstrated in both diabetic and non diabetic patients likely 
attributed to the BP lowering effect (Casas, Chua et al. 2005). However, similar reno-
protective effect was also seen in PD patients not explained by BP reduction (Li, Chow et 
al. 2003, Suzuki, Kanno et al. 2004). Furthermore, minimisation of glucose exposure is 
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desirable given the adverse effect of glucose on peritoneal membrane and metabolic 
profile.  
 
1.2.5 Barriers to achieving euvolaemia in PD patients 
Achieving a normal fluid status is therefore one of the prime objectives of RRT and PD is 
often regarded as a good therapy to achieve this. The combined benefits of a slow but 
sustained UF with relative preservation of RRF provide the optimal conditions to 
accomplish euvolaemic state. This is supported by evidence that shows that early survival 
in PD is excellent, probably superior to HD patients (Vonesh, Snyder et al. 2004), a benefit 
seen over a time frame likely to reflect salt and water management. Other studies have 
shown reductions in antihypertensive requirements and stabilization of LVH which 
coincides with these early survival benefits (Menon, Naimark et al. 2001).  
 
However, longer term survival on PD is less favourable and there are several indicators 
suggesting that this is at least in part due to increasing difficulties with fluid management. 
First, inadequate ultrafiltration is an important cause of PD technique failure (Davies, 
Phillips et al. 1998). In observational studies, low peritoneal UF, especially in anuric 
cohorts is associated with reduced survival (Jansen, Hart et al. 2002, Brown, Davies et al. 
2003, Paniagua, Amato et al. 2008). Interpretation of observational studies must be 
performed with care as low ultrafiltration volume could simply reflect poor dietary intake 
and hence a poor nutritional state.  
 
Secondly, methods used to assess fluid status also predict survival. PD patients who have a 
reduced cell mass for a given overall fluid volume (implying excess ECW) as determined 
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by BIA technique have worse survival (Chen, Guo et al. 2007). This is also true for HD 
patients, emphasising the difficulties in maintaining satisfactory fluid status and salt and 
water balance in the context of changing body composition due to inflammation and 
muscle wasting. While this is not specific to PD it poses particular challenge in the 
regulation of fluid distribution because of the disproportionate hypoalbuminaemia seen 
with this modality.  
 
Thirdly, there is a fine balance to strive for between euvolaemia and maintaining RRF. 
Well conducted observational cohort studies, e.g. NECOSAD (Jansen, Hart et al. 2002), 
have found that episodes of volume depletion predict more rapid loss of RRF independent 
of other known factors such as primary disease, comorbidity, diuretic use and RRF at the 
start of PD (Davies, Carlsson et al. 2009). In randomised trials comparing ultrafiltration 
achieved with icodextrin versus glucose, large reduction in ECW (regardless of the 
solution used) precipitantly caused a significant fall in RRF; in one study, four patients 
rendered anuric with icodextrin were clearly volume depleted on BIA analysis (Konings, 
Kooman et al. 2003, Konings, Kooman et al. 2005, Davies, Garcia Lopez et al. 2008). On 
the other hand, randomized trials of the newer biocompatible PD solutions have observed 
an increase in RRF in patients randomized to solutions that lead to less ultrafiltration 
because of an unexpected change in peritoneal membrane function (Davies 2009). 
 
1.2.6 Albumin as a predictor of fluid status and survival  
Albumin has an inverse relationship with ECW, a marker of tissue overhydration (Jones, 
Smye et al. 1998). In a 4-week intervention study to reduce dry weight by increasing 
peritoneal ultrafiltration, the reduction of ECW has resulted in a rise in serum albumin and 
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improved BP control in PD patients (Jones, Wells et al. 2002). On the contrary, a frequent 
verses normal haemodialysis frequency randomised trial which led to the reduction in 
ECW in the frequent group has failed to elevate albumin level (Kaysen, Greene et al. 
2012). The negative charge acute phase protein also correlates inversely with inflammation 
and the interaction between hypoalbuminaemia, overhydration and inflammation has led to 
the speculation as a possible mechanism in the pathogenesis of malnutrition-inflammation-
atherosclerosis (MIA) syndrome with negative cardiovascular prognosis (Avila-Diaz, 
Ventura et al. 2006).  
 
There is a fundamental difference between HD and PD patients in the barrier to optimise 
fluid status and the fluid removal phenotypes. The problem with HD patients with 
significant cardiac dysfunction is that they repeatedly experience dialysis-induced 
hypotension thus frustrating attempts to achieve euvolaemia; HD patients with more than 
two comorbidities typically have three to five litre fluid excess post dialysis. Comorbidity 
also influences the pattern of longitudinal fluid gain, which is predominantly increased 
tissue hydration at the expense of lean tissue mass (Chan, McIntyre et al. 2009). Although 
worsening fluid status as determined by BIA is strongly correlated with a reduced plasma 
albumin in all dialysis patients (Jones, Akbani et al. 2002, Dumler 2003), this association is 
much stronger in PD patients (Figure 1.6). The single most important determinant of 
plasma albumin in PD is peritoneal protein loss. These losses are greatest in patients with 
larger, fast transport membrane especially when associated with significant comorbidity 
(Perl, Huckvale et al. 2009). In PD patients without comorbidity, increased protein 
synthesis largely compensates for this loss (Kaysen, Yeun et al. 1997). As comorbidity and 
inflammation increase, however, the ability to synthesize extra protein is impaired. This 
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has led to the hypothesis that hypoproteinaemia reduces plasma refilling and thus causes 
mal-distribution of fluid with excess extravascular ECW. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Hypoalbuminaemia with worsening ECW/TBW ratio in different 
dialysis modalities. (=PD, =HD. Unpublished data) 
 
1.3 Measurement of fluid status in dialysis patients using 
bioimpedance analysis (BIA) 
Given the profound impact of hydration status has on patient’s survival through the 
mediation of hypertension, LVH, inflammation, nutrition and organ dysfunction, the 
determination of optimal fluid status of a patient and the subsequent detection of any 
deviation so that corrective measures can be put in place are considered essential clinical 
care. The approach is a clinical one after careful evaluation of physical examination, 
nutritional status and blood pressure. The so-called ‘dry weight’ is the ideal body weight 
where BP is within normal range without the aid of antihypertensive medication and 
patient is found to be oedema free. Peripheral oedema is a late physical sign that lacks 
Tertiles of BIA derived ECW/TBW ratio (1=normal, 3=most abnormal) 
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sensitivity and patient who is oedema free is certainly not synonymous with 
normohydration. This is especially true for younger patient population. Other physical 
signs that indicate hypervolaemia such as raised jugular venous pressure and respiratory 
crepitation can be difficult to discern and non-specific. The well tried and tested method of 
determining optimal dry weight in HD patients is to reduce the post dialysis weight until 
patients experience unpleasant side effects of hypovolaemia. This is less attractive in PD 
for a number of reasons; it is likely to compromise RRF as already discussed and 
necessitates use of hypertonic glucose, which may drive thirst and accelerate obesity which 
in turn further confuses the weight changes.  
 
There is, therefore, a need for a more sophisticated measure of fluid status which would 
ideally discriminate between lean tissue mass, fat mass and ECW, preferably 
discriminating between intravascular and extravascular components of the latter. No such 
single tool exists. Those that have been used to evaluate fluid status in patients including 
BIA (Chen, Guo et al. 2007), echocardiography (Wang, Lam et al. 2006), brain/atrial 
natriuretic peptide (B/ANP) (Paniagua, Amato et al. 2008, Wang, Lam et al. 2009) may 
well have predictive value for both survival and episodes of fluid overload. However, none 
has so far been validated as a longitudinal management tool with clinically relevant 
endpoints. The general principle, techniques, strengths and weaknesses of BIA will be 
discussed here.  
 
1.3.1 Bioimpedance Analysis-The general principle 
Impedance (Z) refers to the degree of opposition of the alternating electric current (AC) of 
a conductor and is dependent on the frequency of the current. In the context of the human 
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body, it is determined by the vector relationship of resistance (R), which is inversely 
proportional to the amount of body water and reactance (Xc) or capacitance, which 
measures the ability of cell membranes to store electrical charges, hence proportional to the 
cell membrane mass (Jaffrin and Morel 2008). Theoretically, at low or zero frequency the 
current only passes through the extracellular fluid which yields the R of extracellular fluid 
(Ro). At infinite or very high frequency, AC passes through both the intracellular and 
extracellular water by penetration through the cell membrane which give rise to R∞. The 
relationship of the alternating electric current through different body compartments at 
different frequencies with their corresponding resistance and reactance values, can be 
demonstrated with Cole-Cole plot (Figure 1.7). 
 
Figure 1.7 Cole-cole plot showing the relationship between resistance (R), 
reactance (Xc), impedance (Z) and the frequency of alternate current. 
 
At low frequencies, the measurement of resistance is only confined to the extracellular 
resistivity as no current is passing through the intracellular compartment. As the applied 
frequency increases, the phase angle (Ф), which is the vector created by the impedance in 
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relation to resistance and can be calculated using the arctangent of the ratio of reactance to 
resistance (Xc/R), increases as more current is passing through the intracellular pathway. At 
very high frequencies, the current is entering both the intra and extracellular fluid 
compartment where capacitance becomes negligible and the reactance becomes zero and 
impedance is purely resistive. The relationship of resistance, reactance and impedance can 
be summarised by the equation. 
𝑍2 P = 𝑅2  +  𝑋𝑋2 
Z = √𝑅2  +  𝑋𝑋2 
Phase angle (Ф) = 𝑡𝑡𝑡−1(Xc/R) 
The resistance (R) to electric current of an object is determined by the shape in terms of its 
length (L) and surface area (A). The bioimpedance model considers the human body as a 
cylindrical object and the relationship between resistance and the human body as the 
conductive material can be described with the following equations: 
R= ρL/A 
Where ρ is resistivity given in Ω.m which measures the ability of a material to resist the 
passage of electric current for a defined unit of tissue. Reactance (Xc) is defined as 
resistance across the whole object and is inversely related to signal frequency (f) and 
capacitance (C) as described below: 
Xc=1/2πfC 
In biological tissue resistance is related to total body water and reactance to the capacitance 
of the body cell membrane. 
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1.3.2 Bioimpedance Vector Analysis (BIVA) 
BIVA is a simple approach in monitoring fluid status by graphical representation of the 
two absolute measurements of resistance and reactance. Developed by Piccoli, the height 
adjusted resistance and reactance derived from the fixed frequency 50 kHz can be plotted 
on RXc graph as a vector which gives rise to phase angle and vector length (Piccoli, Rossi 
et al. 1994). The formulated 50%, 75% and 95% tolerance ellipses are based on the 
bivariate confidence limits for the healthy population and migration of the impedance 
vector in the left and right half of the 50% ellipse indicates the gain and loss of body cell 
mass whereas movement in the lower and upper half corresponds to increasing and 
decreasing fluid status (Figure 1.8). 
 
 
Figure 1.8 Piccoli’s bioimpedance vector analysis in steady state and the 
significance of vector migration on body composition. 
 
In the HD-BIA study, Piccoli et al compared the vector distribution of 1367 HD patients 
with 726 healthy populations(Piccoli 1998). The HD cohort was further subdivided to 
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stable asymptomatic group and recurrent HD hypotensive group. The wet-dry weight 
fluctuation of HD patients as a result of ultrafiltration was mirrored by the cyclical, 
backward-forward displacement of the impedance vector. The vectors of patients 
susceptible to HD induced hypotension were less steep and more often displaced out of the 
reference of the 75% tolerance ellipse than stable patients. In a similar study in PD patients 
the TBW estimation by anthropometric equations was misleading and failed to 
discriminate between oedematous and oedema free patients. However, vector distributions 
of both groups of patients were clearly distinctive with oedema free patients more similar 
to healthy population and oedematous patients close to vectors of nephrotic patients 
(Piccoli and Italian 2004). Such information can be used in the setting of optimal dry 
weight and adjustment of dialysis prescription to minimise cardiac decompensation in 
susceptible patients. In the study of over 3000 HD patients, Pillon et al has demonstrated 
shorter pre-dialysis bioimpedance vector which indicates tissue overhydration is associated 
with diminished survival in HD patients (Pillon, Piccoli et al. 2004). In PD, bioimpedance 
indexes correlates with nutritional markers and patients with phase angle of greater than or 
equal to 6 degree have better survival in observational study (Mushnick, Fein et al. 2003). 
Such predictive power of outcome has been replicated in other disease cohorts including 
HIV patients on highly active antiretroviral therapy (HAART) (Schwenk, Beisenherz et al. 
2000) and advanced malignancies (Gupta, Lammersfeld et al. 2004, Gupta, Lis et al. 2004, 
Gupta, Lammersfeld et al. 2008). Large epidemiological study using BIVA involving over 
15,000 children and 210,000 adults stratified by age and body mass index provides a useful 
healthy reference population for patient groups (Bosy-Westphal, Danielzik et al. 2005). 
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1.3.3 Single frequency and multi-frequency bioimpedance analysis 
Single frequency BIA (SF-BIA) is the earliest proposed method to analysis body 
composition, usually at 50 kHz, mainly to predict the volume of TBW. Earlier study 
showed that H2/R (known as resistance index where H is the height of subject) at frequency 
of 50 kHz has the best fit in regression analysis to the TBW measured by deuterium 
dilution method and this has been validated in subjects with normal hydration status but 
not in diseased states with deranged fluid status (Lukaski and Johnson 1985, Lukaski, 
Johnson et al. 1985, Lukaski, Bolonchuk et al. 1986).  
 
 Multi-frequency BIA (MF-BIA) involves the use of more than two frequencies in the 
analysis and determination of ECW and TBW using low and high frequency currents 
respectively based on the Cole model. Various limits of frequency have been proposed and 
some studies have incorporated isotope dilution techniques to validate ECW and TBW as 
determined by MF-BIA both in healthy subjects and dialysis patients (Chertow, Lowrie et 
al. 1995). One of the advantages of MF-BIA is the ability to discriminate ICW and ECW 
compartment with better accuracy in predicting ECW volume in healthy subjects 
(Simpson, Lobo et al. 2001) though some studies demonstrated the SF-BIA may offer 
better estimation of TBW in critically ill patients (Patel, Peterson et al. 1996). 
 
Bioimpedance spectroscopy (BIS) is a more sophisticated model of MF-BIA using wide 
range of frequency and non linear mathematical models to estimate ECW, ICW and TBW, 
using normal population data as reference. Impedance data is used to calculate Absolute 
Delta Tissue Hydration (A△TH) which represents the discrepancy between the actual 
amount of ECW in the tissue measured by BIA and the amount under normal physiological 
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state of the age and gender match healthy cohort. A△TH is further adjusted to ECW and 
the derived ratio is called Relative Delta Tissue Hydration (R△TH = A△TH/ECW). The 
90th percentile of R△TH of the normal reference population is 7% and value exceeding 7% 
is considered fluid overload (FO) and if over 15%, severe fluid overload. One of the 
instruments that utilises the principle of BIS is the Body Composition Monitor (BCM, 
Fresenius Medical Care, Germany) which has been used in the monitor of fluid status in 
patients receiving dialysis treatments (Devolder, Verleysen et al. 2010, Machek, Jirka et al. 
2010). The estimated fluid overload has been shown to predict mortality both in HD 
(Wizemann, Wabel et al. 2009, Chazot, Wabel et al. 2012) and PD (O'Lone, Visser et al. 
2014) populations. 
 
1.3.4 Strengths and weaknesses of BIA 
There are many advantages of BIA, not least its non-invasiveness and easy portability but 
also highly reproducible measurements correlating fluid status and body cell mass. 
However, there are differing opinions regarding the optimal methodology between 
multiple frequencies BIA and single frequency, although the relationship between these 
two measures from which the hydration status is derived is highly correlated at every 
frequency. However determined, the R/Xc ratio is a strong predictor of survival such that 
patients with a relatively low reactance (tissue mass) in relation to resistance (body water) 
have a worse outcome. 
 
It is also not clear how best to express the measured parameters to allow meaningful 
comparison in different treatment modalities with different body composition. The 
commonly used ratio of ECW/TBW ratio is often increased in PD patients compared with 
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healthy subjects because of the main abnormality in PD patients is an absolute reduction in 
tissue mass, reflecting their muscle wasting (Woodrow, Oldroyd et al. 2004). It is not clear 
whether the ECW/TBW ratio should be adjusted to account for the reduced lean tissue, 
although both PD and HD patients who were considered clinically euvolaemic had 
proportional reduction in ECW matching their reduced body water compared with healthy 
controls (van de Kerkhof, Hermans et al. 2004). There is also the issue regarding the 
extrapolation of absolute volume for TBW and ECW with impedance data using healthy 
population derived algorithms which assume normal tissue hydration index. This was 
clearly not the case as demonstrated in a longitudinal cohort of HD patients where the BIA 
estimated TBW volume was compared with absolute measurements using deuterium 
dilution; patients with more comorbidity were more overhydrated (Chan, McIntyre et al. 
2009). This supports the observations that BIA tends to underestimate ECW the more 
overhydrated the patient is (Konings, Kooman et al. 2003). Finally, BIA is not able to 
discriminate ECW excess in intravascular from extravascular compartment. Clinical 
decision based solely on BIA derived hydration status could be erroneous without taking 
into account the patient’s blood pressure, cardiac status and central volume, thus running 
the risk of compromising RRF. 
 
Therefore, BIA is a promising tool in predicting outcomes and for monitoring longitudinal 
changes in fluid status and body composition as shown in interventional studies to modify 
hydration status in PD patients (Davies, Woodrow et al. 2003, Davies, Carlsson et al. 
2009) but it has not been validated as a routine clinical tool and the optimal application of 
this technique requires further investigations.    
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1.4 Measurement of lung water volume 
1.4.1 Why measure lung water volume? 
The measurement of lung water volume has sparked much interest in the settings of critical 
care and renal failure. This is perhaps not surprising. Prognostically, extravascular lung 
water (EVLW) volume has been shown to correlate with survival in critically ill patients, 
with mortality rate of 65% in patients with EVLW > 15 ml/kg, compared with 33% in 
patients with EVLW < 10 ml/kg (Sakka, Klein et al. 2002)(Figure 1.9). In the same study 
EVLW has been established as an independent predictor of outcome (Figure 1.10). EVLW 
has been shown to predict clinical response to mechanical ventilation. Zeravik and co-
workers have demonstrated patients with higher EVLW benefited from high-frequency 
ventilation whereas patients with subnormal or normal EVLW did well with pressure 
support ventilation (Zeravik and Pfeiffer 1989).  
 
Study in HD patients revealed up to 67% of HD patients were found to have elevated lung 
water volume measured by thermodilution technique, indicating interstitial lung fluid 
excess (Kuhn, Kuhn et al. 2006). More worryingly, these asymptomatic patients did not 
exhibit any overt signs of pulmonary oedema and were considered clinically euvolaemia 
by their given target weight. The presence of subclinical pulmonary oedema HD patients 
was also confirmed by Wallin et al (Wallin, Jacobson et al. 1996) which was removed by 
dialysis, although no correlation was found between changes in lung water volume and 
body weight.  
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Figure 1.9 Using transpulmonary double indicators dilution technique to assess 
EVLW in the critically ill patients, non-survivors have higher EVLW volume. 
 
 
Figure 1.10 Mortality as a function of EVLW and patients were classified into 
four groups according to their highest EVLW volume. 
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The primary function of the lungs, which is to have a conducive environment to allow 
effective gaseous exchange in alveoli, the basic unit of the pulmonary system, is critically 
dependent on the protective mechanism to keep the gas filled air spaces relatively free 
from fluid. Pulmonary oedema is characterised by the abnormal accumulation of fluid in 
the extravascular spaces and may result from an increase in capillary permeability (acute 
lung injuries or acute respiratory distress syndrome) or from an increase in capillary 
pressure (increased hydrostatic pressure from cardiogenic pulmonary oedema). Such 
phenomenons cause disturbance in the ‘Starling equation’ that favours the accumulation of 
EVLW which highlights the importance of the tight regulations between the hydrostatic 
and oncotic pressures in the intravascular and extravascular compartment. 
 
EVLW = (Lp × S) [(Pc–Pi) – ⌠ (∠c–∠i)] – lymph flow 
 
Where Lp=the hydraulic conductivity for water (cm/min/mmHg), S=surface area (cm2), Pc 
and Pi= the hydrostatic pressure in the capillary and interstitial spaces respectively, ⌠ = the 
reflection coefficient for protein, ∠c  and ∠i= the oncotic pressure within the capillary and 
interstitial spaces (mmHg). 
 
The current gold standard to determine EVLW volume is post mortem examination using 
histological or gravimetric technique which clearly is not feasible for routine daily clinical 
use. Normal EVLW volume is approximately <500ml (Sivak, Starr et al. 1982, Sibbald, 
Warshawski et al. 1983, Gallagher, Moore et al. 1985) and physiological impairment 
occurs when the volume exceeds 75 to 100% (Bongard, Matthay et al. 1984). Pulmonary 
oedema can be detected clinically by chest auscultation and conventionally confirmed by 
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the findings of signs consistent with pulmonary congestion on chest radiograph but both 
methodologies are subjective and lack clinical sensitivity and specificity. There is a need to 
develop and validate techniques that are sensitive enough to detect the presence of 
subclinical pulmonary oedema and to monitor the effect of therapeutic intervention. The 
ideal test should be simple, non-invasive, accurate, sensitive, non-expensive and with 
highly reproducible result. Such single test does not exist but there has been a wide array 
of techniques aiming to fulfill the criteria. The current available clinical or research 
techniques can be broadly categorised into two main methodologies: imaging and indicator 
dilution. 
 
1.4.2 Imaging methods 
1.4.2.1 Chest radiograph 
Chest radiography is a common and non-invasive tool used by clinicians to assess, among 
other cardiopulmonary pathologies, the presence of pulmonary oedema from the relatively 
well to the critically ill patients. It produces a visual estimation of excessive total lung 
water (intra and extravascular lung water) content or concentration. Certain radiographic 
features are considered to be characteristic of increased lung water volume such as 
pulmonary congestion, peribronchial cuffing, presence of septal lines (e.g. Kerley’s lines) 
or air bronchograms, interstitial shadowing etc.  As oedema increases, alveolar air space is 
replaced by fluid and the infiltrate becomes denser, particularly in the gravity dependent 
lung regions in mild to moderate pulmonary oedema and in severe cases all lung areas may 
be involved which may give a ‘white-out’ appearance. However, radiographic appearances 
of fluid, blood and inflammatory infiltrates are very similar and the density of infiltrates 
does not discriminate or infer the potential aetiologies.  
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The accuracy of chest radiograph to detect and monitor extravascular lung water has been 
evaluated in a series of studies using various double indicators dilution techniques. 
Pistolesi and Giuntini (Pistolesi and Giuntini 1978) studied the relationship between 
pulmonary oedema graded by a complex scoring system and EVLW measurement by 131I- 
labelled albumin and tritiated water as the non-diffusible and diffusible markers and found 
a significant but curvilinear correlation which makes clinical interpretation difficult. In a 
small study involving 14 critically ill patients, 5 patients were reported to have pulmonary 
oedema on radiological evidence though they have normal lung water measurement, 
indicating the problem of over-scoring in radiological examination (Sivak, Richmond et al. 
1983)). Another study which utilized indocyanine green and 131I-labelled antipyrine as 
double indicators to evaluate EVLW found no correlation with cardiogenic and non-
cardiogenic pulmonary oedema determined by radiographic interpretation (Liebman, 
Philips et al. 1978). 
 
In the 1980’s, Milne et al described the measurement of vascular pedicle width (VPW) 
which reflects the mediastinal silhouette of the great vessels on chest X ray (CXR) as a 
valid technique to measure intravascular volume (Milne, Pistolesi et al. 1984). It measures 
the distance between two points horizontally, first point formed by the crossing between 
the horizontal line and an imaginary vertical line dropped from the origin of left subclavian 
artery at the aortic arch (step 1 in Figure 1.11) and second point the crossing between 
superior vena cava and right main bronchus (step 2 in Figure 1.11) (Ely, Smith et al. 2001).  
Taken at the upright and postero-anterior position they reported the normal mean of VPW 
to be 48+/- 5 mm.  However, there are variation in the measurements in patients with 
differing heights and body habitus. Other factors such as physical rotation, degree of 
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inspiration, upright or supine positions, previous thoracic surgery and trauma will have 
impact on the interpretation of VPW.  
 
Figure 1.11 The vascular pedicle width (VPW) on chest X ray.  
 
Much of the work of VPW measurement was conducted on mechanically ventilated 
patients in the critical setting. The two common challenging clinical scenarios faced by 
physicians are pulmonary oedema caused by acute respiratory distress syndrome (ARDS) 
from acute lung injuries and volume overload from cardiogenic or renal failure, both give 
similar CXR appearance. The differentiation between the two entities is crucial as they 
require different interventional therapies. In a series of clinical investigations Milne and 
coworkers found VPW < 43 mm was most predictive of patients with ARDS whereas an 
increased VPW > 53mm was observed in hypervolaemic state from cardiac or renal failure 
(Figure 1.12) (Milne, Pistolesi et al. 1985).  
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Figure 1.12 Vascular pedicle width in lung oedema.  
 
Subsequent investigation by incorporating VPW and cardiothoracic ratio (CTR), another 
CXR measurement which assessed the ratio between the widest transverse diameter of the 
cardiac silhouette and the widest transverse diameter of the thorax above the diaphragm, 
improved the accuracy of CXR interpretation to differentiate between ARDS and volume 
overload by more than 30% (Thomason, Ely et al. 1998). These two radiological 
parameters correlate with pulmonary artery occlusion pressure (PAOP) which is generally 
considered to be the ‘gold standard’ of measuring intravascular volume. However this is 
done by Swan-Ganz catheter placement in the pulmonary artery and the safety and efficacy 
of such invasive procedure has been of considerable clinical concern.  The clinical 
usefulness of VPW and CTR was examined using computer generated digital CXR in a 
prospective study of 100 critically ill patients who underwent pulmonary artery 
catheterisation. There was a modest increase in the radiologist's accuracy in discriminating 
volume status when clinical data was incorporated and VPW of > 70mm and CTR > 0.55 
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were the best cut off for differentiating a high intravascular volume status from a normal to 
low status (Ely, Smith et al. 2001). Although statistically significant, the association 
between VPW and pulmonary artery wedge pressure is weak and the lack of volumetric 
quantification means VPW cannot accurately predict intravascular volume status.  
 
Overall, chest radiograph is a useful and non invasive tool which provides important 
information regarding lung density and possible aetiology of the disease process but its 
ability to predict lung water is seriously limited by difficult acquisition strategies in the 
critically ill patients and there is a lack of clinical validation in the day to day fluid 
management of dialysis population. It is also worth remembering that the interpretation of 
CXR findings in the clinical study is conducted by experienced radiologist under best 
circumstances, something that is not applicable in real life.  
 
1.4.2.2 Lung ultrasound 
The modality of ultrasound (US) imaging of the lungs has been shown to be of some value 
in discriminating pulmonary oedema from chronic obstructive pulmonary disease in 
patients presented with acute dyspnea (Lichtenstein and Meziere 1998). The resulting 
image that reflects excess extravascular lung water is the product of an artifact of 
hyperechoic reverberation between the pleural and the oedematous pleural septa. Such 
characteristic appearance resembles the flying comets, hence the term lung comets or more 
recently US B lines (Volpicelli, Elbarbary et al. 2012) that correspond with Kerley B lines 
observed in routine chest X-ray. This modality offers many attractive features which 
include non-invasiveness, easy application without the need of specialized operators and 
real time measurements.  
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When dialysis patients were subjected to lung ultrasound examination, most patients had 
evidence of moderate to severe pulmonary congestion but worryingly they were often 
asymptomatic (Enia, Torino et al. 2013, Zoccali, Torino et al. 2013). Even after fluid 
removal with ultrafiltration with haemodialysis, significant number of patients still has 
evidence of significant pulmonary congestion (Zoccali, Tripepi et al. 2013). US lung 
comets have been linked to important clinical outcomes in dialysis population. In a 
prospective observational study of 96 HD patients US lung comets scores were a 
significant predictor of mortality independent of bioimpedance derived parameter of fluid 
status (Siriopol, Hogas et al. 2013). In a cross sectional study of PD patients lung water 
measured by lung ultrasound has been shown to correlate independently with physical 
functioning by the Kidney Disease Quality of Life Short Form (Enia, Tripepi et al. 2012).  
 
Pulmonary congestion is often considered to be a marker of overall volume status but such 
assumption lacks clinical validation, more so in the dialysis population who is often 
associated with abnormal fluid status. One study showed the lung comet score (B lines) is 
not significantly different in patients with overhydration, normal hydration status and 
underhydration as determined by BIA. Possible explanations for this finding are the high 
prevalent of heart failure among dialysis population that frequently associated with lung 
congestion and the phenomenon of increased lung permeability in uraemia that may not be 
volume related. Classical physical signs of volume overload such as lung crackles and 
tissue oedema have shown poor correlation with pulmonary congestion characterized by 
US B lines (Torino, Gargani et al. 2016).  
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1.4.2.3 Computed tomography (CT) 
The density of lung tissue is the composite value of the relative proportion of air, blood, 
EVLW, and lung parenchymal and these elements can be quantitatively studied by the 
evaluation of the attenuation of electron beam with CT. In an experimental animal study, 
CT densitometry technique was able to detect a 69% increase in lung density from baseline 
when lung water weight was increased 250% gravimetrically (Hedlund, Vock et al. 1984). 
In a small study involved 10 HD patients, changes in lung fluid with ultrafiltration was 
reflected by changes in lung density and this corresponded with better alveolar ventilation 
and improved pulmonary function tests (Metry, Wegenius et al. 1997). Further study in HD 
also showed lung density measured by CT densitometry correlated with the measurement 
of the diameter of inferior vena cava (IVC) which is closely related to central blood 
volume and total body water leading to the hypothesis that normalisation of lung water is a 
good indication of dry weight in HD patients. However, CT instruments are not easily 
portable and involve potential harmful ionizing radiation, limiting its use within 
experimental setting. 
 
1.4.2.4 Nuclear magnetic resonance (NMR) imaging  
NMR is another modality that can be used to measure total lung water due to the 
abundance of proton in the water by the alignment of hydrogen nuclei of water molecule 
which can be manipulated with external magnetic field (Mayo 1994). The spin-echo 
sequence is the only one technique used in the measurement of lung water. A number of 
studies have reported good correlation between measurement of lung water by NMR and 
the gold standard gravimetric method (Cutillo, Morris et al. 1986, Phillips, Allen et al. 
1989, Caruthers, Paschal et al. 1998). However, NMR may underestimate lung water by as 
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much as 40% in mild pulmonary oedema due to relatively little signal produced by 
conventional spin-echo sequences on 1.5 Tesla imagers. The issue can be resolved with the 
development of a multi-echo sequence with a much less powerful magnetic field (0.15 
Tesla). This showed good correlation with the gravimetric method and this was 
subsequently validated in human subjects (Mayo, MacKay et al. 1995). 
 
One of the advantages is the ability to measure intravascular lung water (IVLW) volume 
by evaluating the signal strength before and after the administration of the contrast medium 
such as polylysine-(Gd-DTPA). Extravascular lung water can be obtained by subtracting 
IVLW from TLW. Another advantage is the possibility to study the potential aetiology of 
pulmonary oedema.  Due to the different signal intensity emitted by different tissues and 
subsequently acquired at longitudinal relaxation time (T1) and transverse relaxation time 
(T2), it is possible to study the difference in the composition EVLW in hydrostatic 
pulmonary oedema in heart failure (low protein content) and permeability pulmonary 
oedema in ARDS (high protein content).  
 
NMR faces technical challenges as it is susceptible to artifact from chest wall motion 
during respiration. Certainly, the avoidance of ionizing radiation makes it an attractive 
option, but it is expensive, difficult to apply in critically ill or obese patients and 
contraindicated in patients with implanted magnetic materials. 
 
1.4.2.5 Positron emission tomography (PET) 
PET is widely considered to be the gold standard for the measurement of EVLW. A sample 
of sterile water labeled with a positron-emitting isotope such as oxygen -15 (H215O) with a 
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half-life of approximately two minutes is administered intravenously. The radioactive 
labeled tracer is given time (three to four minutes) to equilibrate within the intravascular 
and total water compartment of the lung. The emissions are detected by an external device 
such as gamma camera or a PET scanner and the isotopic activity concentration can be 
determined in the lung tissue. The PET image can be used as a quantitative map of lung 
water distribution. A separate approach is needed for the estimation of EVLW volume. 
First, a standard acquisition of the PET image which contains total lung water distribution 
is performed as described above. Second, trace amounts of C15O gas is inhaled and it binds 
readily with blood haemoglobin. Following the equilibration with the total blood volume 
after a given time another PET image is performed. Assuming 84% of blood is water with 
normal haematocrits, the intravascular water content of the lung can be deducted from the 
total lung water concentration, giving rise to EVLW concentration (Schuster, Marklin et al. 
1986).  
The measurements of EVLW by PET correlated very well with the one obtained by 
gravimetrics. The measurements are highly reproducible with coefficient of variation of 
less than 5% and extremely sensitive to detect even a small increment in extravascular 
water (Schuster, Marklin et al. 1986). However, despite the superior qualities over the 
other modalities, PET scan is expensive, not widely available and involves ionising 
radiation. These severely limit its general application in general clinical setting.   
 
1.4.2.6 Electrical impedance tomography (EIT) 
The basic principle of EIT is based on the presence of air, fluid and lung tissues offering 
various resistances which can be measured by bioimpedance analysis when alternating 
electric current of fixed frequency is applied in the thoracic region. Such measurements 
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have been shown to correlate with gravimetric EVLW adjusted by weight (Spinale, Reines 
et al. 1989, Zellner, Spinale et al. 1990, Nierman, Eisen et al. 1996). In animal studies 
EVLW estimated by EIT and double indicators dilution technique showed good correlation 
with high reproducibility (Spinale, Reines et al. 1989). Lung impedance changed in 
response to diuretic treatment in patients with congestive heart failure where a significant 
increase of 8% of the mean lung resistivity was observed indicating dehydration of the 
lungs, offering the potential to guide medical intervention of this common condition 
(Noble, Harris et al. 2000). In haemodialysis population, total body impedance (TBI) 
measurement has been used to reflect total body water (TBW) changes. However, the 
extremities are responsible for 80% of the signal measured, making TBI a poor indicator of 
thoracic fluid content. During haemodialysis session both TBI and thoracic impedance (TI) 
increased with ultrafiltration, indicating a decrease of TBW and thoracic fluid though 
patients were considered to be euvolaemic and free from overt pulmonary oedema (Vonk 
Noordegraaf, van der Meer et al. 1995). This is partly due to UF induced hypovolaemia 
precipitating a reduction in thoracic blood volume and pulmonary perfusion. The value of 
EIT in patients undergoing peritoneal dialysis has not been investigated before.  
 
There are several factors that need to be taken in account in the interpretation of thoracic 
impedance. The resistance increases with albumin concentration, a phenomenon seen in 
vitro studies and subsequent human study has showed impedance measurements differ in 
cardiogenic (low protein state) versus non-cardiogenic (high protein state) pulmonary 
oedema which gave rise to different lung water measurements (Raaijmakers, Faes et al. 
1998).  Both the variation in tidal volume and density of lung parenchyma may affect the 
analysis of electrical impedance in the thorax. Ventilatory-induced impedance changes 
with tidal volume and patients with emphysema show a significantly lower impedance 
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change between inspiration and expiration in comparison with healthy controls (Kunst, 
Vonk Noordegraaf et al. 1998). Despite the limitations, electrical impedance of the thorax 
is a safe, easy to apply, non-invasive and inexpensive technique which makes it clinically 
attractive but it has not been validated as a useful clinical tool to monitor lung water 
volume. 
 
1.4.3 Indicator dilution methods 
The indicator dilution methods are first described in the 1950s based on mathematical 
concepts and models (Newman, Merrell et al. 1951, Meier and Zierler 1954). When a 
known volume of indicator is injected into a central vein such as the internal jugular vein 
via a central venous catheter and blood is simultaneously sampled at a remote arterial site, 
commonly the femoral artery, the concentration of the indicator can be determined. The 
product of the flow through the system (cardiac output) and the mean transit time (obtained 
from the dilution curve) allows the calculation of the total volume of distribution of the 
indicator. The use of a freely diffusible water indicator (D2O) or a thermal indicator (cold 
saline) would give rise to volume of distribution that includes both the intravascular and 
extravascular lung water. With the incorporation of a non-diffusible indicator (indocyanine 
green dye) which is restricted to the intravascular compartment and can be detected 
simultaneously in the arterial system, a different dilution curve emerges and EVLW 
volume can be estimated by comparing the volume of distribution of the two indicators. 
This is known as the double-indicator method.  
 
The use of a single thermal indicator to estimate EVLW volume in humans was performed 
in the late 1980s requiring the insertion of pulmonary artery catheter and femoral arterial 
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catheter with a thermistor (Baudendistel, Kaminski et al. 1986). It also provides other 
important clinical parameters such as cardiac output, central venous pressure and 
pulmonary wedge pressure but the wider application is limited by its invasiveness and 
inherent high risk of complications.  Moreover, it significantly overestimated EVLW 
volume by as much as 20% in a comparable study with double indicator method (Schuster 
and Calandrino 1991). By using a different approach, Sakka and co-workers evaluated the 
use of a single cold indicator to assess EVLW volume in a cohort of critically ill patients 
(Sakka, Ruhl et al. 2000) based on the physiological relationship between Global End-
Diastolic Volume (GEDV) and Intrathoracic Blood Volume (ITBV). The technique is 
called pulse-induced continuous cardiac output (PiCCO) and the method of measurement 
can be described as follows: After the injection of a bolus of cold saline, the total volume 
of distribution of the cold indicator is obtained as the product of cardiac output and mean 
transit time, which is termed as the Intrathoracic Thermal Volume (ITTV). The pulmonary 
Thermal Volume (PTV), which is the largest chamber for the equilibration of cold 
indicator with lung water can be calculated by multiplying the cardiac output with the 
exponential down slope time of the thermodilution curve. The GEDV is the difference 
between ITTV and PTV. Using the study series, the Intrathoracic blood volume (ITBV) 
can be predicted from GEDV measurements with high accuracy using the equation     
ITBV = (1.25 X GEDV) - 28. The discrepancy between ITTV and ITBV would give rise to 
the EVLW volume (Figure 1.13) (Michard 2007). Although different equations have been 
reported in other human studies, the derived EVLW volumes by transpulmonary 
thermodilution technique were quite similar and shown to correlate closely with the values 
obtained by the double-indicator dilution technique (Figure 1.14) (Reuter, Felbinger et al. 
2002, Michard, Schachtrupp et al. 2005).  
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Figure 1.13 Principles of extravascular lung water (EVLW) estimation by the 
single-indicator dilution method. The intrathoracic blood volume (ITBV) is 
derived from the measurement of the global end-diastolic volume (GEDV), see 
the above equation. EVLW is the difference between the total volume of 
distribution of the thermal indicator and ITBV. CO,, cardiac output; MTt, mean 
transit time; Dst, down slope time; RA, right atrium; RV, right ventricle; PBV, 
pulmonary blood volume; LA, left atrium; LV, left ventricle. 
 
PiCCO is a device capable of measuring several important clinical parameters including 
continuous cardiac output, cardiac preload and systemic vascular resistance. It can be 
performed via a central venous line and an arterial catheter with a thermistor in one of the 
larger systemic arteries such as the femoral artery, something not uncommonly found in a 
typical patient in intensive care unit. It does not require any other additional access and real 
time measurement of cardiac output can be obtained. However, it is still an expensive 
device and repeated bolus injection of cold saline for calibration is important in ensuring 
accuracy of measurement.  
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Figure 1.14 Close correlation between extravascular lung water (EVLW) 
estimated from the double-indicator dilution method (EVLWthermo-dye) and 
transpulmonary thermodilution (EVLWthermo) in humans (Michard, Schachtrupp 
et al. 2005). 
 
The accuracy of technique is based on several assumptions. They include complete mixing 
with circulating blood, constant blood flow, adequate lung perfusion, no gain or loss of 
indicator throughout measurement, no recirculation of the indicator and constant body 
temperature. The thermodilution curve can be affected by the effects of respiration on 
venous return to the right heart, respiratory rate, timing of injection and baseline drift in the 
thermal signal, all which influence the calculation of cardiac output and EVLW. There are 
conditions that may lead to underestimation of EVLW such as pulmonary embolus, focal 
lung injury and lung resection. Other conditions that may give rise to inaccurate 
measurement are intracardiac shunts, aortic stenosis and aortic aneurysm. This technique 
requires regular calibration and considerable expertise to operate. It is also expensive and 
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invasive with the associated risk of infection and thrombosis. Nevertheless, it remains one 
of the most useful apparatus in the monitoring cardiopulmonary functions in critically ill 
patients. 
 
1.5 Deuterium abundance analysis by Flowing Afterglow Mass 
Spectrometry (FA-MS) 
1.5.1 Introduction 
The possibility of using deuterated water to measure lung water volume was first studied in 
1954. Lilienfield et al found an increase in lung water in patients with heart failure when 
compared with normal subjects following central intravenous injection of Deuterium Oxide 
(D2O) (Lilienfield, Freis et al. 1955). However, it required multiple blood sampling and 
results were not available immediately. More recently, using indocyanine green and 
deuterium as the double indicators Wallin et al demonstrated a significantly higher lung 
water index in haemodialysis patients (up to 33%) than in the control group (Wallin, 
Jacobson et al. 1996).  
 
Deuterium, (D or 2H), is a naturally occurring stable hydrogen isotope which is present in 
terrestrial water in very low concentration. The volume of body water compartment can be 
accurately measured following the deuterium enrichment process by isotopic dilution 
technique. The deuterium abundance can be determined conventionally in body fluids such 
as urine, saliva and blood samples by first equilibrating the test sample with gaseous 
hydrogen in the presence of a catalyst. The gas mixture in the headspace above the body 
fluids can then be sampled and the isotopic composition of this gas can be analysed by the 
conventional mass spectrometry, sometimes coupled with gas chromatography (Karasek F 
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1988). However, this approach is complex and time consuming, requiring laborious sample 
preparation and transportation to reference laboratories for further analysis. Hence, 
considerable delay can be expected from sample acquisition and analytical results to be 
available for clinical interpretation. 
 
The advantage of an alternative method that enables immediate measurement at bedside 
that is patient friendly and does not require further complex analysis is obvious. To 
accomplish this, a novel ion flow tube device called flowing afterglow mass spectrometry 
(FA-MS) was developed. Through this approach, the HDO concentration can be 
determined in breath with abundant source of water vapour that can be accessed easily, or 
in the equilibrated headspace of any body fluid such as blood stored in a sealed container. 
This was made possible following the study of the determination of trace gas metabolites 
in breath using the selected ion flow tube mass spectrometry (SIFT-MS) (Smith and Spanel 
1996). When the hydronium ions, H3O+ were introduced into helium carrier gas containing 
water vapour, hydrated hydronium cluster ions at various mass-to-charge ratio (m/z) were 
formed (m/z values of 73,74 and 75 are of particular interest). Such observation has led to 
the development of FA-MS which involves the production of thermalised hydrated 
hydronium cluster ions in the inert helium gas along a flow tube following the introduction 
of a humid air sample. These cluster ions collide with water molecules and when the 
isotopic compositions reach equilibrium the relative magnitudes of the isotopomers can be 
measured by a mass spectrometer located downstream, enabling the measurement of 
deuterium abundance in the air/water vapour sample.  
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1.5.2 Validation in healthy controls 
The measurement of TBW by FA-MS has been compared with other bedside estimates of 
TBW in a cohort of 24 healthy subjects, 12 men and 12 women, with age distribution 
similar to an adult dialysis population (28-79 years)(Smith, Engel et al. 2002). TBW 
measurements by all methods were highly correlated (r=0.95-0.98, P<0.001). However, 
systematic bias was observed especially FA-MS was compared with BIA which tended to 
underestimate TBW in smaller female subjects. The same cohort was re-examined again 
after 12 months to evaluate longitudinal TBW changes (Engel, Spanel et al. 2004). High 
correlations between weight and TBW estimated by FA-MS, BIA and skin fold thickness 
(SFT) at baseline and one year later were observed (R2 = 0.96-0.98) and systematic biases 
were effectively identical. Body composition in this group of healthy individuals was 
remarkably stable with the tendency of weight gain, on average 1.2 kg (non-significant) 
although proportion of TBWD/weight was not different.  
 
1.5.3 Application to the dialysis patients 
1.5.3.1 PD patients 
FA-MS allows multiple samples to be taken in rapid succession and this enables the 
kinetics of D equilibration to be studied and characterised. This has been applied in the 
study of water transport across peritoneal membrane in patients treated with continuous 
ambulatory peritoneal dialysis (CAPD). An artificial deuterated water gradient was created 
following oral ingestion of D2O and a typical full equilibration took place within 90 
minutes. Frequent dialysate samples were taken to determine the abundance of deuterium 
analysed by FA-MS over time to measure water transport across the peritoneal membrane 
(Asghar, Diskin et al. 2003). In a further study using different hypertonic solutions (1.36%, 
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3.86% and extraneal) with increasing osmotic properties, the diffusive and convective 
components of small solute transport, including water, were characterised and as predicted 
by the 3-pore model of peritoneal membrane function (Asghar, Diskin et al. 2005). The 
headspace analysis of deuterium abundance in the dialysate fluid from this experiment 
provides the alternative in assessing TBW in patients following oral ingestion of D2O. 
 
1.5.3.2 HD patients 
A typical hospital based haemodialysis treatment can last up to 12 hours per week and 
considerable more when travelling and waiting time is taken into account. Any further 
delay incurred by evaluation of body composition and fluid status is considered 
undesirable. Therefore, the application of FA-MS to determine TBW in haemodialysis 
patients requires some modification to minimise potential inconvenience. In a study to 
examine the validity of this technique, a protocol was devised where HD patients were 
given D2O after the completion of their HD treatment and had their breath sample taken to 
determine deuterium abundance just prior to their next dialysis treatment 2 days later 
(Chan, Smith et al. 2008). The weight gain between these two treatment sessions was 
showed to match the water intake that caused dilution of deuterium abundance in the 
breath samples. Further deuterium dilution by urine output and insensible loss from sweat 
and breath was close to prediction, estimated to be 400ml per day. Such schedule enables 
the accurate measurement of TBW in HD patients without further aggravating their 
treatment burden.  
 
Having established the validity and acceptability of this technique in HD population, its 
clinical value was further evaluated in prospective cohort study with body composition 
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measures at baseline and 12 months later (Chan, McIntyre et al. 2009). At baseline a strong 
association was found between body composition and the number of comorbidities (e.g. 
diabetes, ischaemic heart disease, peripheral vascular disease, heart failure etc). Patients 
without any comorbidity had the most normal body composition as determined by BIA, 
expressed as the percentage lean body mass (%LBM) in relation to body weight. As 
number of comorbidities increased, %LBM decreased but TBWD actually increased, 
reflecting overall increase in tissue hydration despite the reduction in muscle mass. Such 
discrepancies by comorbidity status became more exaggerated over the 12-month follow 
up without any change in body weight (Table 1.2) (Engel, Spanel et al. 2004, Chan, 
McIntyre et al. 2009). This was especially true for the most comorbid group who actually 
experienced weight loss while becoming more overhydrated. Therefore the imperceptible 
changes of body composition can be identified by combining relative (BIA) and absolute 
(deuterium dilution by FA-MS) measurement of TBW. 
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Table 1.2 Longitudinal changes in weight, percentage lean body mass 
(%LBMBIA) derived from BIA and TBWD from FA-MS breath deuterium 
abundance following D2O ingestion in healthy subjects  and HD patients. 
  Baseline 12 months P value 
Healthy Controls 
(n=24) 
Weight (kg) 75.4 76.6 NS 
%LBMBIA 64.2 64.4 NS 
TBWD(L) 38.7 39.5 NS 
TBWD/Wt% 51.3 52.0 NS 
HD 
patients:Comorbidity 
Score=0 (n=13) 
Weight (kg) 82.9 82.8 0.99 
%LBMBIA 54.9 56.2 0.048 
TBWD(L) 44.2 47.3 0.001 
TBWD/Wt% 53.5 57.6 0.006 
HD patients: 
Comorbidity Score 1 
to 2 (n=22) 
Weight (kg) 78.7 78.4 0.57 
%LBMBIA 48.7 48.8 0.93 
TBWD(L) 39.7 41.8 0.001 
TBWD/Wt% 51.6 54.2 0.004 
HD patients: 
Comorbidity Score >2 
(n=7) 
Weight (kg) 78.4 76.7 0.34 
%LBMBIA 47.2 45.2 0.37 
TBWD(L) 41.6 43.2 0.16 
TBWD/Wt% 54.1 58.0 <0.05 
 
1.5.4 Estimation of lung water volume using FA-MS 
Following the validation of breath deuterium analysis by FA-MS in the measurement of 
TBW,  we now consider the possibility of the application of this technique in lung water 
measurement. Pulmonary oedema is a potentially life threatening spectrum of 
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overhydration and current techniques to measure lung water excess are semi-invasive and 
more suited for critically ill patients in intensive care unit, rather than the relatively stable 
dialysis population who receives treatment in the out patient setting. We want to study the 
deuterium dispersal kinetic from breath analysis following the administration of a known 
amount of deuterated water via two routes. It may be possible to estimate the volume of 
exchangeable water within the airway following mouth inhalation of vapourised deuterated 
water. We also hypothesize following central venous injection of deuterium into the right 
heart, HDO rapidly equilibrates with water in the pulmonary interstitium and alveolar 
space during the first pass pulmonary circulation. The frequent breath sampling to 
determine deuterium abundance in successive exhalation may allow the evaluation of lung 
water volume from the extrapolation of deuterium kinetic curve. Such study design also 
permits the testing of the assumption that the concentration of volatiles in breath reflects 
their alveolar concentration.   
 
1.6 Summary 
This chapter has considered the major causes of poor outcomes in patients treated for 
advanced kidney failure with dialysis from which is can be concluded that cardiovascular 
complications present the major problem. This is undoubtedly a consequence of their 
accumulated cardiovascular comorbidity but it is likely that poor management of fluid 
status remains a major concern. Management of this problem is hindered by the lack of 
well validated tools available to the clinician combined with the other complicating factors 
associated with cardiovascular comorbidity such as cardiac dysfunction, inflammation and 
hypoalbuminaemia, the latter being a particular problem in PD patients. Bioimpedance 
represents a potentially useful tool that could be augmented by other bedside methods if 
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they could be shown to work, such as isotope dilution, but these require proper clinical 
validation. 
 
1.7 Research questions  
The study is designed to address the following research questions: 
1 Does plasma albumin concentration affect the assessment of fluid status and fluid 
distribution in PD patients? How is the fluid status affected by cardiac function? 
This is investigated in Chapter 3. 
2 What is the value of bioimpedance (e.g. vector analysis) in the management of fluid 
status in PD patients? This is the primary objective of the trial presented in Chapter 
4. 
3 Does the use of bioimpedance to manage fluid status affect cardiac function? This 
is the cardiac sub-analysis of the trial in Chapter 5. 
4 Is it possible to estimate total lung water non-invasively using breath analysis of 
deuterium concentration by FAMS? Study investigating this using inhale or 
injected deuterium are described in Chapter 6 and 7 respectively. 
 
 Chapter 2 Materials and methodology  
 59 
2 Chapter 2  Materials and methodology 
2.1 Introduction 
The techniques used in this project will be described in this chapter. The measurement of 
plasma volume by dilution principle using human serum albumin labelled with radioactive 
iodine is a validated clinical technique currently available at the research site of the 
University Hospital of North Staffordshire. The Flowing Afterglow Mass Spectrometer 
(FA-MS) is a prototype built by Trans Spectra Ltd, U.K. It is a novel technique that 
enables the absolute quantification of deuterium concentration in exhaled breath and 
headspace of body fluid in real time and with minimal preparation. We collaborated with a 
local cardiologist with a special interest in echocardiography to measure various 
parameters of cardiac function described in chapter 3 and 5. The use of bioimpedance 
analysis (BIA) for the measurement of body composition is explored in this chapter.  
2.2 Plasma volume measurement by human serum albumin labelled 
with radioactive iodine (125I-HSA) 
The use of 125I-HSA to determine plasma volume has been recommended by The 
International Committee for Standardization in Haematology based on the technique's 
reliability, reproducibility and ease of operation in routine clinical use (Haematology 
1980).  
 
In this experiment a standard bolus of 10ml 0.185Mbq 125I-HSA (Schultz, Hammarsten et 
al. 1953) was injected into a large vein of the subject and a blood sample was drawn at a 
remote site at 10, 20 and 30 minute intervals. This would ensure thorough mixing within 
the systemic circulation. The isotopic concentration of each sample was measured in a 
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scintillation counter and was plotted against time on a semi-logarithmic scale. The best fit 
linear line was drawn through these points and extrapolated to time zero where the 
radioactivity at time zero could be determined (Figure 2.1). Plasma volume could be 
calculated by the equation: 
 
𝑅𝑡𝑅𝑅𝑅𝑡𝑋𝑡𝑅𝑅𝑅𝑡𝑅 𝑅𝑜 𝑠𝑡𝑡𝑡𝑅𝑡𝑠𝑅 �𝑋𝑐𝑐𝑐𝑚 � ×  𝑅𝑅𝑚𝑑𝑡𝑅𝑅𝑡 𝑅𝑜 𝑠𝑡𝑡𝑡𝑅𝑡𝑠𝑅 ×  𝑅𝑅𝑚𝑑𝑐𝑣 𝑅𝑡𝑖𝑣𝑋𝑡𝑅𝑣𝑅
𝑅𝑡𝑅𝑅𝑅𝑡𝑋𝑡𝑅𝑅𝑅𝑡𝑅 𝑅𝑜 𝑐𝑅𝑠𝑡𝑅𝑡𝑖𝑣𝑋𝑡𝑅𝑅𝑡 𝑠𝑡𝑐𝑐𝑚𝑣 (𝑋𝑐𝑐𝑐𝑚 ,𝑡𝑅𝑖𝑑𝑠t𝑣𝑅 𝑡𝑅 𝑡𝑅𝑐𝑣 𝑧𝑣𝑠𝑅)  
 
Plasma volume was further adjusted for gender and body surface area. 
Figure 2.1 Log linear plot of the radioactivity of 125I-HSA in blood sample.  
 
2.3 Flow after glow mass spectrometry (FA-MS) 
FA-MS is a new analytical approach that offers real time and on-line deuterium abundance 
measurements in water vapour in exhaled breath and headspace above aqueous liquids 
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such as blood and urine (Figure 2.2). Previous validation studies with SIFT-MS 
demonstrate that both accuracy and precision (reproducibility) are typically 1% for 
headspace sampling (Spanel and Smith 2000, Spanel and Smith 2001). Further 
improvement of precision of less than 1% can be achieved for breath deuterium analysis 
when the average value of three consecutive breath exhalations is taken.  
 
The details of the FA-MS analytical technique have been given in previous publications 
(Davies, Spanel et al. 2001, Smith and Spanel 2001). Briefly, a swarm of H3O+ precursor 
ions is generated by a microwave discharge in flowing helium carrier gas possessing a 
trace of water vapour. These precursor ions react with the H2O, HDO, H217O and H218O 
molecules in the water vapour contained in a breath sample (or the headspace of an 
aqueous liquid, e.g.serum) introduced into the helium stream resulting in the formation of 
hydrated clusters ions, H3O+(H2O)3 at a mass-to-charge ratio, m/z = 73, and their isotopic 
variant ions H8DO4+ and H917OO3+ at m/z = 74 and H918OO3+ at m/z = 75. By adopting 
the known fractional abundance of 18O in water vapour and accounting for the contribution 
of the isotopic ions H917OO3+ to the ion signal at m/z = 74, a measurement of the 74/75 ion 
signal ratio under equilibrium conditions provides the deuterium to hydrogen abundance, 
D/H, in the water vapour sample (R1vap). The corresponding deuterium abundance in the 
liquid from which the HDO is evaporating, R1liq, is derived from R1vap using a correction 
(coefficient factor of 0.935) that essentially accounts for the difference in evaporation rates 
of H2O and HDO from the liquid to the vapour phase at body temperature. 
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Figure 2.2 Schematic diagram of the FA-MS showing direct samplings of breath 
exhalation and headspace sample. 
2.3.1 Direct breath sampling 
Breath air is sampled directly into the flow tube via a heated calibrated capillary tube 
within the flow tube via a heated stainless steel tubing. The exhaled breath is delivered into 
the tube via a standard 15 mm diameter disposable cardboard mouthpiece which offers 
suitable resistance to the flow of breath such that a steady rate of exhalation can be made 
over a few seconds. The exhaled breath completely displaces the ambient air from the 
entrance of the sampling capillary and enters the coupling tubing and subsequently the 
flow tube/carrier gas (pressure of about 1 Torr). This is followed by oral inhalation where 
the entrance to the capillary is again exposed to ambient air. The flow rate is able to 
generate enough concentration of H2O molecules in the carrier gas that converts of ions 
into the H3O+(H2O)3, i.e. H9O4+ ions, at m/z 73 and its isotopomers at 74 and 75. The m/z 
74/75 ratio signals are analysed using the FA-MS data acquisition programme (SCILIB 
library, virsion 4.96, 2005, Patrik Spanel) which provide the values of the corresponding 
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deuterium abundance R1liq. A typical time profiles of the m/z=74 and 75 ions are shown in 
Figure 2.3. 
 
 
 
Figure 2.3 A typical time profile of breath exhalations directly sampled by FA-
MS. The shaded grey areas represent the alveolar breath content.  
 
 
2.3.2 Liquid headspace sampling 
Deuterium (HDO) above headspace of body fluids such as blood and urine can be readily 
and accurately determined by FA-MS. A typical 10ml of fluid sample is placed in a 200ml 
glass bottle sealed tight with aluminium cap with a rubber septum in the centre. The bottle 
is immersed in a temperature controlled water bath, typically at around 40oC and the 
headspace is allowed to develop for about 10 minutes. A 23G sampling needle attached to 
the input line of the FA-MS instrument then punctures the septum and the vapour in the 
headspace is drawn into the carrier gas. The pressure in the glass bottle decreases slowly 
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during sampling and returns to baseline once the needle is withdrawn from the bottle. The 
sampling sequence consists of the alternating analysis of fluid sample and tap water to 
ensure stability of measurement of the instrument which is typically around 156 ppm to 
164 ppm.  It is critical that the sampling lines are maintained at about 100 oC to prevent 
any condensation of water vapour. 
 
2.4 Bioimpedance analysis (BIA) 
Multifrequency BIA was determined by using the Xitron Hydra device (Model 4200; 
Xitron Technologies, San Diego, CA) in the plasma volume and albumin study in Chapter 
3. Before each measurement the performance and functionality of the device was tested 
using the electronic Verification Module (TS4201) provided by the manufacturer which 
simulate the typical ECW and ICW volume obtained in vivo of a male subject who is of 
175 cm height and 70kg weight. The measured ECW and ICW should read between 15.81-
16.18 liters and 29.39-30.74 liters respectively. Patients were required to empty the 
peritoneal space from all dialysate fluid prior to measurement. Patients were rested for 
approximately 10 mins before measurements took place according to manufacturer’s 
manual instruction. All jewellery was removed and patients with permanent pacemaker 
were excluded from the study. After the skin was clean with alcohol wipes to ensure good 
contact, adhesive pads provided by the manufacturer were placed and connected using the 
standard approach of bipolar electrodes at the dorsum of the wrist and anterior aspect of 
the ankle on the ipsilateral side of the body (Figure 2.4). An unnoticeable alternating 
current was passed through the subject’s body and the whole measurement took 
approximately 10 to 15 seconds. The resistance was measured at different frequencies at 
zero to infinite and finally demographic details such as age, height, weight and gender 
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were entered into the impedance algorithm by Xitron to generate TBW, ECW and 
percentage fat mass. 
A different BIA device (Akern BIA 101 Anniversary, Italy) was used in the multicentre 
BIA study (chapter 6). It is a single frequency (50 kHz) body composition analyser which 
measures the resistance and reactance of the body. Measurements were taken using a 
standardized protocol after patients were rested for approximately 10 mins in a supine 
position. Patients may present with or without dialysate fluid in the peritoneal cavity but 
the approach was consistent throughout the study for each individual patient. Again the 
electrodes were placed at the bony prominences of the wrist and ankle as illustrated in the 
diagram below. An alternating current passed through the body and TBW and ECW were 
determined using a formula with good agreement with the manufacturer’s algorithm. 
(Appendix 2) 
 
 
Figure 2.4 A schematic diagram showing the placement of adhesive pad and 
connection to the electrodes. 
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2.5 Echocardiography 
2.5.1 Two-dimensional and tissue doppler echocardiography 
All subjects underwent full echocardiography examination using a GE Vingmed Vivid 
Seven scanner (Horton, Norway) at rest. At least three sets of images with loops consisting 
of at least three consecutive cardiac cycles each were stored for offline analysis using a 
customized software package (EchoPac, GE). Left ventricular (LV) volume and ejection 
fraction (EF) were measured using the modified biplane Simpson’s method from the apical 
4 and 2 chamber views (Lang, Bierig et al. 2005). Left ventricular mass was calculated 
according to the Devereux formula (Devereux, Alonso et al. 1986) and indexed to body 
surface area (LVMI). Left atrial (LA) volume was calculated using the biplane area-length 
method from the apical 4 and 2 chamber views and indexed to body surface area to derive 
LA volume index (LAVI) (Lim, Ashrafian et al. 2006). The early filling (E) and atrial 
filling (A) peak velocities, E/A ratio, deceleration time (DT) of early filling and isovolumic 
relaxation time (IVRT) were measured from transmitral flow.  
 
The mitral flow propagation velocity (Vp), an index of early diastolic ventricular suction, 
was measured by the slope along the aliasing iso-velocity line in Color coded M-mode 
images of the mitral inflow as previously described (Garcia, Palac et al. 1999, Greenberg, 
Vandervoort et al. 2001). 
 
Peak mitral annular myocardial velocity of two walls of the left ventricle (septal and 
lateral) was recorded with real time pulsed wave tissue Doppler method as previously 
described (Oki, Tabata et al. 1997). The sample volume and gain were optimized, and the 
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Nyquist limit set to 15-20 cm/s. The early diastolic (E’) mitral annular velocities were 
measured and E/E’ was calculated (Nagueh, Middleton et al. 1997). 
 
Color M-mode Doppler was obtained by positioning the scan line through the mitral valve 
with the Nyquist limit and the color baseline adjusted to obtain the best spatial resolution. 
Color coded tissue Doppler images were acquired over three consecutive cardiac cycles for 
four myocardial walls (septal, lateral, inferior and anterior) by placing a 4×4 mm region of 
interest in the midmyocardial area of each wall. Systolic (Sm) and diastolic (Em and Am) 
myocardial velocities were measured and analyzed offline as previously described (Wang, 
Yip et al. 2003, Wang, Yip et al. 2005). Values of all four walls were averaged. 
 
2.5.2 Derived parameters   
Stroke volume was calculated by using the aortic valve pulsed wave Doppler method 
whereby the velocity time integral of aortic annular flow was obtained by tracing the 
pulsed Doppler profile and multiplied by the area of the aortic annulus as previously 
described (Sun, Pu et al. 1997). Chamber stiffness was calculated by using the following 
equation: 70/(Deceleration time-20ms)2 (Little, Ohno et al. 1995). 
 
2.5.3 Speckle tracking 
Left ventricular longitudinal strain, and basal and apical rotation were assessed using the 
speckle tracking method (Helle-Valle, Crosby et al. 2005, Becker, Hoffmann et al. 2006). 
Offline analysis of apical 4 and 2 chamber images, and short axis images at two levels 
(basal and apical) were completed by tracing the endocardium in end-diastole and the 
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thickness of the region of interest adjusted to include the entire myocardium. The software 
automatically tracks the myocardial motion on the subsequent frame and results were 
displayed graphically.  
 
For global longitudinal strain data of three cycles of all six segments of 4 chamber (basal 
septal, mid septal, apical septal, apical lateral, mid lateral, basal lateral) and 2 chamber 
pictures (basal inferior, mid inferior, apical inferior, apical anterior, mid anterior, basal 
anterior) were averaged. 
 
Apical rotation was calculated by averaging all six segments (septal, antero septal, anterior, 
lateral, inferior, posterior) of three cycles of the apical short axis view. Basal rotation was 
assessed by doing the same at the basal level of the short axis view. All segments were 
exported via customized software (XlXtrFun) into an Excel (Version 2003) spread sheet 
that automatically interpolated all cycles regarding to cycle length and R-waves. The 
software calculated twist (Apical rotation – basal rotation) and peak untwist rate (early 
diastolic peak of the first derivative of twist over time) (Excel spread sheet developed by 
A.N. Borg and S.G. Ray, University of Manchester) (Borg, Harrison et al. 2008). 
 
2.6 Deuterium Oxide (D2O) 
2.6.1 Oral ingestion of D2O 
D2O is a stable hydrogen isotope of water present naturally in tap water. The sterile D2O 
of 99.8% purity used in this project was procured from CK Gas limited (Cambridge 
Isotope Laboratory, Massachusetts, United States). It was subsequently divided into 
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smaller vials to the standard of water for oral ingestion at the sterile fluids manufacturing 
units of University Hospital of Birmingham.  
The preparation of D2O for the determination of TBW by FA-MS in Chapter 3 was 
performed on the day of the study. The dose of D2O used was 0.34g/kg and it was weighed 
to the nearest 0.01g using a calibrated digital scale at the research laboratory. After the 
study participants consumed the D2O, equal amount of tap water was used to rinse out the 
container to ensure thorough ingestion of the measured dose of D2O. A typical volume of 
D2O dose according to the body weight of the study participants can be seen in Table 2.1. 
 
Total body water can be calculated from the average of D/H (or R1liq) at equilibration and 
pre deuterium ingestion using the formula: 
     
Volume of D2O=0.34g per kg body weight 
∆(D/H) = average of equilibrated R1liq post ingestion of D2O – average of R1liq pre-
ingestion of D2O.   
The TBW value was then adjusted by 4% to account for non-aqueous exchange of 
hydrogen with body protein. 
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Table 2.1 Volume of D2O dose based on body weight 
 
 
Weight of Patients (kg) Dose of D2O (mls) 
40 to 45  15 
46 to 55 20 
56 to 70 25 
71 to 88 30 
89 to 99 35 
99 to 115 40 
> 116 45 
2.6.2 Intravenous injection of D2O 
D2O of the highest purity (99.9%) was sourced from CK Gas Limited for the investigation 
of lung water measurement by FA-MS analysis of deuterium abundance in exhaled breath 
following intravenous injection of 10% dilution of D2O in Chapter 7 . The neat sample of 
99.9% purity was contained in 100ml sterile bottles which underwent rigorous chemical 
and microbiological testing by the manufacturer (see Appendix 7) prior to arrival in the 
UK. A local NHS facility (Stockport Pharmaceutical, Pharmacy Department, Stepping Hill 
Hospital, Stockport, UK) was contracted to further verify its chemical composition and 
microbiological safety against the European Phamacopoeia 6.3 monographs for Water For 
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Injections (WFI) ((COE) 2008). The sample was then diluted with sterile water to make 
10% D2O mixture and aliquoted into 10ml vials before sterilisation. 
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3 Chapter 3  Fluid distribution in PD patients: associations 
with serum albumin and cardiac function.  
 
3.1 Introduction 
Achieving euvolaemia is difficult in significant proportion of PD patients according to 
evidence from many studies. Previous observational studies have showed a relationship 
between low salt and water removal and poor survival, independent of residual renal 
function (Brown, Davies et al. 2003, Paniagua, Amato et al. 2008). It is not clear, however, 
if this relationship is causal, with tissue overhydration or expanded plasma volume (PV) 
accelerating organ dysfunction or inability to optimise fluid status due to cardiac 
dysfunction, inflammation or malnutrition (Avila-Diaz, Ventura et al. 2006, Davies, Brown 
et al. 2006, Davies, Garcia Lopez et al. 2008). Individual variability in peritoneal 
membrane function may contribute to this problem but there is evidence to demonstrate 
poor ultrafiltration with high solute transport can be overcome using automated PD and 
icodextrin (Yang, Fang et al. 2008, Perl, Huckvale et al. 2009). This pertinent issue 
deserves careful consideration given the high cardiovascular morbidity and mortality in 
this patient population. 
 
Bioimpedance analysis (BIA) has been widely employed in the study of body composition 
of dialysis patients and its data suggests that a significant proportion of PD patients are 
volume expanded (Plum, Schoenicke et al. 2001). The often elevated ECW/TBW ratio is 
extrapolated from the measured resistance and reactance using algorithms that assumes 
fixed tissue hydration which is not applicable for dialysis patients with deranged fluid 
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status. Moreover, BIA fails to distinguish between intravascular and interstitial ECW 
excess. This is especially relevant for PD patients whose serum albumin is often depressed 
from peritoneal loss or inflammation and the reduced intravascular oncotic pressure may 
predispose patients to fluid mal-distribution.  
 
Structural and functional cardiac abnormalities are common and well described in dialysis 
population and LVH and heart failure have been showed to predict morbidity and mortality 
(Foley, Parfrey et al. 1995). Patients with evidence of volume expansion have more severe 
cardiac dysfunction which conferred worst prognosis. Heart failure with normal ejection 
fraction (HFNEF), previously known as diastolic heart failure, accounts for up to 80% of 
symptomatic heart failure PD patients and is associated with volume overload (Wang, 
Sanderson et al. 2003)(see Appendix 1 for HFNEF diagnostic criteria). Markers of cardiac 
damage and overhydration such as troponin T and cardiac natriuretic peptides have been 
shown to predict cardiovascular congestion and mortality (Zoccali, Mallamaci et al. 2001, 
Wang, Lam et al. 2006, Wang, Lam et al. 2007). Compared to HD, PD patients had higher 
plasma atrial natriuretic factor (ANF) and left atrial volume with more severe LVH, 
suggesting that elevated central venous filling contributing to overall volume expansion 
(Enia, Mallamaci et al. 2001). However, plasma volume was not measured in that study. 
There is a need to clarify the relationship between cardiac abnormalities with regards to 
different fluid compartments and whether PD patients are truly intravascularly expanded.  
 
3.2 Aims of the study 
1. To demonstrate that abnormal body composition observed in hypoalbuminaemic 
patients is associated with tissue overhydration. 
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2. To test the hypothesis that this measured tissue overhydration is not associated with a 
proportional increase in plasma volume. 
3. To show that PD patients have more abnormal cardiac morphology with reduced systolic 
and diastolic function compared to age matched healthy controls. 
4. To determine whether abnormal cardiac morphology is associated with increased 
intravascular rather than extravascular volume and whether PD patients with symptomatic 
heart failure with normal ejection fraction (HFNEF) have higher intravascular volume.  
 
3.3 Subjects and study designs 
This was a cross-sectional study of prevalent PD patients treated in a single centre with a 
standard clinical approach to fluid management. They include appropriate dietary advice 
(e.g. salt and fluid restriction), the use of diuretics to maintain urine output and use of 
automated PD and icodextrin to optimise fluid removal and prevent overhydration due to 
dialysate reabsorption.  
 
Membrane function and dialysis adequacy are measured at least every 6 months as part of 
routine clinical assessment. Comorbidity is evaluated using the externally validated 
Stoke/Davies score (Davies, Phillips et al. 2002, Van Manen, Korevaar et al. 2003), 
comprises seven domains (noncutaneous malignancy, ischaemic heart disease, left 
ventricular dysfunction, diabetes, systemic collagen vascular disorder, peripheral vascular 
disease, other life threatening illness).  
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Patients were approached to participate in the study while attending routine clinical review. 
There were no exclusion criteria for the main study to evaluate the effect of 
hypoalbuminaemia on fluid status, providing subjects were willing to comply with the 
study measurements which include BIA, measurement of TBW using D dilution (TBWD) 
and PV using human serum albumin labelled with radioactive iodine (125I-HSA). Out of the 
46 recruited patients, 31 patients had echocardiographic measurements and were enrolled 
in the cardiac sub-analysis study. They were compared with 20 healthy controls with 
similar age chosen from another echo study. Patients with congenital or valvular heart 
disease, pacemakers or implantable cardiac defibrillators, significant lung disease or 
anaemia were excluded from this study. The study was peer reviewed and approved by 
local ethics committee and all patients gave their signed consent.  
 
3.4 Materials and methodology 
BIA was determined using the multifrequency Xitron Hydra device (Model 4200; Xitron 
Technologies, San Diego, CA) using the standard approach as described in Chapter 2. 
Patients were rested for 10 mins before the measurement without any dialysate fluid in the 
abdomen. TBWBIA, ECW and percentage fat mass were measured and compared with the 
normal predicted values as determined by Lindley et al for a healthy European population, 
adjusted for gender, weight and height (Lindley, Devine et al. 2005) and for ECW adjusted 
for weight and gender determined in HD patients (Chamney, Kramer et al. 2002). PV was 
determined according to the dilution principle using 125I-HAS.  
 
Using deuterium dilution principle, TBWD was measured by firstly obtaining a baseline 
blood sample followed by the ingestion of pre-specified dose (15ml to 45ml according to 
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body weight) of 99.8% deuterium oxide (see Chapter 2). After four hours an equilibrated 
blood deuterium was taken and the difference in D concentration in the blood headspace 
between the two samples was measured using FA-MS. TBWD was determined after 
accounting for deuterium exchange with H in body proteins.  
 
Routine blood measurements were made with a Beckman auto-analyzer. Plasma albumin 
was estimated using the Bromocreosol Purple colorimetric method, (normal range 35 to 50 
g/L) and C-reactive protein (CRP) using latex enhanced immunoturbidimetric method. 
Dialysate and urinary sodium were determined using the indirect electrode method.  
 
Echocardiographic measurements such as left ventricular mass index (LVMI), left atrial 
volume index (LAVI), E/A ratio and E/E' ratio were determined as described in chapter 2.  
 
3.5 Statistics 
This is the proposed null hypothesis: The excess ECW associated with low plasma albumin 
is equally distributed between intravascular and extravacular spaces. The expected fluid 
excess associated with a plasma albumin below the median value is approximately 3L and 
that 20% of this  (about 0.6L) should be intravascular if distributed proportionally, then to 
detect a significant difference (P<0.05) with 90% power, assuming a standard deviation 
(SD) for plasma volume of 0.7L, 20 patients are required in each group.  
 
In secondary analysis, a pre-specified univariate and multivariate linear regression analysis 
was undertaken treating the dependent variables (tissue overhydration and plasma volume) 
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and potential explanatory clinical measures (e.g. Plasma albumin, BP, comorbidity score, 
membrane transport status, fluid and sodium removal, log-transformed high-sensitivity 
CRP) as continuous covariates. If the bivariate correlation was significant related to either 
the dependent variable or one of the plausible explanatory clinical measures the covariate 
would be included in the multivariate model.  
 
All data are expressed as means (SD) if the distribution was parametric. Non-parametric 
data are displayed as medians (interquartile range; IQR). Comparisons between patients 
were made by unpaired t test. Pearson correlation was used to study the relationship 
between two variables. P value of <0.05 was considered significant.  
 
3.6 Results 
3.6.1 Body composition analysis 
46 PD patients (20 female) were recruited and therefore the study was adequately powered 
to detect the differences in the primary endpoints. The patient demography and body 
composition characteristics of the whole study are described in Table 3.1. 
 
The measured ECW/TBW ratio of the patients in this study was significantly elevated 
compared to the normal predicted values (0.48 vs 0.45, P=0.001), indicating the 
possibilities of tissue overhydration, muscle wasting, or both. The measured TBWD and 
the estimated TBWBIA were tightly correlated but significantly different from each other 
such that the measured TBWD was significantly higher, +2.02L, (95%CI: 0.96 to 3.07L, 
P=0.001). The almost identical relationship for the BIA data are due to the assumption of 
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fixed tissue hydration in all patients, whereas the TBW measured by deuterium dilution 
indicates variable hydration status. Most patients show evidence of overhydration. This 
difference, expressed as comparative plots of TBWD and TBWBIA both normalised to body 
weight as this relates to BIA estimated body fat mass, is demonstrated in Figure 3.1. The 
two measures of excess tissue hydration, i.e. the difference between measured and 
estimated ECW/TBW using BIA and the difference between the estimated and measured 
TBW by BIA and D dilution were also correlated with each other (r=0.48, P=0.002), see 
Figure 3.2. The latter also inversely correlated with plasma albumin (Figure 3.4). 
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Table 3.1 Patient demography and comparison by plasma albumin category 
(primary endpoint). 
 All Patients 
(mean/% SD) 
Plasma 
albumin   
<31.4 
g/dL 
Plasma 
albumin 
>31.4 
g/dL 
95% CI of 
difference 
P value 
(unpaired 
t test) 
N 46 20 26   
Gender split (M:F) 26:20 8:12 18:8 N/A 0.049 
Age (years) 59.4 17.8 63.1 56.4 -17.3 to 
4.0 
NS 
BMI (Kg/m2) 26.5 4.9 26.0 26.8 -2.1 to 3.8 NS 
BSA (m2) 1.81 0.23 1.71 1.88 0.04 to 0.3 0.021 
TBWD (L) 36.5 7.13 35.6 37.9 -2.2 to 6.8 NS 
ICWBIA (L) 18.1 4.8 16.3 19.4 0.36 to 5.6 0.028 
ECWBIA (L) 16.6 3.5 15.7 17.1 -0.66 to 
3.5 
NS 
Difference between measured 
TBWD and estimated 
TBWBIA (L) 
2.02 3.25 3.55 0.94 0.61 to 4.6 0.012 
Difference between measured 
and predicted ECW/TBW 
ratio (20) 
0.029 0.035 0.036 0.023 -0.03 to 
0.008 
NS 
Measured ECW/TBW ratio 0.48 0.04 0.495 0.472 -0.001 to       
-0.05 
0.036 
Difference between measured 
and predicted ECW (L/kg) 
(21) 
0.0048 0.029 -0.003 
 
+0.018 -0.0035 to      
-0.0007 
0.042 
Plasma Volume (ml) 2703 662 2551 2820 -124 to 
661 
NS 
Corrected plasma volume 
(ml/m2) 
1474 254 1463 1482 -135 to 
173 
NS 
Plasma Volume (% different 
from predicted) 
-2.3 16 -0.94 -3.4 -12.2 to 
7.2 
NS 
Corrected blood volume 
(ml/m2) 
2124 342 2070 2165 -110 to 
300 
NS 
hsCRP, mean g/l,  
(Log CRP) 
13.2 
0.84 
22.9 
0.5 
22.3 
(1.05) 
6.2 
(0.69) 
 
-0.64 to -
0.085 
 
0.01 
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 All Patients 
(mean/% SD) 
Plasma 
albumin   
<31.4 
g/dL 
Plasma 
albumin 
>31.4 
g/dL 
95% CI of 
difference 
P value 
(unpaired 
t test) 
Haemoglobin (g/dl) 11.7 1.34 11.1 12.3 0.52 to 
1.96 
0.001 
Solute transport (4 hour 
dialysate:plasma creatinine) 
0.82 0.15 0.84 0.73 -0.18 to  
-0.025 
0.011 
Peritoneal UF Capacity (ml) 426 194 408 440 -85 to 149 0.011 
Proportion using icodextrin 63% - 60% 65% - NS 
Plasma sodium (mmol/l) 137.1 3.4 137 137.2 -1.8 to 2.2 NS 
Comorbidity Score 1.00 1 1.15 1.00 -0.77 to 
0.47 
NS 
Diabetic (%) 28% - 25% 31% - NS 
Systolic Heart failure (%) 6.5% - 10% 3.8% - NS 
Ejection Fraction (%) 56.4 8.8 56.42 56.44 -7 to 7 NS 
Systolic Blood Pressure 
(mmHg) 
137.9 20 137.6 138.1 -11 to 12.6 NS 
Diastolic Blood Pressure 
(mmHg) 
78.8 13.4 75.1 81.8 -1.1 to 
14.6 
NS 
Peritoneal Kt/V (weekly) 1.51 0.39 1.68 1.38 -52 to  -0.7 NS 
Residual Renal Kt/V 
(weekly) 
0.88 0.79 0.71 1.00 -0.18 to 
0.7 
0.018 
Peritoneal sodium loss 
(mmol/day) 
43.2 59.2 52.2 36.4 -51.4 to 
19.7 
NS 
Renal sodium loss 
(mmol/day) 
51.9 44.4 37.2 63.2 0.20 to 
51.7 
NS 
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Figure 3.1 The relationship between TBW corrected for body weight determined 
from BIA (■) and deuterium dilution (□) and the proportion of body fat 
determined from BIA.  
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Figure 3.2 The two measures of overhydration are correlated, (r=0.48, P=0.002).  
 
However, it was quite different for plasma volume measurement which is an indicator of 
intravascular volume. The measured PV was very similar to the predicted values, with a 
mean difference between measured and predicted of -51.3 ml (95% CI -180 to 78 ml, 
P=0.428). The standard deviation of PV was about twice that predicted indicating greater 
variability than expected for the normal population (Figure 3.3). 
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Figure 3.3 Relationship between measured and predicted plasma volume.  
 
In order to test the primary endpoint the patients were dichotomised into those with plasma 
albumin above or below the median value (31.4 g/L). Participants with albumin below the 
median were more likely to be women, have a lower haemoglobin and with evidence of 
tissue overhydration and inflammation, and increased solute transport. However, the 
absolute and corrected plasma volumes were not different compared to subjects with no 
hypoalbuminaemia (see Table 3.1).  
 
The impact on haematocrit due to the difference in haemoglobin was examined by 
estimating the blood volume using several different published equations corrected for body 
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surface area. The derived measures were not found to be significantly different between the 
two groups.  
 
The summaries of the bivariate correlations for the whole study group are shown in Table 
3.2. Corrected plasma volume was found to have no correlations and therefore multivariate 
analysis was not performed. A number of associations with excess tissue hydration were 
found in this analysis including inverse relationship with peritoneal sodium loss, plasma 
albumin and sodium, positive correlations with solute transport, peritoneal sodium loss and 
the use of Icodextrin. Plasma albumin was inversely related to inflammation as measured 
by CRP. Using the difference between estimated and measured TBW (TBWD-TBWBIA) as 
the dependent variable, plasma albumin was shown to have a negative association and it 
was the only relationship found to be significant in the multivariate analysis of clinical 
measures associated with tissue overhydration (ANOVA P=0.011), see Table 3.3. 
Replacing the ECW/TBWBIA or the difference between measured and estimated ratio as 
the dependent variable yielded similar result. No association was found between BP and 
measurements of body composition and fluid status or other clinical covariates except the 
negative correlations between diastolic BP and both age and comorbidity. Dialysate and 
urinary sodium losses were closely coupled to peritoneal ultrafiltration and urine output, 
respectively. The incorporation of these variables in the multivariate model made no 
difference in the outcome of the analysis.  
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Table 3.2 Univariate correlation matrix 
 Plasma 
albumin 
High 
sensitivity 
CRP 
Comorbidity 
Score 
Solute 
transport 
UF 
Capacity 
Dialysate 
sodium 
losses 
Urinary 
sodium 
losses 
Using 
Icodextrin 
Plasma sodium Corrected plasma 
volume 
TBWD – TBW BIA  -0.408 
P=0.011 
0.053 
P=0.747 
0.139 P=0.399 0.386 
P=0.015 
-0.32    
P=0.048 
0.323 
P=0.045 
-0.334 
P=0.038 
0.414 
P=0.009 
-0.393 P=0.013 0.089 P=0.588 
Plasma albumin  -0.57 
P<0.001 
-0.139 
P=0.399 
-0.2 
P=0.187 
0.19  
P=0.21 
-0.077 
P=0.615 
0.28 
P=0.059 
0.092 
P=0.55 
0.021 P=0.89 -0.074 P=0.62 
High sensitivity 
CRP 
  0.28   P=0.061 -0.016 
P=0.92 
-0.019 
P=0.91 
0.062 
P=0.68 
-0.02   
P=0.9 
-0.16 
P=0.29 
-0.125 P=0.41 0.19       P=0.2 
Comorbidity Score    -0.068 
P=0.66 
-0.15 
P=0.32 
0.214 
P=0.154 
-0.27 
P=0.06 
0.136 
P=0.37 
-0.3 P=0.049 -0.215   P=0.152 
Solute transport     -0.46 
P=0.001 
0.37   
P=0.01 
-0.39 
P=0.008 
0.53 
P<0.001 
-0.2 P=0.183 -0.098 P=0.52 
UF Capacity      -0.19 
P=0.19 
0.232 
P=0.12 
-0.48 
P=0.001 
0.41 P=0.004 0.06    P=0.69 
Dialysate sodium 
losses 
      -0.37 
P=0.011 
0.46 
P=0.001 
-0.224 P=0.134 0.156  P=0.29 
Urinary sodium 
losses 
       0.27  
P=0.07 
0.22 P=0.145 0.17    P=0.25 
Using Icodextrin         -0.45 P=0.002 -0.058 P=0.70 
Plasma sodium           0.079  P=0.60 
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Figure 3.4 Relationship between excess fluid, as determined by the difference 
between measured and estimated body water, and plasma albumin (R=-0.40, 
P=0.011).  
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Table 3.3 Multivariate analysis of clinical measures associated with overhydraion 
using the difference between estimated and measured TBW as the dependent 
variable. 
 
Covariate  Standard 
Error 
Standardised β  t  Significance  
Constant  22.1  1.76  0.089  
Plasma albumin (g/l) 0.12 -0.56  -3.04  0.005  
hsCRP  mg/l 0.025 -0.31  -1.65  0.109  
Solute transport   4.1 0.09  0.50  0.62  
Comorbid Score  0.51 0.096  0.60  0.55  
Use of Icodextrin  1.2 0.225  1.21  0.24  
Plasma sodium  0.15 -0.211  -1.32  0.197  
Dialysate sodium loss  0.009 0.125  0.79  0.43  
Urine sodium loss  0.012 0.049  0.29  0.77  
Model Summary: r=0.67, ANOVA P=0.011. 
 
3.6.2 Cardiac analysis 
3.6.2.1 PD patients verses healthy controls 
A total of 31 PD patients were included in the cardiac subgroup analysis. 20 healthy 
participants from another echo study matched for age and gender were used as controls. 
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The patients and controls demographic and clinical characteristics are summerised in Table 
3.4.  
Table 3.4 Demographic and clinical characteristics of patient and healthy control  
 Patients (n=31) Control (n=20) p-value 
Age (years) 60±16 63±5 0.346 
Gender (female/male) 14/ 17 11/ 9 0.572 
BMI (kg/m2) 26.2±4.1 24.3±3.8 0.118 
NYHA  I: 3 
II: 21 
III: 7 
N/A  
Heart rate (bpm) 72±14 71±10 0.631 
Systolic blood pressure (mmHg) 140±21 139±12 0.952 
Diastolic blood pressure (mmHg) 81±14 80±8 0.726 
Hypertension 31/31 (100%) 0  
Years of hypertension  10.7±8.7 0  
Diabetes 8/31 (26%) 0  
Coronary artery disease 6/31 (19%) 0  
Atrial fibrillation 2/31 (6%) 0  
Duration of peritoneal dialysis 
(months) 
25.9±18.0 
 
0 
 
 
GFR (ml/min/m2) 8.93±5.32 78.67±12.77 <0.001 
BNP (pg/ml) 96.8±99.4 /  
Corrected plasma volume 
(ml/m2) 
1480±246 /  
BMI, body mass index; NYHA, New York Heart Association classification for heart 
failure; BNP, Brain natriuretic Peptide 
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The mean age and gender distribution between patients and controls were similar (60±16 
years, 45% female versus 63±5, 55% female). The medical history and antihypertensive 
medication were summarised in Table 3.5. 28 PD patients had symptoms of heart failure 
with breathlessness on exertion consistent with New York Heart Association (NYHA) 
class II or III. They also had normal left ventricular ejection fraction (LVEF) and left 
ventricular dimension. 2 patients had echocardiographic evidence of systolic heart failure 
with reduced LVEF of 44% and 29%. 20 patients had evidence of left ventricular 
hypertrophy (5 mild, 2 moderate and 13 severe) according to the criteria of the American 
society of Echocardiography (Lang, Bierig et al. 2005). Compared to the healthy controls, 
PD patients had significantly higher LVMI, LAVI, diastolic interventricular thickness and 
E/E' ratio (115.0±31.2 vs 77.5±22.7 g/m2, P<0.001; 32.0±12.5 vs 24.5±8.1 ml/m2, P=0.02; 
1.2±0.3 vs 0.9±0.2 cm, P=0.002; 10.0±3.3 vs 7.9±2.1, P=0.01 respectively) (Table 3.6). 
  90 
 
Table 3.5 Antihypertensive medication taken by PD patients.  
Class of medication Patients 
ACE-Inhibitor 13 (42%) 
AT1-Blocker 6 (19%) 
β-Blocker 10(32%) 
Calcium-Channel-Blocker 12 (39%) 
Furosemide 19 (61%) 
α-Blocker 12 (39%) 
ACE-Inhibitor, Angiotensin Converting Enzyme Inhibitor; AT1 Blocker, Angiotensin 1 
Blocker; Calcium Channel Blocker, Calcium Channel Blocker; α-Blocker, alpha Channel 
Blocker 
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Table 3.6 Standard Echo of PD patients and healthy controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LVEDDI, left ventricular end-diastolic diameter indexed to body surface area; LVEDVI, 
left ventricular end diastolic volume indexed to body surface area; Biplane LVEF, left 
ventricular ejection fraction; FS, fractional shortening; IVSd, diastolic interventricular 
septal thickness; LVMI, left ventricular mass index; LAVI, left atrial volume index; E-
Wave, early mitral diastolic inflow velocity; A-Wave, late mitral diastolic inflow velocity; 
E/A, ratio of early to late mitral inflow velocities; DT, deceleration time of peak early 
Doppler mitral filling velocity; IVRT, isovolumic relaxation time; E/E’, ratio of early 
mitral diastolic inflow velocity to early diastolic mitral annular velocity. 
 Patients (n=31) Controls (n=20) p-value 
LVEDDI (cm/m2) 2.7±0.5 2.7±0.3 0.769 
LVEDVI (ml/m2) 46.6±15.0 43.1±13.2 0.412 
Biplane LVEF (%) 57±9 61±7 0.111 
FS (%) 37±9 40±7 0.160 
IVSd (cm) 1.2±0.3 0.9±0.2 0.002 
LVMI (g/m2) 115.0±31.2 77.5±22.7 <0.001 
LA M-Mode (cm) 4.0±0.72 3.3±0.44 0.002 
LAVI (ml/m2) 32.0±12.5 24.5±8.1 0.023 
E-Wave (cm/s) 0.67±0.22 0.58±0.10 0.110 
A-Wave (cm/s) 0.82±0.17 0.70±0.13 0.009 
E/A 0.82±0.3 0.86±0.2 0.597 
DT (ms) 237.8±66.8 256.3±50.5 0.296 
IVRT (ms) 98.7±23.7 95.1±20.0 0.581 
Chamber Stiffness 
(1/ms2) 
2.02±1.59 1.43±0.7 0.125 
E/E’ 10.0±3.3 7.9±2.1 0.017 
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PD patients had significantly reduced mitral annular velocity both in systole (Sm)(5.0±1.2 
vs 5.8±0.9 cm/s, P<0.05) and diastole (Em and Am)(4.3±1.6 vs 5.4±0.9 cm/s, P=0.017; 
6.5±1.4 vs 8.1±1.6, P=0.002 respectively). In 2D speckle tracking imaging, global 
longitudinal strain (-18.3±3.0 vs -21.3±3.3, P=0.003) and rotation of both apical and basal 
levels of the left ventricular during systole (apical rotation 9.8±3.7 vs 12.2±3.1, P=0.03; 
basal rotation -7.0±4.2 vs -10.2±3.5, P=0.03) were significantly impaired indicating severe 
reduction in global systolic and diastolic function in patients (Table 3.7).  
Table 3.7 Tissue doppler and speckle tracking derived parameters between 
patients and controls. 
 Patients (n=31) Controls (n=20) p-value 
Stroke Volume (ml) 68±19 60±12 0.119 
Cardiac output (l/min) 4.8±1.6 4.2±1.1 0.157 
Peak LVOT velocity (m/s) 1.01±0.2 0.94±0.16 0.184 
Sm (cm/s) 5.0±1.2 5.8±0.9 0.041 
Em(cm/s) 4.3±1.6 5.4±0.9 0.017 
Am(cm/s) 6.5±1.4 8.1±1.6 0.002 
Global Long Strain (%) -18.3±3.0 -21.3±3.3 0.003 
Apical Rotation ( º ) 9.8±3.7 12.2±3.1 0.033 
Basal Rotation ( º ) -7.0±4.2 -10.2±3.5 0.034 
Torsion (º/cm) 2.4±0.9 3.2±0.5 0.01 
Mitral Flow propagation 
velocity (m/s) 
36.3±10.7 38.2±6.9 0.480 
Peak LVOT velocity, peak blood flow velocity in the left ventricular out flow tract; Sm, 
systolic mitral annular myocardial tissue velocity by colour TDI; Em, early mitral annular 
myocardial tissue velocity by colour TDI; Am, late mitral annular myocardial tissue 
velocity by colour TDI 
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3.6.2.2 Relationship between cardiac morphology and fluid status in PD patients with 
and without Heart failure with normal ejection fraction (HFNEF) 
We explored the relationship between cardiac morphology and dimension with regards to 
fluid compartments in PD patients. The baseline characteristics of the 31 PD patients were 
summerised in Table 3.8. In this subgroup analysis LVMI and LAVI correlated with 
corrected plasma volume (PVc) (r=0.487, P=0.01; r=0.446, P=0.01 respectively. See 
Figure 3.5 and Figure 3.6) but no correlation was found with other measurements of 
extracellular volume such a ECW/TBW, ECW/Height or the difference in TBW 
determined by D dilution and BIA predicted (Figure 3.7). LAVI also correlated with BNP 
(r=0.644, P<0.01)(see Figure 3.8). BNP, mean BP, E/E' and E/A showed no correlation 
with PVc. 17 of the 31 PD patients were found to fulfill the criteria for the diagnosis of 
HFNEF and they had significantly higher PVc compared to patients without HFNEF 
(1601±320.8 ml/m2 vs 1381±225.3 ml/m2, P<0.05) (Table 3.9 and Figure 3.9).  
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Table 3.8 Patient demographic and clinical characteristics. 
Males:Females 17 (55%):14 (45%) 
Age (years) 60.8±16.7 
BMI (kg/m2) 27.6±6.0 
Diabetes 26% 
Albumin (g/L) 31.4±4.0 
C-Reactive Protein (mg/L) 11.8±23.4 
PD duration (month) 24.8±19.5 
CAPD:APD 11:20 
Systolic BP (mmHg) 137.0±19.7 
Diastolic BP (mmHg) 79.2±14.4 
Urine volume (ml) 939.4±698.7 
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Figure 3.5 LVMI correlates with plasma volume. 
 
 
 
Figure 3.6 LAVI correlates with plasma volume. 
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Figure 3.7 No relationship between ECW/TBW ratio determined by BIA and 
echographic parameters such as LVMI and LAVI. 
 
 
Figure 3.8 LAVI correlates with serum BNP 
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Table 3.9 Body composition and echocardiographic measurements of PD patients 
with and without HFNEF (* P<0.05) 
 No HFNEF 
(n= 14) 
HFNEF 
(n=17) 
ECF/TBW  0.48±0.04 0.48±0.03 
Corrected Plasma Volume (ml/m2) 1381±225.3* 1601±320.8 
Plasma albumin (g/l) 31.3±3.1 32.7±3.5 
ECF/height (L/m) 9.84±1.5 10.45±1.9 
CRP (mg/l) 10.6±10.7 4.1±4.7 
Age (years) 59.2±17.5 60.7±17.5 
BMI (kg/m2) 26.1±5.0 26.9±3.3 
Systolic BP (mmHg) 141.7±19.1 142.2±13.7 
Diastolic BP (mmHg) 82.5±15.6 79.9±13.5 
LVEF (%) 55.2±10.6 58.0±7.0 
LVMI (g/m2) 102.2±34.1 113.1±33.5 
LAVI (ml/m2) 27.2±9.6 27.8±11.1 
E/A 0.8±0.3 0.7±0.1 
E/E 8.7±1.6 10.4±3.6 
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Figure 3.9 HFNEF PD patients have significantly higher corrected PV (1601 
ml/m2±320.8) than non-HFNEF (1381 ml/m2±225.3); P<0.05 
 
3.7 Discussion 
This study is consistent with previous reports that ECW/TBW ratio is associated with low 
plasma albumin and inflammation and this is relationship is found to be associated with 
measurable fluid excess in PD patients. In support of the study hypothesis the excess fluid 
is not distributed equally in the intravascular compartment and it is therefore reasonable to 
conclude it is predominantly found in the extravascular space. It is thought the reduced 
oncotic pressure secondary to hypoalbuminaemia leads to underfilling of plasma and this is 
supported by the multivariate analysis that plasma albumin becomes the only factor 
determining the hydration status in PD, overriding other clinical measures of 
overhydration. Plasma albumin has been demonstrated to be associated with inflammation 
but in the context of peritoneal dialysis it is also affected by peritoneal protein loss 
(Kaysen, Yeun et al. 1997). This has clinical implications as any attempts to normalise 
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fluid status in hypoalbuminaemic PD patients may lead to central volume depletion and 
loss of residual renal function.  
 
This is the first study to measure plasma volume using 125I-HAS dilution technique and 
hydration status simultaneously in PD patients. Koning et al previously measured similar 
parameters by extrapolating the disappearance rate of Dextran 70 and found slightly higher 
plasma volume of 3200ml compared to the study (2700ml) (Konings, Kooman et al. 2002) 
probably reflecting difference in techniques and gender split (75% male compared with 
56% in this study) hence body sizes between the two groups of participants. The values 
were more similar once corrected for body surface area (1684 verses 1474ml). However 
the discrepancy in PV could be real, indicating overhydration could be more common in 
Konings group since the study was conducted before the use of Icodextrin and 1.36% 
glucose dialysate bag was routinely used for long dwell (Konings, Kooman et al. 2002).  
 
One of the advantages of using 125I-HAS to measure PV, previously not possible with 
Dextran 70 technique, is its use in patients using Icodextrin, thus providing the first 
reported PV measurement in PD patients using this dialysis solution. It was unclear 
whether patients using Icodextrin may experience excessive intravascular depletion leading 
to early loss of residual renal function or relatively preserve it by a given fall in ECW by 
ameliorating a precipitant fall in PV.  Its use was associated with overhydration on 
univariate analysis but not to PV, gender split or any other clinical measures. This 
relationship, however, disappeared on multivariate analysis, underlying the complex 
relationship between peritoneal solute transport, ultrafiltration, plasma albumin, isotonic 
hyponatraemia and residual and peritoneal sodium losses in PD patients. The opposite 
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relationship between overhydration and urinary verses peritoneal sodium losses is 
intriguing. One possible explanation is better fluid status is maintained with preserved 
renal function which enables adequate salt and fluid removal whereas Icondextrin was 
selectively used in patients with higher transport status associated with reduced 
ultrafiltration and sodium removal (Konings, Kooman et al. 2002). The end result is that 
solute transport is not independently associated with overhydration. The correlation 
between low plasma albumin and urinary but not dialysate sodium removal and these 
patients lose less urinary sodium for a given residual renal clearance could be due to 
activation of renin-aldosterone system in the context of hypoalbuminaemia.  
 
The inverse relationship between plasma albumin and abnormal body composition as 
measured by BIA has been shown in previous studies (Jones, Smye et al. 1998, Jones, 
Akbani et al. 2002, Avila-Diaz, Ventura et al. 2006). The elevated ratio of ECW/TBW is 
frequently thought to be a measure of tissue overhydration despite the fact that both raised 
ECW or decreased TBW, for instance in muscle wasting could be responsible. A different 
approach was used in this study by examining the relationship between hydration status 
and the difference between measured TBWD and estimated with BIA. In the Chamney 
model the tissue hydration index is constant and independent of body size and fat and any 
measured extra fluid above this constant is considered a marker of overhydration 
(Chamney, Wabel et al. 2007). In Figure 3.1 the near perfect correlation for TBW 
measured by BIA at a given lean body mass suggests the assumption of constant tissue 
hydration index. Majority of PD patients are shown to be overhydrated. This is especially 
true in hypoalbuminaemic patients, further supporting the study’s hypothesis. This 
provides an independent evidence that low ECW/TBW or raised ECW/weight can reflect 
fluid excess, also in keeping with previous study using sodium bromide dilution to measure 
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ECW in PD patients (Konings, Kooman et al. 2002). Using the similar approach to 
estimate degree of tissue overhydration in a longitudinal study in haemodialysis patients, 
the average fluid excess at baseline postdialysis was just a little less (1.62kg) than that 
observed in this study (2.02kg). Instead of plasma albumin, comorbidity was the most 
important clinical predictor of overhydration in HD patients (Chan, McIntyre et al. 2009). 
This is likely a reflection that the variance in cormobidity is greater in HD patients, 
whereas the spread of plasma albumin levels is greater in PD patients.  
 
The main findings of the cardiac sub-analysis are as follows:  
1. Compared to non-hypertensive age matched controls PD patients treated with standard 
clinical care demonstrate several cardiac abnormalities including LVH, atrial enlargement 
and diastolic dysfunction.  
2. The plasma volume is in the normal range in more than 85% of PD patients. This seems 
to suggest that measured fluid excess is largely extravascular and is associated with 
inflammation and low albumin.  
3. The cardiac structure abnormalities are associated with intravascular volume and not the 
measures of total fluid excess.  
4. Other validated echocardiographic assessment and biomarker of filling pressure such as 
E/E', E/A and BNP do not correlate with plasma volume, hence may not reflect 
intravascular volume.  
5. PD patients with symptomatic HFNEF have a higher plasma volume. 
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Using a cohort of age and gender matched healthy adults from another echo study in our 
local research centre, 93% (28/31) of the PD patients exhibited NYHA class II and III heart 
failure symptom with breathlessness on exertion and 62% (20/31) has varying degree of 
LVH. We further demonstrated that PD patients had significant cardiac structural and 
functional abnormalities from echocardiographic parameters which may account for the 
prevalent symptoms of cardiac decompensation in the absence of other explanations such 
as anaemia. A decrease in mitral annular velocity in systole and diastole, together with 
reduction in global longitudinal strain, apical and basal rotation seems to suggest a picture 
of 'stiffening' of the heart and global systolic and diastolic dysfunction. However, only two 
patients (7%) showed signs of systolic heart failure with reduced LVEF of 44% and 29% 
respectively while majority of the patients (94%) have normal or near LVEF, indicating 
preserved systolic function. This finding is consistent with Wang et al where only 8% of 
PD patients had systolic dysfunction as defined by EF of <45% whereas 80% had diastolic 
dysfunction (Wang, Sanderson et al. 2003).  
 
PD patients are commonly perceived to be volume expanded in both intravascular and 
extravascular compartments but there has been a relative paucity in the study of fluid 
compartments in this cohort of patients. Measurement derived from BIA is not able to 
discriminate between different compartments but most body composition studies have 
employed this technique given its easy application and clinical validation with other gold 
standards particularly in subjects with normal fluid status. Surrogate biomarkers such as 
atrial natriuretic peptides (ANP) have been found to correlate central venous filling or 
pressure. Plum et al showed despite having a higher ECW/TBW ratio than patients before 
haemodialysis treatment, the serum ANP concentration in PD patients corresponded more 
to post HD values (Plum, Schoenicke et al. 2001). This is supportive of the hypothesis that 
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volume expansion in PD patients is predominantly in the interstitial compartment with 
relatively normal intravascular volume. Our study has shown that the plasma volume is 
within the normal range in over 85% of PD patients and it is therefore reasonable to 
conclude that measured fluid excess is chiefly in the extravascular space.  
 
We showed for the first time in this patient group who had predominantly diastolic not 
systolic dysfunction that standard echo parameters such as LVMI and LAVI were related 
to plasma volume but not other measures of fluid excess such as ECW/TBW, ECW/height 
or the difference in the BIA predicted and deuterium determined TBW. It is not clear if 
deterioration in left ventricular function leads to plasma volume expansion or vice versa. 
Future interventional studies designed to improve these cardiac echo parameters by 
rendering patients hypovolaemic would be needed to determine this. However this may 
compromise residual renal function which may not be desirable.  
 
BNP is a cardiac natriuretic peptide and its release is dependent upon ventricular myocyte 
response to stretch with increase in filling pressure. It is universally raised in ESRD 
population on dialysis therapy and the main reasons include high incidence of LVH and 
ventricular dysfunction and reduced renal clearance (Buckley, Sethi et al. 1992). It detects 
cardiac ischaemia and heart failure and predicts prognosis of heart failure (Davis, Espiner 
et al. 1994, Yu and Sanderson 1999, Berger, Huelsman et al. 2002). BNP has been shown 
to correlate with marker of LV filling pressure (E/E') (Mak, DeMaria et al. 2004) and fall 
in parallel with reduction in pulmonary capillary wedge pressure following treatment of 
acute heart failure (Kazanegra, Cheng et al. 2001). This seems to suggest the potential of 
BNP as a surrogate marker of fluid status. Finally, BNP has been shown to correlate with 
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LVMI and LVEF and predict cardiovascular congestion, overall mortality and 
cardiovascular death (Zoccali, Mallamaci et al. 2001, Wang, Lam et al. 2007). However, 
we did not find any relationship between BNP and measures of fluid compartments such as 
plasma volume or ECW/TBW. The association between BNP and LAVI but not LVMI in 
our study is intriguing. LAVI reflects LA pressure and it has been shown that patients with 
more severe diastolic dysfunction have larger LA volume in a large cross sectional study in 
general population (Pritchett, Mahoney et al. 2005). This is likely to be the case in PD 
patients with high incidence of diastolic heart failure with raised BNP.  
 
A large proportion of the patients in the study had breathlessness on exertion, a symptom 
suggestive of heart failure. Majority of them had normal ventricular ejection fraction on 
echographic examination. Previously known as diastolic heart failure, it is now referred to 
as heart failure with normal ejection fraction (HFNEF) or preserved ejection fraction. 
Often found in patients with history of volume overload and LVH, HFNEF is present in 
80% of PD patients (Wang, Sanderson et al. 2003). This is in keeping with previous study 
where hypertensive pulmonary oedema was associated with diastolic and not systolic 
dysfunction (Gandhi, Powers et al. 2001). Diastolic dysfunction was also commonly found 
in patients presenting with systolic heart failure where over 90% showed varying degree of 
abnormal relaxation pattern and those with restrictive filling pattern had the highest cardiac 
mortality (Yu, Sanderson et al. 1996). Our study has indicated for the first time PD patients 
who fulfilled the HFNEF criteria have significantly higher plasma volume compared with 
those who do not. It is not clear if the raised plasma volume is secondary to or the cause of 
HFNEF. It could also be argued that higher intravascular volume is required to enable 
adequate filling into a stiff ventricle. Further clarification in future study is needed to 
address this question. 
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As already discussed the cross sectional nature of this study is its main limitation allowing 
associations rather than causal inferences to be made. It can be argued that the cause of low 
albumin is a consequence of intravascular dilution rather than a cause of extravascular 
fluid accumulation but one would expect higher PV which is not the case in this study. 
However, no correlation was found between PV and plasma albumin or its rate of 
disappearance from the vascular compartment. There was a significant spread of residual 
renal function in this study involving only prevalent patients out of necessity known to 
influence fluid status. This study with relatively small sample size contains many 
covariates and multiple testing may increase the probability of false positive. This can be 
controlled by adopting the Bonferroni correction that set the significance cut-off at the 
acceptable level. However, by being more conservative in the Type I error rate for each 
testing, the chance of missing a genuine difference in the data wound increase. Another 
concern using multivariate regression analysis with several covariates is collinearity. This 
is especially true where there is high correlation amongst some of the covariates. This 
could increase the risk of both false positive and false negative that could cause confusion 
in the interpretation of results from the regression analysis. The TBW volumes were 
measured and estimated by deuterium dilution and BIA respectively. Both were found to 
be highly correlated but significantly different. The degree of agreement between the two 
methodologies can be assessed by the use of Bland Altman plots and any systematic 
difference can be identified. The predicted difference in overhydration between the pre-
defined groups and SD of the PV were similar to the value used in power calculation 
though the degree of overhydration was less in the study. Non-significant difference in 
corrected PV in both groups and lower than predicted SD makes type 2 error unlikely. The 
unequal distribution of gender and haemoglobin between groups was taken into account in 
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the analysis. No association was found between BP and other measures of fluid status and 
this could be confounded by patients taking antihypertensive medication.  
 
3.8 Conclusions 
Hypoalbuminaemic PD patients are overhydrated. Their tissue overhydration is not 
associated with expanded plasma volume; hence by inference fluid excess is 
predominantly in the extravascular space. Tissue oedema is not correlated with the very 
abnormal hearts of PD patients, at least when the predominant abnormality is diastolic 
dysfunction. Symptomatic HFNEF may be associated with modest central volume 
expansion. Attempts to reduce tissue overhydration may result in further intravascular 
depletion and thus may have adverse impact on haemodynamic stability and residual renal 
function.  
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4 Chapter 4  A trial to determine the value of bioimpedance 
vector plots in the longitudinal management of patients on 
peritoneal dialysis 
 
4.1 Introduction 
Optimal fluid management is one of the primary objectives of dialysis treatment and there 
is significant concern that peritoneal dialysis (PD) patients can become progressively fluid 
loaded with time on treatment, especially as residual kidney function declines (Tan, Chan 
et al. 2010, Van Biesen, Williams et al. 2011). There is a growing body of evidence that 
bioimpedance (BI) analysis has a role to play in assisting the clinician in managing fluid 
status (Davies and Davenport 2014). This is primarily based on observational studies 
showing that overhydration as determined from BI, predicts worse survival (Pillon, Piccoli 
et al. 2004, Machek, Jirka et al. 2010, Paniagua, Ventura et al. 2010) and the demonstration 
that BI can detect changes -following interventions designed to improve fluid status 
(Davies, Woodrow et al. 2003). BI data comprises two components, resistance to an 
electrical current, typically passed through the body from wrist to ankle which is inversely 
proportional to TBW, and reactance which is the impedance to this alternating current, also 
measured in Ohms, as it passes through tissues with cell membranes and thus proportional 
to cell mass. These two components can be plotted as a two dimensional vector and used to 
track changes in fluid status that could support clinical decisions (Figure 4.1) However, 
few clinical trials have been conducted that clearly demonstrate a benefit of BI over and 
above good quality standard clinical management. Longitudinal studies of body 
composition indicate that progressive overhydration is usually associated with a decline in 
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muscle mass and a potential failure to adjust the dialysis prescription so as to reduce the 
extracellular water (ECW) volume down in parallel with this (Chertow, Johansen et al. 
2000, Johansen, Kaysen et al. 2003, Chan, Smith et al. 2008, Davies, Engel et al. 2013). 
 
4.2 Aims of the study 
We hypothesised that the longitudinal application of BI alongside clinical evaluation 
would help the clinician identify this problem and thus make appropriate adjustments to 
the prescription. To test this hypothesis we undertook a randomised controlled trial to 
determine whether the additional information available from longitudinal BI over 12 
months could assist in maintaining stable or improved fluid status. Our aim was to 
determine whether routine clinical management supported by the longitudinal plot of the 
BI vector, which shows the direction in which fluid status is changing, resulted in more 
stable fluid status than control subjects. The outcome, to which the clinicians were blinded, 
was fluid volumes, ECW, total body water (TBW) and their ratio (ECW/TBW) as 
determined from the BI measurements after the trial was completed. 
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Figure 4.1 The procedure for documenting clinical interventions. 
Visit number 7 7 Do you need to intervene to achieve target weight? 2-Yes
Date 7 28/12/2011 If the patient is overhydrated, 
Systolic BP (mmHg) 7 135 what are the new intervention(s) used to optimize fluid status?
Diastolic BP (mmHg) 7 77
Target weight (kg) 7 51 Reduce fluid intake 2-Yes
Clinical weight (kg) 7 51 Start diuretics/increase dose
Use 'stronger PD solution 2-Yes
Clin. examination: Start Icodextrin
Raised JVP? 7 3-Not done Others (enter text)
Chest crackles? 7 3-Not done
Oedema? 7 1-No If the patient is underhydrated, 
what are the new intervention(s) used to optimize fluid status?
Bioimpedance data:
Resistance,R (ohm) 7 517.7 Increase fluid intake
Reactance,Xc (ohm) 7 56.2 Stop diuretics/decrease dose
Use 'weaker' PD solution
Stop Icodextrin
Others (enter text)
New Target weight (kg) 7 50
Clinical decision 7 TARGET WEIGHT DECREASED
BP 7 1-Optimum
Fluid status by clin.exam 71-Optimum
Fluid status by BIA 7 2-Overhydrated
050
100150
200250
300350
400450
500
0 10 20 30 40 50
(Height)2/Resistance (m2/Ohm)- increasing  total body water 
(Height)2/Reactance (m2/Ohm) – increasing tissue oedema 
2: Serial Plot BI Data (not done in controls) 
3: Combine BI Data with Clinical to inform decision 
4.  Record interventions 
Study start 
Study end 
Visit 7 
1: Data Entry 
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4.3 Subjects and study designs 
4.3.1 Subjects 
Four independent randomisation groups comprising non-anuric and anuric patients from 3 
UK dialysis centres (Stoke-on-Trent, Leeds and Sheffield) and one Chinese centre 
(Shanghai) respectively. 
 
4.3.2 Study Design 
The study design was a pragmatic, nested, controlled trial based on the PROBE principles 
(Hansson, Hedner et al. 1992), i.e. prospective, randomised, open-label, blinded end-point 
in which patients were allocated 1:1 either to an active arm in which BI measurements 
were available to clinicians in their assessment of fluid status or a control arm in which 
measurements were taken but concealed. Complete blinding of control BI data was 
achieved by using vector analysis which requires two dimensional plotting (Figure 4.1 and 
Figure 4.2) prior to their interpretation. In addition, clinicians were blinded to the primary 
body composition outcome for all participants as BI derived fluid compartment volumes 
(ECW, TBW) were only calculated after completion of the study and data lock. 
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Figure 4.2 Vector plot showing mean changes in bioimpedance and their 
associated vectors for the Shanghai-anuric patients (Controls ◊, Active ▪) 
 
Within this overarching design, 4 groups of patients were recruited each using an 
independent, concealed and randomly generated centralised allocation procedure. The 4 
groups were non-anuric and anuric, defined as a 24 hour urine volume <200 ml, with 
patients recruited from 3 medium sized UK centres, and one large Chinese Centre. The 
rationale underpinning the need for four independent patient groups nested within a 
common trial design is that (1) clinical decisions are likely to be affected by the presence 
of residual kidney function, (2) that the options for therapeutic intervention are different in 
the UK, where automated PD and icodextrin are available compared to China where 
options are more limited despite a higher proportion of anuric patients and (3) that there 
were anticipated important differences in case mix between the two countries, e.g. body 
weight and comorbidity. 
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Pragmatic inclusion and exclusion criteria were employed to mirror routine practice. 
Clinicians were asked to include sequential patients attending clinic who were willing to be 
enrolled only excluding patients unlikely be on peritoneal dialysis for more than 6 months 
for whatever reason. All subjects gave fully informed consent and the trial was pre-
registered with ClinicalTrials.gov Number: NCT00801112 and was later included in the 
National Institute for Health Research Clinical Research Network portfolio (Appendix 4).  
 
Following the obtaining of consent clinicians were allowed up to 3 months to stabilize 
fluid status using standard clinical assessment (but not BI) and ensure that the patients had 
recovered from any inter-current illness, e.g. peritonitis. Immediately following 
randomization fluid assessments (including BI measurements) were undertaken a 
minimum of three monthly over the following year unless the subject left the study. 
Additional assessments were permitted including use of BI in the active limb at the 
clinician’s discretion. The primary outcome was body composition as calculated from BI. 
Secondary outcomes included blood pressure, residual kidney function, peritoneal 
membrane function (solute transport and ultrafiltration capacity) and prescribed dialysis 
dose. 
 
Standard assessment of fluid status was recorded using an electronic database (Figure 4.1-
step 1) that included weight, physical examination (e.g. oedema,) and blood pressure. In 
the BI groups a vector plot was automatically generated (Figure 4.1-step 2) and clinicians 
were trained prior to the study to use the longitudinal plot of the H2/Resistance (≈Total 
Body Water) and the H2/Reactance (≈Extracellular Water) to determine the significance of 
longitudinal changes in fluid status and change the target weight so as to keep the vector 
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length and angle as stable as possible (Figure 4.1-step 3). This was then combined with 
clinical observations to inform the decision and the methods apply to achieve this was 
recorded in step 4. Lengthening of the vector represents an increase in total fluid content, 
shortening the opposite; increase in the vector angle indicates less lean tissue, and thus 
more fluid in the extracellular space whereas a reduction in the vector angle implies 
increased lean tissue thus either reduced extracellular water or increased muscle depending 
on whether the vector shortened or lengthened (see Figure 4.3).  
 
 
Figure 4.3 Changing BI vector plot and the associated clinical interpretation of 
body composition.  
 
If the patient weight remains stable then this interpretation is relatively straight forward; 
for example if the vector lengthened but the weight is unchanged this implies more fluid is 
present, and the change in the vector angle indicates whether this is extracellular or 
intracellular. As clinicians were asked to keep the vector stable this would have led to a 
reduction in target weight if the vector widened. However if the patient’s weight changed 
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spontaneously then the interpretation of the data was done with the help of the algorithm 
shown in Figure 4.4. 
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Figure 4.4 Algorithm to facilitate clinical decision making. 
 
Overhydration 
with reduced cell 
mass – reduce 
target weight 
Increased body water 
due to increased cell 
mass (muscle), -  
reset target weight to 
current weight 
Underhydration 
– allow weight 
to increase, e.g. 
more fluids  
Underhydration with 
relatively preserved cell 
mass – only change 
weight if clinically 
indicated 
Reduced body water due 
to reduce cell mass 
(muscle) – reset target 
weight at current weight 
Overhydration with 
relatively preserved 
cell mass – only 
change weight if 
clinically indicated 
Confirm significant weight change >1kg 
Body weight ↑  Body weight ↓ 
↑ ↑ ↓ ↓ 
Vector length ↓ Vector length ↑ 
= = 
Phase angle 
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In this way changes (or not) in actual bodyweight and clinical examination can be 
interpreted alongside trends but not absolute measures of body composition. The 
interventions employed by clinicians were at their discretion and availability but included 
adjustment of dry weight (e.g. by asking the patient to reduce salt and fluid intake), altering 
the dialysis prescription of glucose or icodextrin, changing modality (CAPD or APD) or 
altering diuretic prescription (see Table 4.7 for summary of practice patterns). These were 
recorded along with the rationale behind the decision.  
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4.3.4 Examples of longitudinal vector plots and how they supported 
clinical decision making 
Case 1 
 
In this case the vector and the weight remained very stable so no interventions were made. 
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Case 2 
 
In this example the patient spontaneously lost weight, but the vector was kept stable by re-
setting the target weight in a downwards direction. 
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Case 3 
 
In this example there was an initial increase in weight associated on the vector plot with 
overhydration – reported increase in fluid intake on holiday - treated by fluid restriction 
and stronger dialysate glucose prescription. There then followed a period of stability, but 
subsequently he became dehydrated. He then switched temporarily to haemodialysis for a 
period – assessment 14 – associated with a reduction in the dry weight, and later returned 
to PD (data not shown) and stable vector. 
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Case 4 
 
At visit 2 considered to have become overhydrated despite no change in weight. Despite 
progressive reduction in the target weight and interventions to get better fluid control – 
which stabilised the vector – there was further deterioration in his fluid status associated 
with a total knee replacement (TKR), during which is albumin dropped significantly 
postoperatively as part of an inflammatory response to infection.  
 
4.4 Materials and methodology 
4.4.1 Bioimpedance Measurements  
All units were issued with BI 101 ASE (Anniversary Sport Edition, Akern, Italy) body 
composition analyzers. These devices measure resistance and reactance at a single (50 
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MHz) frequency utilising the RJL Quantum technology previously validated in dialysis 
patients (Chertow, Lowrie et al. 1995, Mushnick, Fein et al. 2003, Jankowska, Debska-
Slizien et al. 2006). BI measurements were taken using a standardized protocol, with 
documentation of the placement of electrodes, without draining the abdomen of dialysate 
and after the patient had been lying recumbent for at least 5 minutes.  Using this approach 
we have previously documented within patient on the same day CV of <1% and inter-class 
correlations to determine intra-observer error of >0.96. 
 
4.4.2 Clinical measurements 
Comorbidity was characterized using the externally validated Stoke scoring system 
(Davies, Phillips et al. 2002). Blood pressure was measured in clinic attendance using 
standard equipment. Residual renal function was determined from 24-hour urine 
collections and calculated as the mean urea and creatinine clearance normalized to body 
surface area of 1.73m2. Dialysis dose was determined from 24-hour collections and 
expressed as weekly Kt/Vurea. Membrane function was determined using the peritoneal 
equilibration test and expressed as the four hour dialysate: plasma creatinine ratio (solute 
transport rate) and net ultrafiltration corrected for overfill (ultrafiltration capacity). Glucose 
utilization was calculated from the product of the volume and the concentration and 
expressed as grams used per day. Plasma albumin was determined using the bromocresol 
purple (BCP) colorimetric method in the UK and bromocresol green (BCG) method in 
Shanghai. The systematic difference between these methods is AlbBCG=5.5+AlbBCP (Clase, 
St Pierre et al. 2001), but data here is expressed after correction to the BCG method to 
enable comparison. 
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4.5 Statistical analysis and power calculations 
The trial was powered so as to be able to detect a clinically meaningful longitudinal change 
in body composition from baseline, specifically ECW volume, with an a priori assumption 
that spontaneous changes would occur in the control group that would be prevented in the 
active group. Based on pilot data obtained from longitudinal studies of body composition 
in PD patients over 12 months in which the SD of the difference in ECW was 1.22 L, then 
to detect a 1 L difference in ECW, assuming a 5% type 1 error with 80% power would 
require a 25 patients per group with 1:1 randomization; to detect a 0.8 L change would 
require 38 in each arm (WinSSD version 1.6.1). The plan was to recruit sufficient numbers 
to detect a 1 kg difference, but allow over-recruitment within the predefined window. For 
non-anuric and anuric patients the anticipated drop-out was 25% and 35% respectively 
necessitating ~130-150 patients enrolling per country. 
 
 The predefined primary analysis was planned as follows: after study completion and data 
lock (August 2012) the R and Xc data were converted to estimates of ECW, TBW, (and 
ECW/TBW) using an algorithm based on the software provided with the BI device and the 
change at 12 months from baseline determined by paired t-tests, to include changes in 
target and actual weight and secondary outcomes. To assess drop-out between group 
differences in patient and study survival were determined from Kaplan Meier survival 
curves and the log rank test. Mean values and frequencies of parameters including fluid 
assessments and interventions were compared using ANOVA or χ2 tests as appropriate.  A 
secondary multi-level regression analysis with BI derived fluid volumes as the dependent 
variables was undertaken to include all observations (level 1), individuals (level 2) and 
centres (level 3) and adjustment for the baseline covariates associated with BI volumes on 
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exploration of the dataset: age, gender and comorbidity. Models were fitted separately for 
active and control limbs in anuric and non anuric groups with random intercepts at 
individual and centre. All statistical analyses were undertaken using SPSS software version 
20, (IBM, US), except for the multilevel analysis for which we used MLwin (Version 2.22, 
Centre for multilevel modelling University of Bristol, UK).  
 
4.6 Results 
4.6.1 Patient characteristics. 
Recruitment, randomisation and dropout to and from the four study groups are summarised 
in the consort diagram (Figure 4.5). With the exception of the UK-anuric group, 
recruitment was sufficient to test our primary outcome with 80% power to detect a 1 kg 
change (in ECW) in the Shanghai (non-anuric and anuric) patients and 0.8 kg change in the 
UK non-anuric (UK-non-anuric) patients. Failure to achieve power in the UK-anuric group 
was due to a combination of lack of recruitment indicative of the low proportion of anuric 
patients in the 3 UK centres and a high dropout (66%). There was a non-significant 
increase in deaths in this patient group randomised to the BI intervention; careful analysis 
of these 4 deaths (cancer, sepsis) and adverse outcomes did not indicate any common 
factor or plausible relationship to the intervention but this group was excluded from further 
analysis apart from the multivariate models. Dropout in the remaining groups was well 
balanced over the course of the study as shown by Kaplan-Meir plots and log-rank tests 
(Figure 4.6).  
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Figure 4.5 Consort Diagram (failed criteria *unlikely to remain on PD for 6 months due to planned transplant or modality transfer, † 
unable to achieve clinical euvolaemia during run in). 
 
 
 
 
 
 
 
 
Control 
Total =37 
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Follow-up =25 
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Active 
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Transfer to 
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Follow-up = 5 
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HD = 0 
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up = 1 
 
Control 
Total =73 
Completed 
Follow-up =54 
Transfer to 
HD = 6 
Transplant = 5 
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up = 4 
 
Active 
Total =58 
Completed 
Follow-up = 40 
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HD = 7 
Transplant =6 
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up = 1 
 
Chinese Centre (Shanghai) 
Pool of eligible patients = 319 
Screened = 173; 8 declined; 7 failed criteria† 
UK Centres (3 sites) 
Pool of eligible patients = 217 
Screened = 202; 29 declined; 24 failed criteria* 
Fulfilled criteria 
and agreed to 
randomization  
N=159 
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and agreed to 
randomization  
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Randomization 1:1 
Anuric 
N=75 
Randomization 1:1 Randomization 1:1 Randomization 1:1 
Non-anuric 
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Anuric 
N=18 
Non-anuric 
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Figure 4.6 (a) UK-Non-Anuric 
patients (controls:  blue; BIA 
intervention: green). 
Figure 4.6 (b) SH-Non-Anuric 
patients (controls:  blue; BIA 
intervention: green). 
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Figure 4.6 Kaplan Meier survival plots for patient drop out by group. 
 
There were no significant differences between patients randomised to the BI-intervention 
or control arm in any of the groups in terms of their baseline demography, dialysis 
prescription, residual kidney function, peritoneal membrane function, blood pressure or 
body composition (see Table 4.1). Shanghai patients tended to be younger (mean age 54.0 
v. 58.6 years), have less comorbidity (20% v. 60% with at least one other diagnosis) and 
weigh significantly less that UK patients (58.9 v. 76.8 kg) which was reflected in a lower 
dialysis prescription volume. The average blood pressure and peritoneal solute transport 
rates (PSTR) were lower in the SH patients. Comparing the non-anuric patients, 
normalised residual renal clearances were higher in UK patients, as was the absolute 
residual urine volume unless this was corrected for body weight when the difference was 
non-significant (16.7 v. 17.4 ml/kg). As expected, anuric patients had been on peritoneal 
Figure 4.6 (c) Shanghai-Anuric 
patients (controls:  blue; BIA 
intervention: green). 
  127 
dialysis for longer, Shanghai-anuric 58 (26-90) v. Shanghai-non-anuric 19 (7-41) and UK-
anuric 57 (36-72) v. UK-non-anuric 22 (7-33) months.
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Table 4.1 Baseline characteristics of patient groups according to randomisation 
 UK-NON-ANURIC UK-ANURIC SH-NON-ANURIC SH-ANURIC 
 INTERVENTION CONTROL INTERVENTION CONTROL INTERVENTION CONTROL INTERVENTION CONTROL 
N 58 73 11 7 42 42 38 37 
PD duration 
(months, range)  
18 (7-32)  22(8-34)  
67(34-81) 45(36-60) 17(7-37)  24(11-41)  52(22-86)  65(31-105) 
age (year)  58.3±15.3  56.9±14.7  64±14.7 56.4±11 56.6±11.2  52.5±14.4  51.1±13.1  55.5±13.5  
D/P creatinine  0.70±0.12  0.68±0.12  0.69±0.1 0.79±0.07 0.60±0.09  0.58±0.11  0.61±0.09  0.65±0.11  
albumin (g/L)  33.41±4.47 33.48±3.85 33.4±1.9 34.3±5.2 32.57±2.90 32.54±3.61 32.8±4.3 33.4±2.9 
Gender F/M  20/38  29/44  7/4 4/3 26/16  31/11  19/19  14/23  
Comorbidity 
(low/med/high)  25/29/4  28/39/6  
 
5/6/0 
 
2/5/0 34/7/1  35/7/0  31/7/0  27/10/0  
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 UK-NON-ANURIC UK-ANURIC SH-NON-ANURIC SH-ANURIC 
 INTERVENTION CONTROL INTERVENTION CONTROL INTERVENTION CONTROL INTERVENTION CONTROL 
ECW (L)  18.3±4.3 19.2±4.0  16.4±4.0 14.5±3.0 16.7±3.1  15.9±2.6 16.3±3.2  17.4±3.5 
TBW (L)  41.5±8.2 42.3±8.5  37.4±5.6 36.1±8.6 35.0±5.2  33.9±4.8 34.6±6.6  35.8±6.9 
ECW/TBW  0.44±0.07 0.46±0.06  0.45±0.1 0.42±0.1 0.48±0.06  0.47±0.05 0.47±0.06  0.49±0.06 
H2/R (cm2/Ω)  58.6±13.6 59.6±13.2  51.9±9 47.6±12 49.4±11.8  48.8±8.1 49.5±12.3  51.9±12.4 
H2/Xc  (cm2/Ω)  538.9±172 570.1±162  487.7±164 384.2±102 526.3±132  497.5±129 502.6±135  560.9±159 
Target weight 
(kg)  76.2±15.7 78.4±18.5  72.4±12.2 72.4±20.6 59.9±8.2  58.4±8.9 58.0±9.5  59.0±11.0 
Systolic BP 
(mmHg)  136.8±20.1 143.4±22.5  131.8±28 136.4±16.6 130.2±14.8  130.5±17.7 128.3±20.4  127.2±23.0 
Diastolic BP 
(mmHg)  79.7±11.4 81.3±12.3  75.0±10.3 73.9±12.3 82.7±11.2  83.5±9.5 79.9±12.1  79.5±10.2 
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 UK-N0NANURIC UK-ANURIC SH-NONANURIC SH-ANURIC 
 INTERVENTION CONTROL INTERVENTION CONTROL INTERVENTION CONTROL INTERVENTION CONTROL 
N 58 73 11 7 42 42 38 37 
Diuretics 
(%) 54.3 54.8 9.1 0 29.3 28.6 0 2.6 
Beta-
blockers  
(%) 
25.7 27.4 18.2 0 34.1 26.2 18.9 26.3 
ACE-
inhibitors 
(%) 
24.3 21 0 28.6 9.8 21.4 24.3 18.4 
ARBs (%) 18.6 12.9 18.2 14.3 46.3 50 24.3 48.4 
Calcium-
channel 
blockers 
(%) 
22.9 24.2  6.4 
 
14.3 63.4 71.4 59.6 71.1 
Alpha-
blockers 
(%) 
14.3 21 
 
18.2 
 
0 
2.4 4.8 0 2.6 
ECW = Extracellular water, TBW = Total Body Water, H2/R = Height2 /Resistance, H2/Xc = Height2 /Reactance; ACE = Angiotensin converting 
enzymes; ARB = Angiotensin Receptor Blocker
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4.6.2 Primary outcome; longitudinal change in ECW and body 
composition 
In both the UK- and Shanghai-non-anuric controls and the Shanghai BI intervention group 
there were no significant changes in body composition over the 12-month study period (see 
diagram a and b in Figure 4.7 and Table 4.2). In the UK-non-anuric BI intervention group 
there was a reduction in TBW (-0.9 kg, 95%CI: 0 to – 1.74) that was associated with a 
reduced target weight set by clinicians (-1.7 kg, 95%CI: -0.39 to -2.96) and actual weight 
(-1.3 kg 95%CI: -0.09 to -2.69). Despite this there was no change in the ECW (+0.3 kg, 
95%CI: -0.69 to 1.24) or the ECW/TBW (0.01 95%CI: -0.04 to 0.01 Figure 4.7-a). In the 
Shanghai-anuric patients a significant deterioration in body composition occurred in the 
control patients due to a fall in TBW (-1.76kg, 95%CI: -2.70 to -0.82), increase in ECW 
(+0.59kg, 95%CI: -0.67 to 1.86) and thus worsening of the ECW/TBW ratio (0.04, 95%CI: 
0.01 to 0.06), whereas body composition remained stable in the BI intervention group 
(Figure 4.7-c). This was associated with stability of the BI vector plot used to aid clinical 
decision making in the intervention group whereas in the controls there was a reduction in 
Height2/Resistance in keeping with reduced muscle mass and worsening in the phase angle 
(-0.58°, 95% CI: 0.08° to 1.07°), indicating a relative excess in tissue hydration (Figure 
4.2). On multilevel analysis combining the data from both countries and all study visits 
these differences remained significant and independent of baseline determinants of fluid 
volumes including gender, age and grade of comorbidity (Table 4.3). By visit 5 (12 
months) the ECW/TBW ratio worsened significantly in both the anuric control and 
intervention group.  
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Figure 4.7 Net changes in body composition (weight in Kg, fluid volumes in L)  at 
12 months for (a) UK-NonAnuric, (b) Shanghai-NonAnuric and (c) Shanghai-
Anuric patients (Active BIA intervention group: solid bars, Controls: open bars, 
±95% CI). 
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Table 4.2 Longitudinal changes on body composition 
 UK-Non Anuric  Shanghai – Non Anuric  Shanghai – Anuric  
Control BI Intervention Control BI Intervention Control BI Intervention 
Base 
line 
12 
month 
P Baseline 12 
month 
P Baseline 12 
month 
P Base 
line 
12 
month 
P Base 
line 
12 
month 
P Baseline 12 month P 
ECW (L)  
19.5 
±4.2 
19.7 
±4.6 
0.70  18.2 
±4.3 
18.4 
±4.0 
0.57 
16.0 
±2.4 
16.1 
±2.6 
0.84  17.2 
±2.5 
16.7 
±3.2 
0.25  17.7 
±3.2 
18.3 
±4.6 
.342 
16.3 
±3.2 
16.2 
±2.6 
.787 
TBW (L)  
42.9 
±8.6 
42.8 
±8.8 
0.92  41.3 
±8.4 
40.4 
±7.9 
0.05 
34.3 
±6.6 
34.2 
±6.9 
0.82  35.4 
±5.2 
34.7 
±5.8 
0.10  37.2 
±6.0 
35.5 
±5.9 
.001 
35.0 
±6.5 
34.0 
±5.5 
.179 
ECW/ 
TBW  
0.46 
±0.06 
0.46 
±0.07 
0.56  0.44 
±0.08 
0.46 
±0.06 
0.17  0.47 
±0.06 
0.47 
±0.06 
0.75  0.48 
±0.08 
0.48 
±0.07 
0.89  0.48 
±0.06 
0.51 
±0.09 
.013 
0.47 
±0.06 
0.48 
±0.08 
.221 
H2/R  
(cm2/Ω)  
59.8 
±14.0 
59.9 
±14.4 
0.93  58.3  
±14.5 
56.9 
±13.8 
0.13  49.5 
±17.4 
48.9 
±10 
0.61  48.5 
±10.4 
49.3 
±9.8 
0.08  54.7 
±10.5 
50.4 
±9.8 
.001 
50.5 
±12.3 
48.5 
±10.4 
.168 
 
  134 
 
 UK-Non Anuric  Shanghai – Non Anuric  Shanghai – Anuric  
 
Control BI Intervention Control BI Intervention Control BI Intervention 
 
Baseline 12 
month 
P Base 
line 
12 
month 
P Baseline 12 
month 
P Base 
line 
12 
month 
P Base 
line 
12 
month 
P Baseline 12 
month 
P 
H2/X  
(cm2/Ω)  
576 
±171 
595 
±221 
 
0.39  
539 
±175 
543 
±176 
 
0.88  
499 
±127 
498 
±154 
 
0.98  
538 
±146 
529 
±183 
 
0.72  
567 
±147 
621 
±253 
.209 
505 
±139 
511 
±145 
.815 
Phase 
angle 
(degrees)  
6.14 
±1.2 
6.13 
±1.55 
0.91  
6.59 
±2.08 
6.25 
±1.35 
0.25  
6.14 
±1.20 
6.13 
±1.55 
0.82  
5.50 
±0.82 
5.66 
±1.49 
0.42 
5.72 
±1.30 
5.15 
±1.72 
0.03  5.90 
±1.36 
5.75 
±1.68 
0.50  
Target 
weight 
(kg)  
78.7 
±19 
78.3 
±19 
0.44  
75.2 
±15 
73.6 
±15 
0.01 59.2 
±9.0 
58.7 
±9.1 
0.20  
60.7 
±8.6 
60.3 
±8.6 
0.30  61.4 
±10.2 
60.8 
±10.5 
.099 
58.3 
±9.8 
58.1 
±8.9 
.588 
Clinical 
weight 
(kg)  
79.3 
±18 
79.0 
±19 
0.72  
75.8 
±16 
74.5 
±15 
0.07 59.2 
±9.0 
60 
±9.7 
0.13  
60.7 
±8.6 
60.6 
±8.8 
0.94  61.2 
±10.4 
60.9 
±10.9 
.586 
58.3 
±9.8 
57.9 
±8.4 
.622 
ECW = Extracellular water, TBW = Total Body Water, H2/R = Height2/Resistance, H2/Xc = Height2/Reactance Phase angle is calculated as the 
arc tangent ((H2/R)/(H2/Xc)) expressed in degrees. 
  135 
Table 4.3 Multilevel analysis of determinants of BI derived fluid volumes (TBW and ECW/TBW) incorporating all visits (level 1), 
patients (level 2) and centres (level 3). 
 
6 models are presented; in each case the BI fluid volume (TBW = Total Body Water, ECW = Extracellular water) is adjusted for baseline age, gender and 
comorbidity (ⱡ compared to Grade 0 = no comorbid conditions, Grade 1 = 1-2, Grade 2 = 3 or more comorbidities); TBW at baseline is greater by 8.5 – 10 
litres in men and falls over visits (spontaneously in anurics, due to target weight reduction in non-anurics) whereas the ECW/TBW at baseline is elevated by 
age, female gender and comorbidity and increases over visits in anuric patients, § = Change from baseline visit; †P<0.05, *P<0.01. 
 Control (All) BI Intervention (All) Controls          (Non-
Anuric) 
BI intervention 
(Non-Anuric) 
Controls        (Anuric) BI intervention        
(Anuric) 
Number of patients 158 149 115 100 44 49 
Number of visits 666 637 491 435 175 202 
Mean TBW (L,  95%CI) 
Baseline constant 34.7    (31.6, 37.8) 34.1    (31.1- 37.0) 33.7   (31.0, 36.5) 33.6  (30.4, 36.7) 31.8   (29.3,  34.3) 33.1    (29.6,  36.7) 
Gender (male) 10.1*    (8.4, 11.9) 8.8 *     (7.2 -10.4) 11.7*   (9.6,  13.9) 9.2*    (7.1, 11.3) 8.6 *    (5.8,  11.4) 8.8*      (6.4,  11.3) 
Age (year) 0.06    (0.0, 0.12) -0.01  (-0.07- 0.05) 0.00   (-0.07, 0.07) -0.01 (-0.09, 0.06) 0.21*   (0.09,  0.32) -0.03   (-0.12,  0.06) 
Comorbidity Grade 1 ⱡ -0.84   (-2.81, 1.13) 0.73    (-1.13, 2.60) 0.38   (-1.91,  2.67) 1.86  (-0.42, 4.14) -2.46  (-5.55, 0.63) -1.70   (-4.59,  1.18) 
Comorbidity Grade 2 ⱡ -1.96   (-6.27, 2.4) 0.95    (-3.63, 5.53) -1.53  (-5.86, 2.80) 1.43  (-3.33, 6.20) None in this category 
Visit 2 v. baseline§ 0.40    (-0.07, 0.86) -0.12  (-0.55, 0.30) 0.44   (-0.08, 0.96) -0.44 (-0.91, 0.03) 0.23    (-0.72,  1.19) 0.57   (-0.30,  1.43) 
Visit 3 v. baseline§ 0.11  (-0.36 - 0.59) -0.41  (-0.83, 0.0) 0.12   (-0.41, 0.65) -0.57†(-1.03, -0.10) 0.06    (-0.91,  1.03) -0.08  (-0.92,  0.76) 
Visit 4 v. baseline§ -0.45   (-0.95- 0.05) -0.51† (-0.9, -0.06) -0.13  (-0.68,  0.42) -0.52†(-1.01, -0.02) -1.49* (-2.58, -0.41) -0.46  (-1.35,  0.42) 
Visit 5 v. baseline§ -0.45  (-0.96 - 0.06) -0.79† (-1.24, -0.4) -0.15  (-0.71, 0.41) -0.81*(-1.30, -0.31) -1.52* (-2.67, -0.37) -0.79  (-1.70, 0.12) 
ECW/TBW ( ratio, expressed as percentage, 95%CI) 
Baseline constant 46.3     (43.8,  48.7) 46.4    (43.9,  48.8) 46.9     (45.1,  48.7) 46.3    (43.8, 48.9) 47.6   (42.1,  53.1) 46.8   (43.0, 50.5) 
Gender (male) -2.78 * (-4.37, -1.18) -3.32*  (-4.97, -1.67) -3.53* (-5.36, -1.69) -2.58* (-4.54, -0.62) -3.68†  (-7.00,-0.36) -4.26*  (-7.37, -1.14) 
Age (year) 0.07†   (0.01, 0.12) 0.14*    (0.08, 0.20) 0.06†    (0.00, 0.12) 0.12*  (0.05, 0.19) 0.05  (-0.08, 0.18) 0.17*   (0.05, 0.28) 
Comorbidity Grade 1ⱡ 1.54     (-0.28, 3.36) 2.30† (0.43, 4.16) 1.15    (-0.79, 3.08) 1.31 (-0.81, 3.42) 1.21  (-2.62, 5.05) 3.97†  (0.33, 7.62) 
Comorbidity Grade 2ⱡ 8.81*   (4.83, 12.78) 1.61   (-2.96, 6.18) 8.72*    (4.97, 12.46) 1.71 (-2.69, 6.11) None in this category 
Visit 2 v. baseline§ 0.08     (-0.89, 1.04) 0.57   (-0.43, 1.57) -0.29   (-1.37, 0.79) 0.32 (-0.93, 1.57) 1.05   (-0.97,  3.06) 1.11  (-0.51, 2.72) 
Visit 3 v. baseline§ 0.52     (-0.46, 1.51) -0.09  (-1.07, 0.89) 0.44    (-0.67,  1.55) -0.26 (-1.49, 0.97) 0.74   (-1.29, 2.78) 0.35   (-1.22, 1.91) 
Visit 4 v. baseline§ -0.49    (-1.53, 0.55) 0.45   (-0.58, 1.48) -0.39   (-1.54, 0.76) 0.37   (-0.94,  1.67) -0.83  (-3.10, 1.45) 0.71 (-0.94, 2.36) 
Visit 5 v. baseline§ 0.96     (-0.10, 2.03) 0.85   (-0.19, 1.90) 0.31   (-0.85, 1.47) 0.50  (-0.81,  1.81) 3.25*  (0.85, 5.66) 1.79† (0.09, 3.48) 
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4.6.3 Secondary clinical outcomes – blood pressure, residual kidney 
function, membrane function and dialysis dose 
There were no significant longitudinal changes in blood pressure in any of intervention or 
control groups (Table 4.4). In all the non-anuric patient groups over 12 months there was a 
significant fall in the residual Kt/Vurea associated with reductions in urine volume with the 
exception of the UK intervention group in whom residual urine volume was maintained. 
Although relative preservation of urine volume in the context of loss in solute clearance is 
in keeping with increased diuretic use it was not possible to demonstrate this (Table 4.4). 
The reduction in residual function in the non-anuric groups was associated with increases 
in the prescribed dialysis dose (volume) in all patient groups. There were no changes in 
plasma albumin, ultrafiltration capacity or PSTR in any of the groups with the exception of 
a significant increase in PSTR in the Shanghai-anuric cohort, seen in both study arms, 
slightly greater in the intervention arm.  
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Table 4.4 Longitudinal changes in secondary outcomes and dialysis presription. NC=not collected. 
 UK-Non Anuric  Shanghai – Non Anuric  Shanghai – Anuric  
 Control BI Intervention Control BI Intervention Control BI Intervention 
 Baseline 12 month P Baseline 12 mon P Baseline 12 month P Baseline 12 month P Baseline 12 month P Baseline 12 month P 
Systolic BP  
(mmHg)  144 ±25 140 ±20 .209 137 ±20 136 ±20 .845 133 ±16.2 135 ±18.4 .375 131 ±15 130 ±21 .637 128 ±24 123 ±27 .638 130 ±22 128±26 .776 
Diastolic BP  
(mmHg)  81.2±13 79.1±10 .235 79.7±11 79.2±11 .815 85.5±8 86.1±13 .991 83.3±11 81.9±11 .410 79.7±9 76.2±16.2 .246 79.8±13.1 81.6±14.9 .613 
Input Volume 
(L)  8.8 ±2.5 9.4 ±3 .032 8.7 ±2.7 9.0 ±3 .079 6.1 ±1.8 6.5 ±1.8 .025 6.6  ±1.5 6.9  ±1.4 .025 8.3 ±1.3 8.6 ±1.4 .083 7.8 ±1.2 8.0 ±1.2 .157 
Total Glucose 
(g)  121.7±5 126.7±6 .395 119.1±51 126.8±57 .067 104.2±35 120.0±39 .001 116.0±31 130.0±36 .003 181.2±41 186.7±51 .398 167.5±39 176.3±46 .037 
Average  
[Glucose] (g/L)  1.36±0.28 1.3±0.4 .257 1.31±0.37 1.34±0.39 .417 1.71±0.32 1.86±0.34 .009 1.75±0.27 1.87±0.34 .006 2.16±0.31 2.15±0.39 .888 2.13±0.33 2.19±0.39 .342 
daily UF(UF)  
326 
±629 
446 
±435 .113 
339 
±539 
439 
±418 .203 
160 
±437 
352 
±487 .003 
166 
±514 
316 
±568 .012 
876.4 
±296 
792 
±402 .384 
833 
±327 
831 
±363 .819 
Urine 
Volume(ml)  
1,298 
±746 
1,007 
±599 .003 
1,165 
±661 
1,170 
±896 .957 
1,084 
±621 
746 
±559 .000 
1,005 
±571 
723 
±654 .000 NC NC  NC NC  
Renal Ccr (ml)  94.6±63 78.1±57 .020 93.1±66.1 72.3±62.6 .001 40.1±35.3 33.9±38.7 .012 41.7±33.1 27.2±26.5 .000 NC NC  NC NC  
Renal KtV  1.3±0.8 1.1±0.7 .023 1.2±0.8 1.0±0.8 .006 0.8±0.6 0.6±0.6 .007 0.7±0.5 0.5±0.5 .000 NC NC  NC NC  
Albumin (g/L)  33.5±4.0 32.9±3.7 .301 33.2±4.7 33.2±5.0 1.00 38.0±3.4 38.2±4.6 .466 37.8±2.8 38.4±3.3 .307 38.9±3.3 38.2±4.3 .548 39.2±3.0 38.0±3.5 .130 
UF capacity  274 ±216 244 ±220 .572 226 ±266 279 ±294 .357 253 ±111 291 ±138 .147 221 ±174 266  ±130 .299 274 ±139 252 ±153 .701 241 ±196 267 ±129 .247 
Solute  
Transport  0.66±0.11 0.68±0.10 .156 0.70±0.14 0.73±0.11 .175 0.58±0.11 0.60±0.12 .231 0.60±0.10 0.62±0.10 .255 0.64±0.11 0.67±0.11 .032 0.62±0.11 0.67±0.11 .001 
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4.6.4 Analysis of interventions related to fluid management 
A key aspect of the study design was to capture decisions at the point of fluid management 
assessments so as to better understand how clinicians were utilising the additional 
information from BI. Of a potential 1,274 visits and 1,394 assessments (additional 
assessments were allowed in the active BI group) of fluid status, data was captured and 
recorded for analysis at 1,106 visits (89.6%), 568 for Shanghai with >95% data validity, 
538 for the UK with 85% validity, proportions not significantly different by randomisation 
group. Frequency of intervention type were highly variable by patient, usually multiple and 
often repeated (see Table 4.5), but not demonstrably different according to randomisation, 
with the exception of significantly higher glucose prescription in the Shanghai-anuric BI 
group (Table 4.4). By taking a change in target weight of ≥ 1 kg in either direction as a 
cut-off value for a clinically significant decision, it can be seen (Table 4.6) that the weight 
was more likely to be reduced in the intervention compared to control groups in all three 
sub-studies with the primary reason given as ‘to improve control of high blood pressure’, 
whereas hydration status on clinical examination was less likely to be a factor (although 
reduction of weight in the Shanghai-anuric BI group was borderline significant).  Overall 
this effect on decision making was most marked in the UK-non-anuric BI patients, so 
explaining the overall greater likelihood of weight reduction in this intervention group as 
already discussed (Figure 4.7-a).  
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Table 4.5 Clinical interventions by different centres. 
Intervention UK Centres Shanghai Total 
Reduce Fluid Intake 14.8% 29.9% 22.5% 
Increase Fluid Intake 6.8% 1.8% 4.4% 
Commence/increase 
diuretics* 
2.4% 2.2% 2.3% 
Reduce/stop diuretics 1.0% - 0.05% 
Increase Dialysate 
Glucose prescription 
14.5% 7.9% 11.3% 
Decrease Dialysate 
Glucose prescription 
1.0% 0.07% 0.085% 
Commence icodextrin 0.04% N/A  
Decrease icodextrin 0.03% N/A  
* Denominator adjusted for number of interventions in non-anuric patients. 
N/A = not applicable as unavailable in China 
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Table 4.6 Analysis of interventions according to changes in target dry weight defining ≥ ± 1 kg as being clinically significant. ↓ : target 
weight decreased by ≥ 1 kg; =: change in target weight < 1 kg; ↑: target weight increased by ≥ 1 kg P=values are for the χ2 test. 
ND=Not done 
Clinical decision Randomisation  UK-NA S-NA S-A All Groups 
Change in target weight  ↓ = ↑ P  
value 
↓ = ↑ P  
value 
↓ = ↑ P  
value 
↓ = ↑ P  
value 
Reason given for changing 
weight to achieve lower 
blood pressure 
BI intervention 10 30 1  6 27 1  6 29 3  22 86 5  
Controls 13 31 12 0.004 11 36 4 0.03 2 26 1 0.002 26 93 17 0.008 
                 
Reason given for changing 
weight to achieve better 
fluid status based  
on clinical examination 
BI intervention 6 20 1  9 33 1  8 21 2  23 74 4  
Controls 7 23 4 0.24 8 37 0 ND 4 28 2 0.056 19 88 6 0.15 
                 
Overall decision to change 
weight in either direction 
regardless of reason 
BI intervention 38 159 19  27 135 13  24 110 13  89 404 45  
Controls 31 177 36 0.003 25 142 16 0.58 19 109 13 0.51 75 428 65 0.006 
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Table 4.7 Summary for practice patterns used to manage fluid status by the participating centres. 
Centre Dietetic support and advice Use of diuretics Use of ACE/ARBs Use of icodextrin 
UK: Stoke-on-Trent Dietician available in clinic. Advice on 
fluid restriction tailored to the individual 
aiming for salt intake of 5-7.5g 
depending on nutritional state 
Continued on commencing PD. 
Usually Furosemide 240mg. Dose 
maximised before using >1.5% 
dialysate glucose. Stopped when 
anuric. 
Used in all patients 
unless intolerant; 
antihypertensive drugs of 
choice 
Used in all patients requiring 
a long dwell. Only replaced 
by glucose if clinically 
volume depleted. 
UK: Leeds Dietician available at clinic with periodic 
review of all patients. Salt restricted to 
<6g/24 hours and fluid intake allowance 
individualised to patient 
Continued on commencing PD, and 
start/increase dose used before 
more hypertonic exchanges except 
where there is negative UF. 
Stopped when anuric. 
First choice of 
antihypertensive agent 
where one is required. 
Used in majority of patients 
having a long dwell. 
UK:  Sheffield Dietician available in clinic with period 
review of all patients. Aim for 6g salt 
intake per day and no added salt. 
Continued on commencing PD. 
Furosemide dose titrated up to 
240mg daily. Dose maximised 
before using >1.5% dialysate 
glucose. Stopped when anuric. 
Used in all patients 
unless intolerant; 
antihypertensive drugs of 
choice 
Used in majority of patients 
having a long dwell. 
China: Shanghai Dietician not available in clinic. Nursing 
staff and physician give advice on fluid 
restriction and salt intake. Rather than 
giving fixed target of salt and fluid 
intake, the advice is to alter to be more or 
less than the patient’s current intake 
levels. 
Usually used if urine volume less 
that 500 ml and start/increase dose 
before changing PD regime to 
achieve more daily fluid removal. 
Maximum dose is 100mg.  Stopped 
when anuric. 
First choice of 
antihypertensive agent 
where required, unless 
for economic reason as 
short acting calcium 
channel blocker and 
clonidine is cheaper 
option. 
Not available 
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4.7 Discussion 
The most important finding of this trial was the greater than anticipated stability over 12 
months of BI derived fluid volumes, especially in non-anuric patients. Where significant 
changes were seen, with or without adjustment for baseline factors associated with BI 
volumes (gender, age, comorbidity), these were reductions in the TBW with or without 
parallel change in the ECW. In anuric subjects this was spontaneous and likely to reflect 
loss in lean tissue, as we originally hypothesised, leading to an increase in the ECW/TBW 
ratio. There was marginal evidence that this could be ameliorated in the Shanghai BI-
intervention group who achieved greater stability of the BI vector associated with higher 
dialysate glucose prescription, but no difference in blood pressure which was well 
controlled in both groups. In the UK non-anuric BI-intervention group the fall in TBW was 
due to the setting of a lower target weight but no change in the ECW/TBW ratio or 
improvement in blood pressure. Taken together these findings suggest that longitudinal BI 
vector plotting adds little additional value to clinical fluid management.  
 
The spontaneous fall in BI derived TBW with increase in ECW/TBW seen in the anuric 
patients is in keeping with our own study of longitudinal body composition in 
hemodialysis patients in which increased ECW/TBW associated with comorbidity 
reflected overhydration supported by independent measures of TBW from deuterium 
dilution (Chan, McIntyre et al. 2009) as well as longitudinal studies using various methods 
in peritoneal dialysis patients (Johansen, Kaysen et al. 2003). It is important to emphasise 
that our study design was intended to address this problem by showing how BI may be 
used to detect longitudinal changes in body composition and adjust for these rather than 
using it as a tool to drive patients to a specific target hydration status. This approach is in 
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contrast to other current (Su, Gangji et al. 2011, Liu, Long et al. 2012) or recently 
completed study protocols (Hur, Usta et al. 2013, Onofriescu, Hogas et al. 2014) and was 
chosen in order to minimise risk, especially premature loss of residual kidney function. 
Indeed a recent study using the overhydration index to reduce dry weight was associated 
with significant loss of urine output in non-anuric hemodialysis patients (Hur, Usta et al. 
2013). This problem was not reported in the only other trial completed in PD patients that 
did find BI improved fluid status and blood pressure but follow up was limited to three 
months only (Luo, Lu et al. 2011). Our decision to use vector plots of BI data rather than 
calculated volumes is also worthy of comment. This was driven by a number of 
considerations. First, given the lack of a known value for optimal ECW volume in the PD 
population in which overhydration is driven by many factors such as comorbidity and 
hypoalbuminaemia we were reluctant to set absolute targets. This was mainly for the 
reasons already given, and the vector plot approach discourages clinicians from making 
such judgements. Second, this made it very easy to blind clinicians from the BI data which 
necessitates plotting before it can be interpreted and by delaying the calculations of 
interpolated volumes on which the study was powered until after the study data lock 
applied we were able to minimise the effect of clinician bias. Third, there are very large 
databases giving normal values for vectors in the general population (Bosy-Westphal, 
Danielzik et al. 2005) as well as the dialysis population in which both phase angle and 
vector length have been shown to be highly predictive of survival (Pillon, Piccoli et al. 
2004). At the time of study design this data was not available for other methods, in 
particular the overhydration index. Finally the BI devices we used have a well established 
record in reproducibility and were relatively inexpensive. Of interest a similar approach 
has been adopted in the FLUID study protocol (Su, Gangji et al. 2011). 
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One of the purposes of our study was to capture information on decision making by 
clinicians in an attempt to see how the use of BI informs practice. Overall, most clinical 
assessments did not lead to a change in target weight and it should be recognised that 
spontaneous changes in weight without a change in hydration will have occurred in many 
patients, reflecting, for example, changes in body fat. In the control groups the decision to 
increase or decrease target weight was remarkably symmetric, whereas increasing the 
weight in the intervention groups was less likely. It is possible that for the UK clinicians 
the tendency to make greater weight reductions in the intervention group so as to achieve 
better blood pressure control was due to study bias. The types of intervention used, 
although recorded, proved difficult to analyse as these were usually multiple, i.e. of several 
types and repeated within patients and not demonstrably different between control and BI 
groups. The relative maintenance of urine volume, despite a reduction in target weight, 
could be explained by diuretics, as observed in a previous trial comparing diuretic use with 
placebo, (Medcalf, Harris et al. 2001) but this could not be clearly shown here due to the 
fact that most patients were already on diuretics and that most interventions were complex. 
In any case this did not translate into improvements in hydration status as judged by ECW 
volume, ECW/TBW, phase angle or blood pressure management. However this does 
support observational data indicating that preservation of residual urine volume does not 
depend on maintaining overhydration (McCafferty, Fan et al. 2014). There is a concern 
that the loss of weight might reflect a reduction in muscle mass, but the change in TBW 
was not associated with a significant change in the raw electrical data, e.g. resistance, and 
is therefore dominated by the weight change fed into the algorithm used to extrapolate 
TBW, and so might be due to loss in body fat. This complex effect deserves further 
evaluation and a better understanding of how patients respond to requests to reduce their 
target dry weight that should inform future trial design. The trend to reduce weight, 
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especially for the purpose of blood pressure control was also seen in the Shanghai patients 
but the absolute changes were not so great, perhaps reflecting the overall better blood 
pressure measurements in the Chinese patients. The value of BI in the anuric intervention 
group here appears to have been a better targeting of decision making combined with a 
significant increase in glucose prescription so preventing the drift towards worsening tissue 
oedema. This increase in glucose use will also have increased calorie intake so protecting 
against loss of lean tissue which was less severe in this group. 
 
This study has a number of limitations. Although we went to great lengths to conceal 
allocation process and blind clinicians to the control BI data and outcomes, it was by 
definition impossible to avoid the knowledge of randomisation group and thus eliminate 
decision bias by clinicians. It may well be, for example, that the more aggressive weight 
reduction in the UK-non-anuric intervention group reflected this rather than specific 
information obtained from the BI measurements per se. Reasons not to be included in the 
study differed by country, being planned modality transfer, especially transplantation, in 
the UK versus greater likelihood of failing to achieve stability in the run-in period in 
Shanghai, which suggests that the Chinese anuric patients could be more selected. 
However it can equally be argued that this selection applied to the UK even more so given 
the greater difficulty in recruiting anuric patients. The unequal numbers in the UK 
randomisation which in retrospect should have been stratified by centre, did not affect the 
balance of measured baseline patient characteristics and the failure to recruit sufficient 
anuric patients from the UK, has been partially addressed by including a multivariate 
analysis incorporating both data from both countries. This analysis showed that age, gender 
and comorbidity are the main determinants of body composition and that any differences 
between centres were a function of patient level characteristics and interventions available. 
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More detail in describing the dietetic interventions would have been desirable, e.g. patient 
level data on salt intake as this turned out to be more important than was initially 
appreciated; we considered measuring sodium losses but these have previously been shown 
to be an unreliable indicator of dietary change in PD patients (Cheng and Wang 2006). The 
strengths of the study were its multicentre, pragmatic design which enhances its 
generalisability. 
 
4.8 Conclusions 
In conclusion, routine use of longitudinal BI to inform fluid management in PD patients 
had minimal impact over 12 months. Although this was partly because body composition is 
very stable in non-anuric patients it could be because we chose to maintain a stable BI 
vector rather than intervene more aggressively to normalise fluid status. Future studies are 
needed to evaluate such an approach but will require careful choice of clinically relevant 
outcomes such as residual kidney function and blood pressure control. Importantly this 
study demonstrates just how difficult it is to capture and interpret the complex 
interventions and practice patterns associated with fluid management and thus attribute 
cause and effect. An increase in glucose prescription was the only intervention associated 
with benefit. 
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Chapter 5  Bioimpedance, fluid management and longitudinal 
cardiac function: A secondary outcome analysis of single centre 
data from the UK-Shanghai BIA study 
5.1 Introduction 
Patients with end stage renal disease (ESRD) on dialysis therapy have a much higher rate 
of cardiovascular death compared to the age and gender matched population without renal 
disease. Despite the progressive improvement in the death rate over the past two decades, it 
still accounts for approximately 27% of all cause mortality (Registry, 2014).  Congestive 
heart failure (CHF) is common among dialysis population. It was found in 31% of ESRD 
patients commencing on dialysis therapy and 25% of patients without CHF at baseline 
showed evidence of CHF subsequently with a median survival of 36 months (Harnett, 
Foley et al. 1995). This cardiac syndrome is closely associated with LVH, IHD and 
systolic failure which all contribute to the high cardiovascular burden (Parfrey, Foley et al. 
1996).  
 
Beyond the usual conventional cardiac risk factors such as coronary artery disease, 
diabetes mellitus, hypertension and dyslipidaemia that dialysis patients need to deal with , 
they are also exposed to the renal or dialysis related negative cardiac predictors such as 
uraemia, anaemia, hypoalbuminaemia and inflammation. Fluid overload is increasing 
being recognised as a concerning cardiac risk factor in ESRD patients which predicts 
mortality independent of hypertension (Wizemann, Wabel et al. 2009, Agarwal 2010). The 
mechanism by which overhydration aggravates cardiovascular death is complex and 
multifaceted. PD patients with uncontrolled hypertension are more volume overloaded as 
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determined by BIA and antihypertensive medication alone is unlikely to be effective 
without salt and fluid restriction (Wang, Axelsson et al. 2005). PD patients with history of 
volume overload have more severe left ventricular hypertrophy and left ventricular 
dilatation and 80% have evidence of diastolic dysfunction with normal ejection fraction 
(Wang, Sanderson et al. 2003). The loss of residual renal function (RRF) with time on 
dialysis has been showed to be an independent predictor of survival both in PD (Bargman, 
Thorpe et al. 2001, Paniagua, Amato et al. 2002) and HD (Termorshuizen, Dekker et al. 
2004) cohorts. This leads to inadequate sodium removal, thus compounding the problem of 
overhydration by increasing the incidence of hypertension and LVH in dialysis patients 
(Enia, Mallamaci et al. 2001, Khandelwal, Kothari et al. 2003).  
 
PD enjoys similar if not better survival benefit compared with HD at least for the first 2 
years of therapy but subsequent outcome has not been as good (Collins, Hao et al. 1999, 
Gokal, Figueras et al. 1999, Tanna, Vonesh et al. 2000). This was despite the common 
perception that PD was thought to be a better treatment option due to its continuous 
ultrafiltration with less cardiovascular haemodynamic upheaval. The mortality risk of 
patients with CHF treated with PD increased with time independent of the diabetic status in 
a two year observational study (Stack, Molony et al. 2003). This suggests a possible 
deleterious effect of suboptimal volume status on the progression of CHF in PD patients. 
The primary findings of the multicentre BIA study suggest a relatively stable body 
composition in patients with residual renal function. We want to explore the impact of 
fluid management using BIA on cardiac function in non anuric PD patients over the 12 
month period.  
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5.2 Aims of the study 
We hypothesized the use of BIA in the fluid management of PD patients leads to a 
significant reduction of target weight and a better preservation of cardiac function. We also 
wanted to examine the impact on the residual renal function. 
 
5.3 Subjects and study design 
This was a predefined sub-analysis of the BIA study. The patient population was derived 
from the multi-centre BIA study. (Developing Bioimpedance (BIA) as a tool for fluid 
management in Peritoneal Dialysis Patients: A validation Study ClinicalTrials.gov NO: 
NCT00801112.) Patients recruited from the University Hospital of North Staffordshire 
who had echocardiographic measurement as part of their baseline and final follow up visit 
were included in this sub-analysis.  
 
Inclusion criteria were similar to the BIA validation study (see Chapter 4). Briefly, the 
eligible patients had to be 16 years old or above and had been established on PD for more 
than 3 months and deemed clinically stable. Patients with acute inflammation, e.g. 
peritonitis within one month or with life expectancy less than six months were excluded. 
Fluid status was determined and optimised clinically at baseline prior to study enrollment. 
Patients were excluded from the study if optimal fluid status, which was defined as the 
minimal body weight that patient can achieve without adverse effect, e.g., hypotension, 
could not be achieved by clinical means. Following optimisation of fluid status the patients 
were randomized into active and control groups. In the active group bioimpedance vector 
plots were used in combination with clinical assessment (BP, oedema) to manage fluid 
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status. In the control group, BIA measurements (resistance and reactance) were recorded 
but were not used in decision making.  
 
5.4 Materials and methodology 
5.4.1 Clinical measurements 
Comorbidity was recorded at the time of enrollment by the consultant. Stoke comorbidity 
score were used in the study. In brief, 7 comorbidity domains were considered, including 
non-cutaneous malignancy, ischemic heart disease (IHD), peripheral vascular disease 
(PVD), left ventricular dysfunction (LVD), diabetes mellitus (DM), systemic collagen 
vascular disease, and any other condition thought to reduce life expectancy. The 
comorbidity score was the number of these domains affected. The comorbidity grade was 
then derived from the comorbidity score. Grade 0 (low risk) was a zero score, grade 1 
(medium risk) was a score of 1-2, and grade 2 (high risk) a cumulative score of ≥ 3. 
 
Membrane function was evaluated by standard peritoneal equilibration test (2.27% PET). 
The clinical routine biochemistry profiles were measured as part of clinical practice. The 
sampling date of the biochemistry profile may or may not be on the same day as BIA 
measurement but the interval between measurements was kept less than a month.  
 
5.4.2 BIA measurement 
BIA parameters were measured by a single frequency (50Hz) BIA device (Akern BIA 101 
Anniversary) in the study. The total body resistance and reactance were measured 
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according to the operator’s manual for the further calculation of total body water (TBW) 
and extra-cellular water (ECW). (Appendix 2) 
 
5.4.3 Echocardiographic measurements 
Left ventricular mass and left atrial volume were determined from standard 2-dimentional 
echocardiography and corrected for body surface area (BSA). E/A ratio, a parameter for 
mitral inflow or diastolic function and E/E' ratio, a surrogate marker for left ventricular 
filling pressure were measured concurrently as described in chapter 2. 
 
5.5 Statistical analysis 
Continuous data were expressed as mean values ± SD or median (inter quartile range), as 
appropriate. For data not normally distributed, Kruskal Wallis H test was applied to test the 
difference between groups. Unpaired t-test were applied to compare difference between 
two independent variables. Paired t-test was used to compare the difference between 
baseline and follow up data. Multi-level strategy was applied in the multi-variant analysis. 
P values <0.05 was considered to be statistically significant. Multi-variant analysis was 
done by MLwin. Other statistical analyses were performed using IBM SPSS software, 
version 20.0 (SPSS, Chicago, IL) 
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5.6 Results 
5.6.1 Baseline patient characteristics: body composition and cardiac 
parameters 
57 patients from University Hospital of North Staffordshire were recruited in the BIA 
study of which five anuric patients were excluded from this sub-analysis due to the limited 
number. Hence, this sub-analysis was only confined to the 52 non anuric patients. 
 
Recruitment, randomization and dropout were summarized in the consort diagram in 
Figure 5.1 and no significant difference was found regarding dropout rate or reason 
between active and control group. More patients were randomised to the control compared 
to the active group (n=31 vs 21) and after accounting for dropouts 24 and 15 patients 
completed the study for final analysis respectively. Patients in the active group were 
significantly older than the control group (63.2±13.7 vs 54.52±15.8 years, P=0.05). Both 
groups showed similar Stoke comorbidity grades, dialysis vintage, residual renal function, 
blood pressure and body composition as determined by BIA measurements. The data are 
summarised in Table 5.1 and Table 5.2. 
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Figure 5.1 Consort diagram of recruitment, randomization and drop out 
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Table 5.1 Baseline clinical characteristics of active and control group 
  Control  Active P value 
N 31 21   
Gender (female/male) 13/18 6/15 0.39  
Age (year) 54.52±15.8 63.2±13.7 0.05  
Time on PD (mon) 25.26±23.8 22.9±20.1 0.71  
Urine volume (ml) 1,512±832 1,228±633 0.20  
Renal Kt/V 1.28±0.8 1.0±0.6 0.28  
Albumin(g/L) 33.1±4.2 32.0±5.5 0.46  
Systolic BP(mmHg) 154.8±22.6 144.7±21.7 0.13  
Diastolic BP (mmHg) 86.4±12.2 79.2±15.2 0.08  
Clinical weight (kg) 78.9±20.1 82.7±12.5 0.41  
Dialysate dose (ml) 8,560±1,932 8,920±2,067 0.53  
Total Glucose(g) 118.9±44.2 114.1±39.1 0.71  
Average Glucose (g) 1.37±0.3 1.4±0.2 0.82  
TBW(L) 40.86±8.2 44.0±7.0 0.16  
ECW (L) 18.73±4.0 20.3±3.4 0.14  
ECW/TBW 0.46±0.1 0.5±0.1 0.76  
Height2/Resistance(cm2/Ω) 56.55±12.0 61.9±12.0 0.12  
Height2/Reactance(cm2/Ω) 551.06±149.9 614.3±156.8 0.15  
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Table 5.2 Stoke comorbidity grade in randomization group 
Stoke Comorbidity Grade Control Active Total 
0 13 7 20 
1 15 12 27 
2 3 2 5 
Total 31 21 52 
 
Left ventricular mass index and ejection fraction were comparable in both control and 
active groups. However E/E’ was significantly higher in the active compared with  control 
group at baseline (11.9±6.0 vs 8.95±2.9, P=0.05). Echocardiographic tissue velocity in 
systolic and diastolic phases were similar in both groups. Cardiac data were summerised in 
Table 5.3. 
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Table 5.3 Baseline echocardiograph characteristics of active and control group 
  Control Active P value 
N 31 21   
Left Vent. Mass Index  (g/m2) 114.78±38.6 116.3±37.2 0.89  
Left Atrial Volume Index  (ml/m2) 32.31±10.5 36.4±12.9 0.22  
LV Ejection Fraction (biplane, %) 54.39±9.8 49.9±11.1 0.14  
Stroke Volume (VTI, ml)  67.71±24.8 79.2±20.5 0.09  
Cardiac Output  (l/min) 4.61±1.6 5.2±1.4 0.17  
E/E’  8.95±2.9 11.9±6.0 0.05  
Systolic TV (septal/lateral walls) cm/s 5.61±1.6 5.4±1.5 0.62  
Early diastolic  TV (cm/s) 5.71±2.4 4.7±2.4 0.13  
Late diastolic (atrial) TV (cm/s) 6.66±1.9 7.2±1.8 0.29  
Systolic TV (4 walls) cm/s 5.53±2.5 4.7±2.4 0.24  
TV - tissue velocity 
 
5.6.2 Longitudinal change in active and control group: Body 
composition and cardiac parameters 
Taken as a whole, patients from both study groups demonstrated progressive worsening of 
LVEF (-2.8%, 95% CI -5.6 – -0.025, P<0.05), E/E’ (+1.3, 95% CI -0.43 – 2.1, P<0.05) and 
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systolic wall tissue velocity (four walls) (-0.46, 95% CI -0.11 – -0.81, P<0.01) (see Table 
5.4). The paired t-test showed a significant decrease in LVEF in controls over 12 months 
(56.9±6.1 vs 52.5±6.5, P=0.013), whereas change in the active group was non-significant 
(54.0±7.4 vs 52.3±5.2, P=0.33). E/E’ worsened in control group (8.6±2.3 vs 10.8±2.8 
P<0.01) but no change was observed in active group (11.0±3.2 vs 11.5±2.6 P=0.416) (see 
Table 5.5). E/E’ was associated with ECW/TBW but showed inverse relationship with 
RRF, both at baseline and 12 month. Target weight was more likely to be reduced in the 
active group (-3.3kg vs -0.05kg, P<0.05) resulting in greater decrease in clinic weight 
compared with the control group (-3.0kg vs -2.6kg, P<0.05). No significant change in 
ECW/TBW ratio was observed in both groups longitudinally (+0.012 in control vs +0.02 in 
active, P=NS). Urine volume was better maintained in the active group but no between 
group differences was found in residual renal clearance or glucose exposure (see Table 
5.6). On multivariate analysis LVEF and E/E’ at 12 months were independently predicted 
by their respective baseline values and study randomisation group after controlling for 
comorbidity status, age, gender and baseline BIA (Table 5.7 and Table 5.8). Decision to 
reduce target weight was more likely to be made in active group than in control group 
(Table 5.9). 
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Table 5.4 Longitudinal cardiac patients for all patients from both groups 
combined 
  change  95% CI 
Left Vent. Mass Index  (g/m2) +2.3 (-4.7, 11.8) 
Left Atrial Volume Index  (ml/m2) +2.8 (-2, 6.9) 
LV Ejection Fraction (biplane, %)  -2.8 (-5.6, -0.025)  
Stroke Volume (VTI, ml)  -4.6 (-12.7, 3.5) 
Cardiac Output  (l/min) -0.23 (-0.7, -0.001) 
E/E’   +1.3** (0.43, 2.1) 
Systolic tissue velocity (TV) (septal/lateral walls) cm/s  -0.37* (-0.73, -0.001) 
Early diastolic  TV (cm/s) +0.06 (-0.4, 0.5) 
Late diastolic (atrial) TV (cm/s) -0.23 (-0.63, 0.17) 
Systolic tissue velocity (4 walls) cm/s -0.46** (-0.11, -0.81) 
*, P<0.05; **, P<0.01; Ɨ, P=0.05 
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Table 5.5 Longitudinal change of echocardiograph characteristics in active and 
control group 
  control active 
N 24 15 
Left Vent. Mass Index  (g/m2) -0.96 (-15,+14) +14 (-4.5, +33) 
Left Atrial Volume Index  (ml/m2 +4.2 (-1.1, +9.5) +2.5 (-7.5, +12) 
LV Ejection Fraction (biplane, %)  -4.4 (-1, -7.8)* -1.6 (-5.3, +1.9) 
Stroke Volume (VTI, ml)  -3 (-15, +9) -7.6 (-27, +12) 
Cardiac Output  (l/min) -0.12 (-0.8, +0.6) -0.27 (-1.3, +0.8) 
E/E’   +2.3 (1.2, 3.3)** -0.45 (-0.7, +1.6) 
Systolic tissue velocity (TV) (septal/lateral 
walls) cm/s 
 -0.47 (-0.02, -
0.93)* 
-0.17 (-0.86, 
+0.52) 
Early diastolic  TV (cm/s) -0.11(-0.6, +0.4) +0.18 (-1, +1.3) 
Late diastolic (atrial) TV (cm/s) -0.08 (-0.6, +0.45) 
-0.61 (-1.6, 
+0.37) 
Systolic tissue velocity (4 walls) cm/s 
-0.19 (-0.74, 
+0.34) 
-0.24 (-0.8, 
+0.35) 
*, P<0.05; **, P<0.01 
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Table 5.6 Longitudinal change of patient characteristics in active and control 
group 
  control active 
N 24 15 
Target weight (kg) -0.05 (-1.7,1.6)  -3.3 (-0.7, -5.8)* 
Clinic weight (kg) -2.6 (+2.3, -7.5)  -3.0 (-0.33, -5.6)* 
Urine volume (ml)  -405 (-139, -762)** -149 (-442, +144) 
Renal Kt/V  -0.3 (-0.5, -0.55)*  -0.24 (-0.4, +0.05)* 
Systolic BP  -12 (-2, -21)* -3.5 (-11, +18) 
Diastolic BP  -4.9 (+0.1, -9.8)Ɨ -0.5(-9, +8) 
Albumin (g/l) -0.11 (-0.03, +0.01) +0.11 (-0.05, +0.26) 
Daily UF (ml) 167(-43, 376)  -41(-265, 183) 
Total dialysis glucose (g/day) +3.8 (-20, +27) +6.6(-12, +25) 
ECW (L) +0.64 (-0.7, +2.0) +0.3 (-1.8, 2.5) 
TBW (L) +0.36 (-0.9, +1.6)  -1.58 (-3.1, +0.01)Ɨ 
ECW:TBW ratio +0.012 (-0.01, +0.04) +0.02 (-0.02, +0.06) 
Hight2/Resistance(cm2/Ω) 1.09(-1.77, 3.94)  -2.56(-6.21, 1.09) 
Hight2/Reactance(cm2/Ω)  45.59(-33.49, 124.67) 24.57(-89.43, 138.57) 
*, P<0.05; **, P<0.01; Ɨ, P=0.05 
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Table 5.7 Multivariate modelling of longitudinal change of echocardiograph 
parameters for LVEF. 
  model for LV EF     
  β standard error P value 
Constant 52.73 1.88 <0.01 
LV EF (Baseline) 0.41 0.12 <0.05 
Comorbidity -2.91 1.39 <0.05 
Gender -1.59 1.67 NS 
Age -0.16 0.06 <0.05 
Active (compare with control)  4.44 1.76 <0.05 
ECW/TBW (Baseline) -5.04 15.09 NS 
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Table 5.8 Multivariate modelling of longitudinal change of echocardiograph 
parameters for E/E’ 
  model for E/E'     
  β standard error P value 
Constant 11.32 0.73 <0.01 
E/E’ (Baseline) 0.62 0.12 <0.01 
Comorbidity 0.60 0.58 NS 
Gender -0.23 0.69 NS 
Age 0.03 0.03 NS 
Active (compare with control)  -1.47 0.76 0.05 
ECW/TBW (Baseline) 7.88 6.29 NS 
Table 5.9 Clinical decision in active and control group 
  Target decrease  Target unchanged Target increase 
Control 19 85 18 
Active 17 64 5 
Chi square P value     <0.05 
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5.8 Discussion 
In this single centre secondary analysis of the UK-Shanghai BIA study it was observed that 
non anuric PD patients with BIA guided fluid management had better preservation of 
residual renal function and echocardiographic cardiac parameters namely the left 
ventricular ejection fraction and the early mitral inflow velocity to peak mitral annulus 
velocity (E/E’) ratio. However, the incorporation of BIA information in the clinical 
assessment of fluid status had very little impact on body composition as determined by 
BIA despite the decision to reduce target weight being more likely to be made in this 
group. The finding of stable fluid status over the 12-month study period in the non-anuric 
PD patients was consistent with the result of the main study.  
 
It is important to state that over time patients in both study group showed progressive 
deterioration in LVEF and E/E’. The multivariate analysis indicated that the most 
important predictors of cardiac function at follow-up were their base line cardiac function 
and comorbidity as well as randomisation group. Baseline fluid status (ECW/TBW) was 
not a predictor. Although we found, probably for the first time, that better preservation of 
both of the echocardiographic parameters was seen in the active BIA group, the reason for 
such findings are not immediately apparent. Fluid status was not different in these two 
groups despite the intervention to reduce weight, but strikingly, and perhaps surprisingly 
RRF was better preserved in the BIA group. RRF had been showed to correlate with LVH 
and LVEF in PD patients (Wang, Wang et al. 2002) and regression of LVH was observed 
in ESRD patients who had successful kidney transplant (Parfrey, Harnett et al. 1995, 
Rigatto, Foley et al. 2000). One could speculate better clearance of uraemic toxic with 
higher urine output and this may have slowed down the deterioration of left ventricular 
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systolic function. We did not measure the central or intravascular volume in this cohort 
that could have more impact on RRF but we do not expect any significant difference given 
our previous study has revealed plasma volume in PD patients was not expanded (see 
Chapter 2). It is possible, therefore, that BIA directed therapy resulted in interventions that 
protected loss of RRF; however it was not explained by increased diuretic prescription.  
 
The use of early mitral inflow velocity to peak mitral annulus velocity (E/E’) ratio by 
tissue doppler imaging has been validated as a surrogate parameter of elevated left 
ventricular filling pressure (LVFP) and is a powerful predictor of survival in cardiac 
patients with systemic hypertension and left ventricular systolic dysfunction (Wang, Yip et 
al. 2005, Wang, Yip et al. 2005). Studies in a PD population revealed up to 60% of patients 
had evidence of elevated E/E’ which added significant prognostic value for all cause 
mortality and cardiovascular death (Wang, Wang et al. 2008). Moreover, loss of RRF was 
found to be a significant factor associated with increased E/E’ in the same study. A recent 
study in ESRD patients indicated an E/E’ ratio of 15 or more has a sensitivity of 82% and 
specificity of 88% in predicting a LVEDP of 15 mmHg or more which, in turn predicts 
mortality (Sharma, Pellerin et al. 2006). The mean E/E’ ratio in our study was 10.45± 5.0 
(8.95±2.9 in control and 11.9±6.0 in active group) which was less than the threshold value 
reported in the study by Sharma et al and significantly much lower than reported in the 
Chinese PD population by Wang et al (20.1± 9.7) (Wang, Wang et al. 2008). Such 
magnitude of discrepancy may indicate different ethnicity in the study population with 
varying body composition, preservation of residual kidney function and cardiac function or 
different clinical practice or a combination of these factors. 
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There are several limitations in our study which was only designed as being exploratory 
and not powered to the predefined outcomes. This is a small single centre study with 
considerably fewer patients randomised to the active group. This randomization imbalance 
arose from the failure to stratify by centre. We did not include anuric patients in the 
analysis considering the small number of such patients in our population. The problem 
with older patients with higher E/E’ ratio in the active group has been discussed. 
 
5.9 Conclusions 
In conclusion, we found that cardiac function declines over time on PD in particular LVEF, 
E/E’ ratio and systolic wall motion. The clinical significance of these changes is unclear 
and warrants further investigation. The use of BIA has led to a systematic reduction in 
target weight, better preservation of urine volume and less deterioration in cardiac 
function. The mechanism of this benefit, which might be subject to Type 1 error, is 
unclear. Further studies to evaluate the use of BIA to target fluid management with the 
hope of protecting both the heart and residual kidney function are desirable.  
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6 Chapter 6  Dispersal kinetics of deuterated water in the 
lungs and airways following mouth inhalation; an 
exploratory real-time breath analysis by flowing afterglow 
mass spectrometry (FA-MS) 
 
6.1 Introduction 
The lungs are relatively dry organs and complex mechanisms exist to maintain this state to 
facilitate gas exchange across the alveolar interface that separates the blood from the lung 
air. Accumulation of fluid in the lungs (pulmonary oedema) is a common manifestation of 
many illnesses ranging from severe infection to heart or kidney failure. The development 
of pulmonary oedema is an insidious process and the clinical signs such as the presence of 
raised jugular venous pressure, chest crepitation on auscultation and peripheral oedema 
often present late. The routine use of chest radiograph is too insensitive to discriminate 
pulmonary oedema from other lung pathologies (Sivak, Richmond et al. 1983, Eisenberg, 
Hansbrough et al. 1987). Currently, there is a lack of a suitable clinical tool to aid 
clinicians in the management of this condition. 
 
The gold standard method for measuring extravascular lung water volume, EVLW, is the 
post-mortem gravimetric method (Pearce, Yamashita et al. 1965). This ex-vivo method is 
clearly of no use for clinical purposes. There are other techniques that evaluate EVLW 
such as computer tomography (CT), positron emission tomography (PET) and nuclear 
magnetic resonance (NMR) imaging. These have been validated against gravimetric 
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measurement providing quantitative estimation of EVLW (Meyer, Schober et al. 1984, 
Cutillo, Morris et al. 1986, Lange and Schuster 1999). Unfortunately, they are 
cumbersome, expensive, involve radiation and require specialist input. These shortcomings 
severely limit their general application outside the research setting.  
 
The dilution method using single or double indicators is another technique that is 
frequently used at the bedside. This method is based on mathematical concepts that enable 
calculation of the volume of distribution of an indicator injected into the circulation 
(Isakow and Schuster 2006). This requires the presence of a central venous access for 
indicator injection and a detector in the arterial system commonly inserted in the femoral 
artery. Due to its invasive nature, this technique is only employed in the intensive care 
setting where the monitoring of haemodynamic parameters is crucial to guide therapeutic 
intervention. This precludes its use in outpatient setting such as for patients with renal 
failure attending for haemodialysis treatment or heart failure monitoring. 
 
Deuterium labelling was used as early as the 1950’s to investigate the exchange of water 
molecules across pulmonary capillaries (Lilienfield, Freis et al. 1955). However, early 
techniques for measuring deuterium concentration, such as the spectrophotometric method, 
were labour intensive and the results were not immediately available to the clinician. 
Wallin et al has showed experimentally that patients with renal failure undergoing 
haemodialysis are more likely to have subclinical pulmonary oedema compared with 
healthy controls (Wallin, Jacobson et al. 1996). In this study, a double indicator dilution 
densitometric technique was employed using D2O and Indocyanine Green (ICG), a non-
diffusible indicator. A mixture of the two was administered via the venous limb of the 
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arterio-venous fistula which is a readily available vascular access, and blood was sampled 
in the arterial limb.  By studying the cardiac output and mean transit time from the dilution 
curves of the indicators, it is possible to deduce the lung water volume. However, real time 
measurement is not possible and specialised equipment is needed to detect ICG. 
 
Flowing afterglow mass spectrometry (FA-MS) is a relatively new technique that offers 
on-line, real time determination of deuterium abundance in water vapour in exhaled breath 
and in the headspace of donated fluid such as blood and urine. It does not require sample 
preparation and with a typical precision and accuracy of 1% it is a powerful tool in the 
study of body composition, in particular diseased states (Smith and Spanel 2001, Spanel 
and Smith 2001). So far, it has been used to measure total body water (TBW) by breath 
analysis following the ingestion of known quantity of D2O and to study the characteristics 
of water transport across the peritoneal membrane in patient treated by continuous 
ambulatory peritoneal dialysis (CAPD) (Davies, Spanel et al. 2001, Smith and Spanel 
2001, Asghar, Diskin et al. 2003). We now propose FA-MS may be of use in the study of 
lung water measurement.  
 
6.2 Aim of the study 
The main hypothesis is that following the delivery of a known quantity of deuterated water 
vapour, D2O, to the pulmonary airway, it rapidly equilibrates with lung water to form 
HDO. Then, by determining the exhaled breath HDO concentration and adopting the 
principle of isotope dilution (Meier and Zierler 1954), lung water volume can be estimated. 
The purpose of this preliminary pilot study is to observe the dispersal kinetic of HDO in 
the major pulmonary airway and alveoli following the inhalation of D2O vapour.  
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6.3 Study subjects and methodology 
Three healthy adult volunteers gave informed consent and were recruited for this limited 
pilot study. All three are non smokers and have no known lung pathology. 1 ml of neat 
D2O liquid (99.9% pure, Cambridge Isotope Laboratories, USA) was injected into a Tedlar 
bag inflated with clean, dry cylinder air to a volume of about 5 litres where the D2O 
vapour reached its saturated vapour pressure at room temperature – about 2 kPa. Baseline 
measurements of breath HDO abundance were then performed using FA-MS following 
which the three subjects were asked to inhale deuterium from essentially identical bag 
preparations just once at maximum inspiration. This was followed by immediate sampling 
of the exhaled breath by FA-MS to determine the HDO abundance in sequential single 
exhalations. These exhalations continued until the HDO abundance reached the pre-
ingestion baseline level. The measurements were carried out as the subjects sat upright 
adjacent to the FA-MS instrument, exhaling into a wide bore disposable cardboard tube 
having minimum resistance given by the standard breath sampling T-piece. The exhaled 
breath was sampled into the instrument via a heated capillary maintained at about 100oC. 
The details of the FA-MS analytical technique have been described in Chapter 2.  
 
6.4 Results 
Typical breath time profiles of HDO abundance before and after D2O vapour inhalation 
are shown in Figure 6.1 and Figure 6.2, plotted as the signal levels, ion counts per second, 
c/s, of the m/z 74 and m/z 75 analytical ions (see FA-MS section in Chapter 2). These data 
provide the D/H levels that are shown in Figure 6.3 (a) and (b). The first part of Figure 6.1 
shows several exhalations profiles prior to D2O vapour inhalation. These provide the 
baseline D/H value in the exhaled water vapour, which is typically 160 parts-per-million, 
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ppm, of the exhaled water vapour. As can be seen, the D/H value is much greater in the 
first exhalation following the inhalation of the D2O vapour, and then there is a steady 
decrease towards the pre-inhalation baseline level (see Figure 6.1). The high values of D/H 
in the early phase of the experiment in all subjects is largely due to HDO rich air contained 
in the mouth and trapped/released from the saliva. We observed small differences in the 
peak HDO abundance for the three volunteers and a rapid decay in the exhaled breath D/H 
value for all three volunteers, especially rapid for the healthy female A (Figure 6.3-a). 
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Figure 6.1 Multi ion profile provided by the FA-MS analysis software given as 
counts-per-second, c/s (left axis), of the analytical ions indicated.  
 
 
 
Figure 6.2 Expanded view of the shaded area in Figure 6.1.  
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Figure 6.3 (a) The rapid decay of the breath HDO abundance following D2O 
vapour inhalation. There is variation in the peak breath HDO level probably due 
to the differing inhalation techniques and lung capacities. (b) Log-transformed 
HDO abundance plotted against time; note the similar forms of the three decay 
curves. 
 
 
  
(a) 
(b) 
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6.6 Discussion 
This preliminary study was intended to pave the way towards a rapid, non-invasive 
measurement of lung water volume and the monitoring of pulmonary oedema. The 
inhalation of a given amount of D2O followed by the immediate measurement of the level 
of deuterated water in exhaled breath and applying the principle of isotope dilution 
provides a value for the lung water. Ideally, all the D2O must pass into the lungs, fully mix 
with the alveolar water, then liquid water/vapour phase equilibrium must be quickly 
established before the vapour is exhaled along the airways without modification, then to be 
measured immediately using FA-MS. However it must be expected that rapid D/H 
exchange will occur when D2O vapour contacts the liquid H2O (mucosa) that lines the 
airway entry to the lungs, and so partial conversion of the D2O to HDO will occur. 
Furthermore, it is likely that a fraction of the D2O and the newly produced HDO will be 
absorbed into the airway mucosa and only an indeterminate fraction will reach the lung 
water in the alveolar space where the desired dilution will occur. Then, on the exhalation 
cycle, further dilution may occur when the HDO again makes contact with the airways 
mucosa. Finally, exhaled water vapour enriched with HDO emerges. The simplest aspect 
of this is the immediate determination of the exhaled breath D/H level using FA-MS. 
These phenomena have been described in some detail for a variety of trace compounds in 
inhaled and exhaled air (Anderson, Babb et al. 2003). 
 
Complex as this scenario is, the data given in Figure 6.3 may provide some confidence in 
the pursuit of lung water measurement. The measured peak D/H values range from 2,600 
ppm to 6,200 ppm for the inhalation of about 0.1 mL of D2O (this corresponds to 4 L of 
inhaled air containing 3% of D2O vapour). Given none of the absorption effects mentioned 
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above, this would equate to an effective water exchange volume of 16 mL to 37 mL. On 
this basis, it would appear that a great loss of D2O/HDO does not occur and perhaps the 
peak D/H value is providing a sensible approximation to the volume of readily available 
water in the airways involved in mixing with inhaled vapour. The reason for the small 
variation in the peak D/H levels most probably lies in differences in the inhaled amount of 
D2O, breathing rate and lung volume capacity, but given that lung water volume is quite 
similar in healthy individuals it is probable that this variation is due to the first two 
variables. These are the important issues that need to be addressed to take this technique 
forward when more control is introduced into the measurements. 
 
The rapid decay of the exhaled breath D/H indicated by the data is very likely due to the 
absorption of the HDO into the total body water via transmission/mixing across the 
airways and, especially, flow into the blood (then body water) and due to exchange with 
water present in the inhaled ambient air. The similarity of the decay curves and the derived 
decay time constants is presumably because the HDO transmission rates in healthy 
individuals are similar. It may be that in pulmonary oedema, where the alveoli are partially 
blocked, the decay rate may be discernibly slower – a valuable medical parameter if shown 
to be the case.  
 
There are several limitations of this study, these including the small number of healthy 
participants and no inclusion of patients. As mentioned above, no strict control was placed 
on the inhalation procedure, which should be easy to control for healthy people, but this 
might be more challenging for sick patients. The amount of D2O/air inhaled was not 
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varied, but by doing so it might provide insight into the role of mucosa absorption, as 
mentioned above.  
 
6.7 Conclusions 
Pulmonary oedema is the worst spectrum of fluid overload characterized by abnormal 
accumulation of fluid in the alveolar space. The current gold standard bedside 
measurement of EVLW is the dilution method using various indicators but required 
invasive instrumentation. In this preliminary experiments, the dispersal kinetics of 
deuterium in exhaled breath of healthy participants following the inhalation of D2O vapour 
are described. The basic idea of lung water estimation and future work using this novel 
technique is discussed.  
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7 Chapter 7 Injection of deuterated water into the 
pulmonary/alveolar circulation; measurement of HDO in 
exhaled breath and implications for breath analysis 
7.1 Introduction 
Patients with severe renal impairment, especially those with end stage renal failure 
dependent on renal replacement therapy have extraordinary high risk of cardiovascular 
morbidity and mortality. Salt and water homeostasis is severely disrupted and fluid 
overload is increasingly being recognised as the major obstacle in the effort to reduce 
cardiac disease burden. Patients with little or no urine output on dialysis therapy are 
critically dependent on the ultrafiltration function to remove enough fluid to avoid the 
detrimental effect of hypervolaemia. Patients with abnormal fluid status may exhibit little 
signs or symptoms to alert the clinicians as most have imperceptible tissue oedema in the 
internal viscera and organs. While subcutaneous oedema detected in the peripheral limbs 
causes minor inconvenience to the patients, it is often a late sign and cannot be relied upon 
for early detection and intervention for abnormal fluid status. One of the crucial and 
susceptible organs of such issue is the lung. The pulmonary system is a relatively 
anhydrous organ and for a good reason. Effective gaseous exchange simple could not take 
place if such environment is compromised, causing a state of hypoxia and progressive 
organ dysfunction with life threatening consequences.  
 
Not surprisingly dialysis patients are prone to the development of pulmonary oedema, a 
medical condition characterised by abnormal accumulation of fluid in the extravascular 
space in the alveoli. Effective oxygenation is impaired and this leads to significant short- 
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and long-term morbidity and mortality. Therefore the detection and monitoring of 
pulmonary oedema by measuring lung water volume is crucial in the initiation and 
guidance of therapeutic intervention. The current gold standard bedside measurement of 
extravascular lung water volume (EVLW) are the dilution methods using various 
indicators, but despite the good correlation of the results with those obtained using the 
post-mortem gravimetric method, the invasiveness of the dilution technique limits its 
general application in the wider clinical setting.  
 
The dispersal kinetics of deuterated water in the lungs and airways following mouth 
inhalation with real-time breath analysis using flowing afterglow mass spectrometry (FA-
MS) have been characterized in Chapter 6 in the bid to evaluate the feasibility of 
measuring lung water volume. This particular study has provided some insights regarding 
the phenomenon of absorption of HDO into the airways and predictably how the inhalation 
approach to determine lung water volume was compromised by D/H exchange between 
HDO and H2O in the airways in both the inhalation and exhalation phases.  
 
There is another equally important parallel objective to this study. It has been generally 
assumed that the concentrations of endogenous trace gas metabolites present in exhaled 
breath are representative of their concentrations in the general blood/alveolar circulation 
and thus, for many years, this premise has driven breath analysis research aimed at clinical 
diagnosis of particular diseases and for physiological study (Miekisch, Kischkel et al. 
2008, Spanel and Smith 2011). However there has been some consideration given to the 
relationship between concentrations of breath metabolite and their concentrations in 
different parts of the respiratory system recently, firstly by Anderson et al (Anderson, Babb 
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et al. 2003), and then by King and his colleagues (King, Unterkofler et al. 2011, King, 
Unterkofler et al. 2012) using multi-compartment mathematical models that are compared 
with breath concentrations seen during exercise and for varying breathing patterns. Special 
attention was given to acetone, a highly soluble metabolite (King, Unterkofler et al. 2011, 
King, Unterkofler et al. 2012), and isoprene that is much less soluble, both being present in 
the exhaled breath of most humans (Salerno-Kennedy and Cashman 2005, Smith, Spanel et 
al. 2010). The relation of breath concentrations of isoprene and acetone to their arterial and 
venous blood concentrations had also been previously studied experimentally (O'Hara, 
Clutton-Brock et al. 2009). 
 
The general finding of these modelling/experimental studies is that those water soluble 
metabolites, e.g. Acetone, released at the alveolar interface and appeared in exhaled breath 
are subject to efficient exchange at the surfaces of the various parts of the airways. If the 
steady state concentrations within the fluid lining of the airways are disturbed from those 
in the systemic circulation, exchange can take place as the air/acetone passes along the 
bronchial tree and the exhaled concentrations can differ from the alveolar (O'Hara, O'Hehir 
et al. 2008, Storer, Dummer et al. 2011, King, Unterkofler et al. 2012). Low solubility 
isoprene is a different case; it is established that this compound is stored in the major 
muscle groups of the body and is released into the systemic circulation during exercise 
(Koc, King et al. 2011) where the concentration may increase initially and then decrease as 
the store is depleted. Given isoprene exchange between the exhaled breath and the airways 
is not as efficient as for acetone, the exhaled breath concentration is a better reflection in 
the blood concentration. Similar basic ideas may be applicable to other metabolites, 
including the abundant carbon dioxide present in exhaled breath (Brewer, Orr et al. 2011), 
and this phenomenon throws into question the concept of an alveolar plateau (Meyer, Mohr 
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et al. 1990), which assumes that carbon dioxide is entirely released at the alveolar 
interface. It is obvious that exhaled carbon dioxide increases above that to the resting state 
during exercise but such increment is not observed in the exhaled acetone, whilst the 
carbon dioxide concentration rises from about 4% to 6% (Smith, Pysanenko et al. 2009). 
This can be explained by the fact that acetone is an entirely systemic compound in 
equilibrium amongst the blood/exhaled breath/urine, between which phases it readily 
exchanges, and the production of this compound is not significantly altered by moderate 
exercise (Pysanenko, Wang et al. 2009). This also throws into question the idea that breath 
concentrations of trace gas metabolites should be controlled or normalised against the 
concomitantly measured carbon dioxide concentrations (Schubert, Spittler et al. 2001, Liu 
and Pawliszyn 2007). 
 
It is also relevant to mention that mouth-exhaled breath is known to be contaminated by 
trace compounds generated in the oral cavity and the airways. It is well observed that 
mouth-ingested exogenous compounds can be partially trapped and retained in the saliva 
and their release can contaminate the mouth-exhaled breath for period of minutes until the 
salivary circulation effectively removes them. This is best illustrated graphically in the 
study of using mouth ingestion of D2O for the measurement of total body water (TBW) in 
renal patients and the analysis of the exhaled breath deuterium content using the principle 
of isotope dilution in Figure 7.1 (Davies, Spanel et al. 2001). The initial steep rise and fall 
of the D/H ratio is due to the contamination/decontamination of the saliva, with the peak 
value of the HDO concentration being inordinately high; typically, 60 to 90 minutes need 
to pass before the equilibrium concentration of HDO in the exhaled breath is achieved, 
which reflects equilibration with TBW.  
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Figure 7.1 An example of a typical time variation of R1liq in parts-per-million, 
ppm (filled squares) determined from breath HDO measurements using FA-MS 
following oral ingestion of 18.7 g of D2O by a volunteer. The open squares are 
simultaneous measurements for a control who has not ingested D2O (data from 
(Smith and Spanel 2001)). 
 
7.2 Aims of the study 
In the continuation of the challenge of lung water measurement, we chose to 
investigate another approach involving the injection of a known amount of an 
HDO/H2O mixture directly into the pulmonary circulation. We also seek to 
investigate the effects of HDO concentration in the exhaled breath as it travels 
through the pulmonary circulation and into the alveolar space before finally being 
sampled and measured by FA-MS ( 
Figure 7.2). 
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Figure 7.2 Flow chart demonstrating the pathway of HDO/water mixture through 
the cardio-pulmonary circulation following injection into the internal jugular vein 
prior to FA-MS sampling of the exhaled breath. The theoretical assumptions 
underpin the methodology are included.  
 
7.3 Study subjects and methodology 
7.3.1 FA-MS: Determination of the D/H content of water vapour 
The details of the FA-MS analytical technique have been discussed before. Briefly, a 
swarm of H3O+ precursor ions is generated by a microwave discharge in flowing helium 
carrier gas possessing a trace of water vapour. These precursor ions react with the H2O, 
HDO, H217O and H218O molecules in the water vapour contained in a breath sample (or the 
headspace of an aqueous liquid, e.g. urine, serum) that is introduced into the helium 
stream. This results in the formation of hydrated clusters ions, H3O+(H2O)3 at a mass-to-
HDO/water mixture injection 
Internal jugular vein 
Pulmonary arteries and 
arterioles (Assumption 1: 
Complete mixing of 
deuterated water with 
pulmonary blood) 
 
Bronchial tree 
(Assumption 3: 
No loss of HDO 
along the 
airway) 
 
Right heart 
Alveolar capillaries/space 
(Assumption 2: HDO 
containment within the 
pulmonary circulation i.e. 
without significant 
leakage into the systemic 
circulation) 
 
Exhaled breath with HDO 
sampled by FA-MS 
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charge ratio, m/z = 73, and their isotopic variant ions H8DO4+ and H917OO3+ at m/z = 74 
and H918OO3+ at m/z = 75. By adopting the known fractional abundance of 18O in water 
vapour and accounting for the contribution of the isotopic ions H917O16O3+ to the ion 
signal at m/z =74, a measurement of the 74/75 ion signal ratio under equilibrium conditions 
provides the deuterium to hydrogen abundance, D/H, in the water vapour sample (R1vap). 
The corresponding deuterium abundance in the liquid from which the HDO is evaporating, 
R1liq, is derived from R1vap using a correction (a coefficient of 0.935 at a liquid sample 
temperature of 37 °C) that essentially accounts for the difference in evaporation rates of 
H2O and HDO from the liquid to the vapour phase (Smith and Spanel 2001, Spanel and 
Smith 2001). It is important to note that a conventional mass spectrometric approach to 
analysing breath water vapour for its deuterium content, which would involve electron 
ionisation, would be seriously compromised since electron collisional ionisation does not 
produce a predictable distribution of H2O+ and HDO+ ions. In FA-MS, an equilibrium 
distribution of the analytical ions is produced, according to the theory of isotope exchange, 
as indicated above.  
 
7.3.2 Protocol of the injection of D2O/H2O mixtures 
An accurately known volume of a D2O/H2O mixture of known composition was injected 
directly into the pulmonary circulation and to monitor the immediate changes in breath 
HDO, and hence the D/H ratio, using the FA-MS real time analytical method. Assuming 
this is a closed system, then in principle the breath deuterium content, as measured 
continuously in sequential breath exhalations, should provide an estimate of the volume of 
water/blood in the pulmonary circulation. 
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Nine haemodialysis patients were recruited to the study. Permission for the study was 
obtained from the Local Ethics Committee and informed consent was obtained from each 
patient. Total body water estimated by bioimpedance analysis was performed prior to 
deuterium injection. All patients had central venous catheters fitted to facilitate 
haemodialysis, which was situated in the right internal jugular vein (RIJ). Specified 
volumes of the sterile D2O/H2O mixture (10%, Cambridge Isotope Laboratories, USA) 
were injected into the RIJ via the catheter and flushed with saline to eliminate dead space 
in the catheter. The RIJ drains into the right atrium and then passes into the right ventricle 
of the heart, which then contracts and delivers the deuterated water into the pulmonary 
vasculature via the pulmonary artery. We presume that thorough mixing of the injected 
deuterated water and blood has occurred. The water/blood mixture travels through a 
successive series of arterioles and eventually arrives at the pulmonary alveoli where release 
of HDO and H2O occurs into the lung air. The number density ratio of these molecules in 
the vapour/gas phase depends on their solution phase ratio and the temperature, which 
must be close to 37 °C. Then the oxygenated blood is returned in the venous system and 
eventually drains back into the left atrium via the pulmonary vein. This will then be 
delivered to the rest of the body tissues by the left ventricle. If thorough mixing of the 
HDO occurs within the pulmonary loops and is sampled by the lungs, this would result in 
an alveolar air/vapour phase D/H ratio according to that given by the amount of deuterated 
water injected and the total volume of water in the pulmonary circulation. (Note- the lung, 
including the airway bronchi and bronchioles, relies on the blood supplied by the bronchial 
arteries for oxygen and nutrients and is a part of systemic circulation rather than pulmonary 
circulation). 
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7.4 Results 
7.4.1 Basic demographics and exploratory measurements 
Demographics of all HD patients are summarized in Table 7.1. First of all, the amount and 
concentration of deuterated water needed to be determined that can be injected safely that 
would result in measurable D/H ratios in exhaled breath following the general principle 
described before. By estimating the volume of the pulmonary blood and extra vascular 
water to be a maximum of one litre (1L) (Brigham, Ramsey et al. 1971, Lange and 
Schuster 1999), the injection of 1 mL of D2O should result in an increase of the vapour 
headspace D/H ratio by at least 1000 parts-per-million, ppm, which can be easily handled 
by the FA-MS analytical technique.  
 
The exhaled breath of the first patient, P1, was first analysed (in several single exhalations) 
to obtain the baseline value of D/H ratio (which should be close to that of the local tap 
water which is 150 ppm) and then 10 mL of a 10% mixture of D2O in pure water was 
injected into the central venous catheter in the patient’s RIJ vein and breath samples were 
analysed in real time every 30 seconds or so. Breath measurements on a healthy volunteer 
were interspersed with the patient data as control measure and to check the proper 
operation of the FA-MS instrument; the invariant D/H value at close to 150 ppm served as 
verification. The results are presented graphically in Figure 7.3. The D/H ratio increased 
rapidly after a delay for about 2 minutes and then reached a plateau with the increment in 
D/H being only about 70 ppm. This was barely 10% of the predicted 1 L of total lung 
volume on the assumption that the vapour released at the alveolar interface and the D/H 
ratio in the lung air was undisturbed as it flows along the bronchial tree and left the 
respiratory system via the mouth for direct sampling.  
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Further on in the experiment the D/H value began to fall from the plateau value 2 to 3 
minutes after injection. Several further sequential injections were performed in the same 
patient with similar results. The protocol was repeated on another patient, P2, and the 
results obtained were shown in Figure 7.3, where a similar form of D/H plot is evident.  
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Table 7.1 Patients demography, TBW and TLW estimation 
Patients Age Gender Height (cm) Weight (kg) 
TBW 
BIA 
(L) 
TBW 
D_Breath 
(L) 
TBW 
D_Blood 
(L) TLW(L) 
1 32 F 164 80.1 32.5 17.99 22.81 NA 
2 61 M 161.4 74.6 39.5 24.75 24.51 NA 
3 63 M 171.1 88.4 44.1 41.67 44.94 15.5 
4 57 F 157.8 66.4 34.6 33.24 35.71 13.9 
5 41 M 174.7 76.5 41.5 42.55 34.48 11 
6 70 F 167.8 73 37.5 29.82 33.15 18.4 
7 79 F 162.6 57.2 33.6 28.99 32 18.5 
8 63 M 175.2 88.4 51.1 50.63 48.78 27.5 
9 70 M 171.2 71.6 44.4 37.04 43.01 19.4 
TBW = total body water, BIA = Bioimpedance analysis, D = Deuterium,  
TLW = total lung water, NA=Not applicable. 
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Figure 7.3 Plots against time, t in minutes, of the values of the D/H ratio as 
measured by FA-MS in parts-per-million, ppm, in single breath exhalations 
following sequential injections (at times indicated by the arrows) of 10 mL of a 
sterile 10% mixture of D2O in pure water into the right internal jugular vein of 
two haemodialysis patients. Note the pre-injection value of D/H measured as 150 
ppm.
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7.4.2 Further IV D2O injections with larger volume 
The following patient received a single larger volume (30 ml) of the 10% mixture 
intravenously and the expected increase and decrease in D/H and the approach towards an 
equilibrium value from which TBW can be estimated was observed, as exemplified by the 
oral ingestion data shown in Figure 7.1. After this it was decided that the remaining six 
patients should received 40 ml of the 10% mixture to further enhance the measured D/H 
values. The data obtained for all patients showed similar forms after the injection of the 40 
ml mixture, and three examples are presented in Figure 7.4. The D/H ratio in the exhaled 
breath increased rapidly to peak values after about three or four minutes but the fractional 
increase of the D/H at the peak is still only about 10% of the value deduced from the 1 L 
estimate of the total lung water volume. The expected decrease in D/H occurs as the 
deuterated blood enters the systemic circulation as deuterium exchanges with the TBW, 
similar to that seen in the data in Figure 7.1. 
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Figure 7.4 Plots against time, t in minutes, of the values of the D/H ratio in parts-
per-million, ppm, as measured by FA-MS in single breath exhalations following 
single injections of 40 mL of a sterile 10% mixture of D2O in pure water into the 
right internal jugular vein of three haemodialysis patients, P3, P4 and P5, given in 
Figures 7.3a, b and c respectively.  
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It is instructive to fit curves to the data plots given in Figure 7.4, since this can provide four 
interesting parameters: (i) the time constant at early times, t1, associated with the increase 
in the D/H value; (ii) the time constant t2 for the decay of D/H at later times; (iii) the late 
time equilibrium value of D/H, De, from which TBW can be estimated; (iv) the nominal 
maximum value for D/H at zero (injection) time, D0, that accounts for dispersal of the 
HDO from the combined effect of pulmonary circulation leaking into the systemic 
circulation and loss of HDO as the breath passes along the bronchial tree. The functional 
form describing the time dependence of D/H, indicated as D(t), using the above parameters 
together with the natural D/H abundance present in breath prior to injection (Dn, typically 
150 ppm) may be written as: 
 
D( t ) =  De + ( Dn −  D0) e−t/t1 + ( D0 −  De) e−t/t2   (1) 
 
The experimental data were fitted numerically by this function using the ordinary least 
square method of non-linear regression. The results are indicated by the solid lines in 
Figure 7.4.  Additionally, the values of D0 indicated are obtained by extrapolation using 
the first and the third terms of the right side of equation (1) only (dashed lines). 
 
The respective parameters can be considered in turn and their likely interpretation. 
 
 (i). The time constants t1 obtained from the data given in Figure 7.4 are: P3, 2.5 min; P4, 
0.85 min, P5, 0.65 min. If the pulmonary circulation is completely contained for a period 
long enough for complete mixing of the HDO in the blood/water volume and no loss of 
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HDO along the bronchial tree occurred, then the D/H in the exhaled breath would rise 
rapidly to much higher values than the observed peak values, as explained previously. The 
speed of the blood flow in the pulmonary circulation is fast at an estimated 1 m/s 
(calculated from the typical values cardiac output and internal diameters of the jugular 
vein). Therefore, it is reasonable to conclude that either mixing of the bolus of the injected 
deuterated water with the pulmonary blood is not rapid and does not evenly distribute into 
alveolar blood or leakage of this blood into the systemic circulation rapidly occurs or loss 
of HDO occurs along the bronchial tree. It is likely that all three possibilities occur. What 
is interesting is that the t1 for P3 is 3 to 4 times longer than for P4 and P5. 
 
(ii). The time constants t2 obtained from the data given in Figure 7.4 are: P3, 14.0 min; P4, 
15.7 min, P5, 15.5 min. Hence, the approach to equilibrium of the breath D/H value, and 
hence mixing of D within the TBW, occurs in similar times for all three patients, although 
it is somewhat faster for P3. The actual values of t2 in minutes are unremarkable and very 
similar to those we have commonly observed in healthy volunteers and patients. 
 
(iii). The De values obtained from the data given in Figure 7.4 are: P3, 238 ppm; P4, 270 
ppm, P5, 241 ppm. To estimate TBW the initial (baseline) value, Dn, of 150 ppm must be 
subtracted from these figures to provide the increase in D/H, i.e. ΔD, due to the injection of 
the 4 mL of D2O. Thus, the ΔD values in ppm are 88, 120 and 91 respectively. The TBW 
is given by the volume of D2O (mL) injected divided by ΔD (Davies, Spanel et al. 2001), 
which gives for P3 45.5 L, for P4 33.3 L and for P5 44.0 L. A more instructive parameter 
is the percentage water content, %W, of the body as given by (TBW/weight, W). Thus, for 
P3 (Male; W = 88.3 kg; BMI = 30.2), %W is 51.5 %. For P4 (Female; W = 66.4 kg; BMI = 
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26.7), %W is 50.2% and for P5 (Male; W= 76.5 kg; BMI = 25.0), %W is 57.5%. These 
derived %W values are within the expected range (Davies, Spanel et al. 2001, Smith, Engel 
et al. 2002), but the low value for the male patient P3 is somewhat lower than the average 
and this is in accordance with his larger BMI, which is indicative of excessive body fat. 
The lower value of %W for the female P4 is in accordance with expectations that female 
subjects, on average, have more body fat than males and thus fractionally less muscle in 
which the body water is largely located. P5 has the ideal BMI and this goes with the mid-
range %W for males.  
 
(iv). The D0 values obtained from the data given in Figure 7.4 are: P3, 395 ppm; P4, 425 
ppm, P5, 481 ppm. Following the arguments given above, these would correspond to 
pulmonary water volumes of about 16, 14.5 and 12.5 L, which are clearly too large 
(Michard 2007). This anomalous result is likely due to the passage of HDO into the 
systemic circulation and loss along the airways that reduces the breath HDO concentration. 
Therefore original assumptions do not hold and the revised flow diagram of HDO/water 
mixture pathway is demonstrated in Figure 7.5. 
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Figure 7.5 Revised flow diagram showing the pathway of HDO/water mixture 
following injection into the internal jugular vein. The low HDO concentration in 
the exhaled breath is incompatible with the original assumptions (see Figure 7.2). 
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7.5 Discussion 
The initial objective of these studies was to research a method for estimating lung water by 
breath analysis, which, if successful, would be of great value to clinicians.  But it was 
immediately obvious that the chosen approach was not viable and so the goal of lung water 
determination via breath analysis is proving to be elusive. However, the experiments have 
revealed some interesting physiological results that do impinge on the general area of 
breath research. As outlined before, the loss along the bronchial tree of trace compounds 
that are released from the blood stream at the alveolar interface is an important 
phenomenon that must be considered when relating metabolites in exhaled breath to their 
systemic (blood stream) concentrations. The importance of the influence of the airways is 
indicated by the loss of HDO in the airways after its deliberate elevation in the 
pulmonary/alveolar blood stream. This phenomenon is most significant in the early phase 
after injection, that is, before equilibrium of HDO within the TBW has been reached. Then, 
D-H exchange between the vapour HDO in the exhaled breath and the H2O in the water in 
the airways surfaces can occur, thus modifying the exhaled HDO concentration. However, 
this does not invalidate the measurements of TBW using the isotope dilution principle 
because it is the equilibrium breath and blood concentrations of HDO that is utilized for 
TBW measurement when HDO in both exhaled breath and the water in the airways is 
equilibrated and exchange losses along the bronchial tree do not occur. This is further 
supported by the close correlation between TBW by deuterium analysis derived from 
exhaled breath and blood headspace in this experiment (see Figure 7.6). 
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Figure 7.6 TBW estimated by FA-MS deuterium analysis of exhaled breath and 
blood headspace after equilibration 
 
The significance of the present study to breath analysis in general is clear. If the 
concentrations of gases released at the alveolar interface are higher or lower than those 
within the body fluids then the breath concentrations can be increased or decreased as it 
passes along the bronchial tree. This will be particularly severe for highly water-soluble 
compounds that are not in systemic equilibrium. Acetone, although highly soluble in water, 
is also truly systemic being equilibrated amongst the blood, urine, TBW and exhaled 
breath, and so this compound is undisturbed in breath by passing along the airways. 
Isoprene, on the other hand, is not very water soluble and not seriously absorbed along the 
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airways. However, it is soluble in lipids and muscle, which act as a storage compartment 
for this compound, but exercise releases the isoprene into the blood stream (Koc, King et 
al. 2011). This release is readily observed by its increase in exhaled breath during the early 
phase of exercise; it is seen to fall during continued exercise as the source of it diminishes. 
These influences can presumably occur for other metabolites, so the temptation to tacitly 
relate breath concentrations to blood concentrations must be done with circumspection for 
each individual trace compound.  
 
7.6 Conclusions 
In conclusion, the measurement of HDO in exhaled breath and the maximum D/H 
abundance following the injection of deuterated water into the pulmonary and alveolar 
circulation via the dialysis catheter in haemodialysis patients was very much lower than 
anticipated. This has vastly overestimated the predicted volume of the total lung water and 
therefore rendering the accurate measurement of this important clinical parameter to detect 
and monitor pulmonary oedema using this technique unfeasible.  We have proposed a 
number of possible reasons for the reduced D/H in the exhaled breath. The data presented 
in study indicate that the concentrations of soluble compounds in exhaled breath do not 
always correspond to their equilibrated alveolar concentrations. Whilst this is now clear to 
some researchers, as well explained in the literature (Anderson, Babb et al. 2003, King, 
Unterkofler et al. 2011, Koc, King et al. 2011, King, Unterkofler et al. 2012), the 
assumption of equivalence between exhaled and alveolar breath still appear in the current 
literature. This study strives to contribute to the clarification of this issue. 
 
  
  
Chapter 8  Conclusions and future directions 
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8 Chapter 8  Conclusions and future directions 
One of the primary objectives of renal replacement therapy is to attempt to restore 
euvolaemia by a combination of ultrafiltration by dialysis, fluid restriction and dietary 
modification, in particularly curbing salt intake. There is a growing evidence to 
demonstrate that volume expansion is common among dialysis patients and more 
importantly, its association with markers of cardiac dysfunction such as raised cardiac 
biomarkers, left ventricular hypertrophy, inflammation and muscle wasting, all of which 
predict mortality. Cardiovascular disease (CVD) represents the leading cause of death in 
dialysis patients, responsible for 40 to 60% of all deaths in the United States and 
Australasia (Johnson, Dent et al. 2009) and some studies also suggest PD patients suffer 
from higher risk of congestive heart failure and myocardial infarction compared with the 
HD patients (Johnson, Dent et al. 2009, Kim, Kim et al. 2015).  
 
LVH is an important predictor of cardiovascular death (Parfrey, Harnett et al. 1990, Foley, 
Parfrey et al. 1995) and PD patients have been found to have higher incidence of LVH and 
overhydration compared to HD patients in several prospective studies (Takeda, Nakamoto 
et al. 1998, Enia, Mallamaci et al. 2001).  The progressive loss of RRF and altered 
membrane transport status causing UF failure with time on PD treatment could have a 
negative impact on hydration status. On the other hand haemodialysis patients are not 
subjected to such constraints and the fluid status can be manipulated readily by altering the 
desired UF volume. A retrospective study suggested that long term good BP control and 
regression of LVH could be achieved with tight control of fluid status by means of 
progressive UF and strict salt restriction (Ozkahya, Ok et al. 1998). Similar results were 
demonstrated in a prospective randomised trial using BIA target fluid removal in HD 
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patients (Hur, Usta et al. 2013). Onofriescu et al showed survival benefit in HD patients 
where strict volume control was achieved by BIA guided UF although cardiac assessments 
by echocardiography were not performed (Onofriescu, Hogas et al. 2014).  
 
The conventional method of fluid assessment based on physical examination is subjective 
and crude. Clinical biometrics such as blood pressure and body weight are informative but 
often confounded by the presence of cardiac dysfunction, multimorbidity and 
imperceptible changes in body composition longitudinally without any significant 
deviation from baseline weight. The practice of titrating target dry weight down to achieve 
normovolaemia without a validated clinical monitoring system risks hypovolaemia, 
causing loss of residual renal function in PD and cardiac stunning in HD patients, both 
associated with poor survival (Bargman, Thorpe et al. 2001, Termorshuizen, Dekker et al. 
2004, Selby and McIntyre 2007). Accurate assessment and monitor of fluid status to 
inform clinical decision is therefore a crucial part of renal replacement therapy.  
 
One of the potential candidates to aid clinical assessment of fluid status is bioimpedance 
analysis. The derived impedance when an alternating current is applied to biological tissue 
at a given voltage has two components: resistance which is inversely proportional to the 
total content (intracellular and extracellular water) and reactance, a measure of electrical 
capacitance which is proportional to the cell mass. The two parameters can be used in the 
vector format called bioimpedance vector analysis, after adjusted for height, to track 
changes in body composition longitudinally (Piccoli 1998). These simple measurements 
can be further transformed into volumetric expression of different fluid compartments such 
as ECW and TBW, often with assumptions incorporated into the algorithms. 
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Overhydration as determined by vectors or ECW/TBW ratio has been shown to correlate 
with worse survival in dialysis cohorts (Pillon, Piccoli et al. 2004, Paniagua, Ventura et al. 
2010, Koh, Wong et al. 2011).   
 
One of the abnormal features of body composition as determined by BIA in chronic 
dialysis patients is progressive reduction in muscle mass coupled with disproportional 
increase in ECW with time, something not dissimilar to other chronic diseases (Plum, 
Schoenicke et al. 2001, Woodrow, Oldroyd et al. 2004, van Biesen, Claes et al. 2013). 
Overhydrated patients tend to be older, more likely to be diabetic, have more comorbidities 
and have a lower serum albumin. Hypoalbuminaemia has been shown to predict poor 
survival in patients on dialysis and it is much more prevalent in PD than HD patients, 
partly due to significant peritoneal protein loss but increasingly seen to be associated with 
inflammation (Kaysen, Yeun et al. 1997, Plum, Schoenicke et al. 2001). In patients on PD, 
hypoalbuminaemia is strongly associated with overhydration as determined by BIA but it 
was not clear if the excess fluid is distributed equally between the intravascular and 
extravascular compartment.  
 
The study in chapter 3 confirmed the association between raised ECW/TBW ratio and low 
albumin and inflammation in PD patients and the measured fluid excess was 
predominantly in the interstitial space, i.e. extravascular, given that the measured plasma 
volume was not expanded. In the multivariate analysis, hypoalbuminaemia became the 
only predictor of tissue overhydration, displacing other relevant clinical determinants of 
hypervolaemia. We also proposed a different approach to characterising tissue 
overhydration by using the difference between measured TBW by deuterium dilution and 
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estimated by BIA which correlated with the difference between the measured and 
estimated ECW/TBW by BIA. The advantage of this approach is that it combines an 
absolute determination of body water with a technique that relies on data derived from 
populations that often differ from the relatively sick dialysis population to which it is being 
applied. This is especially the case at the extremes of body composition such as obesity 
and malnutrition. This approach also demonstrated PD patients to be overhydrated, 
especially when hypoalbuminaemic. The clinical implications of this are twofold:  
 
(a) given the high frequency of hypoalbuminaemia in PD patients due to their peritoneal 
protein losses (transport status being a function of intraperitoneal inflammation and the 
single most important determinant of plasma albumin concentration), then inevitably tissue 
overhydration will be more common in PD than HD patients, and 
 
(b) that any attempt to normalise fluid status in the context of hypoalbuminaemia may 
unnecessarily cause central volume depletion and loss of RRF. No intervention currently 
exists that can alter this, but it is reassuring that the reduced survival associated with lower 
plasma albumin, seen in both dialysis modalities, is if anything less marked in PD patients 
(Mehrotra, Duong et al. 2011).  
 
The cardiac sub-study in chapter 3 revealed that a high proportion of PD patients (93%) 
had NYHA class II and III heart failure symptoms with varying degree of LVH (62%). The 
predominant pathology was diastolic dysfunction and many fulfilled the diagnostic criteria 
of HFNEF. Biomarker of cardiac damage such as serum BNP and elevated ECW/TBW 
ratio determined by BIA have been shown to predict survival in PD (Paniagua, Amato et 
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al. 2008, Koh, Wong et al. 2011) but the relationship between BNP and differing fluid 
compartments remains unclear. We found for the first time in this study, no correlation 
between BNP and intravascular volume as measured by plasma volume, or other validated 
echocardiographic parameters of left ventricular filling pressure such as E/E’ or E/A. 
Although the measured plasma volume is in the normal range in over 85% of the patients, 
PD patients with HFNEF tended to have higher plasma volume. We propose that higher 
intravascular volume may be needed for adequate ventricular filling to compensate for 
reduced myocardial compliance but the real clinical significance is unclear at present. This 
is further reason to be cautious about normalising fluid status in this patient population 
until appropriate studies have been conducted. 
 
BIA is a highly reproducible measurement, with inter-observer and intra-observer error of 
less than 2%. It is an ideal technique to monitor and measure impact of intervention on 
changes in body composition, as shown in the longitudinal study of icodextrin by Davies et 
al (Davies, Woodrow et al. 2003). We hypothesized that PD patients develop worsening of 
fluid status over time on treatment due to loss of RRF and progressive muscle wasting and 
BIA has the potential to aid clinical decision by detecting and informing such changes. 
This hypothesis was tested in chapter 4 where we undertook a prospective, randomised, 
open-label, blinded end point controlled trial in 3 UK centres (Stoke, Sheffield and Leeds) 
and 1 Chinese centre (Shanghai) to evaluate the clinical benefit of having longitudinal 
bioimpedance measures presented as vector plots to help clinicians maintain stable fluid 
status over 12 months. The primary endpoints were changes in ECW, TBW volumes and 
(ECW/TBW ratio) by converting the resistance and reactance data using algorithm based 
on the software provided by the BIA device after study completion. The decision to use 
bioimpedance to monitor the direction of body composition change using vector plots 
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rather that attempting to normalize fluid status from predicted normal volumes was based 
on safety concern, specifically to avoid risk of hypovolaemia causing premature loss of 
RRF, largely based on our observations in chapter 3. We found overall stability over the 
study period of bioimpedance derived fluid volume non-anuric patients, whereas, as 
predicted, fluid status worsened due to loss in total body water, indicative of muscle 
wasting, without a concomitant fall in the ECW. This effect was ameliorated by use of BI 
in the Shanghai population, but the effect seems to have been achieved by increasing the 
glucose prescription and preventing loss in TBW, so the mechanisms of action may be 
different to that initially postulated. Nutritional status is a key determinant of body 
composition, so the additional calories supplied by the increased glucose prescription could 
have been the explanation. The aim to optimise fluid status by setting a lower target weight 
in the UK non-anuric bioimpedance intervention group may have had the opposite effect as 
it led to the reduction in TBW without any parallel change in ECW or ECW/TBW ratio. 
Marginal benefit was seen in the bioimpedance intervention group in Shanghai anuric 
patients where fluid status was better maintained compared to the control group. Taken as 
a whole, the impact of BIVA on informing clinical decision for fluid management in PD 
patients was small, not least because of the stability of fluid status in non-anuric patients 
and certainly more complex than anticipated.  
 
For example, one interesting aspect of the study was how the availability of bioimpedance 
information affect clinical decision making, given patient’s target weight was more likely 
to be reduced compared to the control group where changes in target weight were very 
balanced. This could be due to study bias or clinicians may be more inclined to reduce 
target weight in response to another clinical parameters, such as hypertension. Little is 
known about how patients have actually responded to requests to reduce target weight. 
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Suboptimal adherence to dialysis treatment, dialysis prescription and dietary advice is 
common in dialysis population which leads to poor clinical outcome and there are evidence 
to suggest psychological interventions may improve treatment compliance (Clark, 
Farrington et al. 2014). This interesting but complex area deserves further evaluation in 
future study.  
 
Another signal coming from this study is the importance of maintaining residual kidney 
function. In the cardiac sub-group analysis of the longitudinal fluid management by BIVA 
described in chapter 5, all patients in this single centre study showed progressive 
worsening of systolic and diastolic functions characterised by reduction in LVEF and 
increased in E/E’ over the 12 month period but patients in the BIVA group had better 
preservation of cardiac function and RRF. Multivariate analysis indicated that the most 
important predictors of the echocardiographic parameters at 12 months were the respective 
baseline cardiac measurements, comorbidity and randomisation group. It may be tempting 
to assume the incorporation of BIVA in fluid management helps to preserve cardiac 
function longitudinally but it is a premature suggestion and potential confounders need to 
be considered. The degree of cardiac preservation may be statistically significant but the 
clinical and functional benefits are not clear. The BIVA group had more patients compared 
to the control group as a result of unbalanced randomisation process and they were older 
with worse E/E’ ratio at baseline. Therefore it is possible that the absolute deterioration in 
cardiac function was not so great simply because of the poorer baseline measurement. 
However the relative preservation of RRF is the best candidate for a mechanism given 
previous evidence that this is strongly associated with cardiac deterioration (Wang and Lai 
2006), providing more evidence if it were needed of the value of this commodity to 
dialysis patients. Further studies using BIA should consider using this as their surrogate 
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endpoint, especially following the recently performed meta-analysis of interventions on 
left ventricular hypertrophy showing the lack of translation into clinically relevant 
outcomes, specifically survival (Badve, Palmer et al. in press 2016). 
 
The last two chapters of the thesis explored the potential of breath analysis of deuterium 
abundance by FA-MS as a novel technique to measure lung water volume. Pulmonary 
oedema is a potential life threatening condition characterised by excessive accumulation of 
fluid in the alveolar space causing impaired gaseous exchange and hypoxaemia. 
Asymptomatic or subclinical pulmonary oedema was confirmed in haemodialysis patients 
by indicators dilution method and removed by dialysis treatment (Wallin, Jacobson et al. 
1996). Current analytical techniques to evaluate lung water volume are invasive and results 
are often delayed due to complicated sample processing, seriously compromise its use in a 
busy outpatient dialysis unit. FA-MS offers a potential solution to this problem with its on-
line, real time measurements to inform clinical decision and more importantly, it is patient-
friendly. Deuterium abundance in exhaled breath was measured using FA-MS after mouth 
inhalation in the first experiment, followed by intravenous injection of the known quantity 
of deuterium mixture in the second. However, the deuterium measurement in the breath 
was far lower than expected and this vastly overestimated the volume of distribution of 
lung water. It is therefore not a feasible tool to estimate lung water in its current form. This 
has raised questions regarding the assumption that the concentrations of soluble 
compounds are equivalent both in exhaled breath and the equilibrated alveolar space by 
failing to take into account the ‘dilutional’ phenomenon as HDO exchange with water 
molecules in the mucosal lining of the bronchial tree which can be substantial.  
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Final reflections 
 
1. Pre-existing pathologies such as heart failure, hypoalbuminaemia, comorbidities are 
more important determinants of abnormal fluid status than dialysis therapy and the 
associated ultrafiltration limitations. There is currently a lack of effective interventions to 
optimize fluid status. 
 
2. There are limitations in the current techniques to measure and monitor fluid status. 
Although BIVA is easy to use and patient friendly, the significance of vector changes 
longitudinally is difficult to understand without important data regarding lean muscle and 
fat. The graphical representation of changing fluid status poses a clinical challenge for 
clinicians who are more familiar with absolute volume expression. Large scale plasma 
volume measurement is limited by the inherent radioactivity and lung water measurement 
by FAMS is not a feasible tool at present.  
 
3. Residual kidney function is repeatedly shown as being important to fluid management 
and maintaining stable cardiac function, nutritional status and body composition. 
Preserving this should continue to be a goal for future research. 
 
4. Methods of intervention to optimise fluid status are different between dialysis 
modalities. For PD it is the interplay between altering PD prescription with varying degree 
of glucose exposure to enhance ultrafiltration and advising patients to adjust target weight 
likely involves calorie restriction which may not be desirable.  
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5. There is a need for future qualitative studies to assess patient’s understanding and 
behaviour in response to clinical advice to optimize fluid status.  
  
  
Appendix  
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Appendix 
Appendix 1: Diagnostic flowchart on ‘How to diagnose HFNEF’ in a 
patient suspected of HFNEF. 
 
 
LVEDVI, left ventricular end-diastolic volume index; mPCW, mean pulmonary capillary 
wedge pressure; LVEDP, left ventricular end-diastolic pressure; τ, time constant of left 
ventricular relaxation; b, constant of left ventricular chamber stiffness; TD, tissue Doppler; 
E, early mitral valve flow velocity; E′, early TD lengthening velocity; NT-proBNP, N-
terminal-pro brain natriuretic peptide; BNP, brain natriuretic peptide; E/A, ratio of early 
(E) to late (A) mitral valve flow velocity; DT, deceleration time; LVMI, left ventricular 
mass index; LAVI, left atrial volume index; Ard, duration of reverse pulmonary vein atrial 
systole flow; Ad, duration of mitral valve atrial wave flow (Paulus, Tschope et al. 2007). 
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Appendix 2: The transformation of the resistance and reactance 
measurements to TBW and ECW using Akern BIA 101 Anniversary 
device. 
172 sets of patient information (including gender, height and body weight) and 
resistance and reactance were entered into the software of Akern BIA 101 
Anniversary. The TBW and ECW output from the software were recorded. Based on 
the work by De Lorenxo et al (De Lorenzo, Andreoli et al. 1997) the first 100 records 
was used to generate a set of formulas to calculate TBW and ECW from height, body 
weight, gender and raw resistance and reactance readings. The formulas were then 
applied to calculate TBW and ECW for all records. The formulas generated were as 
following. 
 
 For TBW, If female, 
𝑇𝑇𝑇 = 0.511 × hight43 × weight13resistance23 + 6.87 
 For TBW, if male  
𝑇𝑇𝑇 = 0.608 × hight43 × weight13resistance23 + 3.37 
 For ECW 
ECW = TBW1 + 22.907576(resistance + reactancereactance )−1.255081 
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Appendix 3: Ethical approval for ‘Developing BIA as a tool for fluid 
management in PD patients: A validation study. 
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Appendix 4: Inclusion letter for BIA guided fluid management study on 
the NIHR CRN Portfolio. 
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Appendix 5: Patient information leaflet and consent form for BIA guided 
fluid management study. 
 
PATIENT INFORMATION LEAFLET 
(Version 2.0 dated 10th March 2009) 
Project title: Bioimpedance as a tool for fluid management in PD patients 
 
Invitation to participate 
We are asking if you are willing to take part in a clinical study. Please take time to read 
and consider the following information carefully, and feel free to discuss it with whomever 
you wish. If anything is unclear, please do not hesitate to contact your consultant or your 
named nurse. 
 
What is the purpose of the study? 
Patients with kidney failure often have abnormal fluid balance, especially when treated 
with dialysis. When peritoneal dialysis (PD) patients have excess fluid in their body this 
can cause high blood pressure and heart disease. When too much fluid is removed through 
dialysis the patients can feel unwell with dehydration and reduced urine production. In 
order to avoid this we need to have a simple, accurate and patient-friendly clinical tool that 
is able to monitor fluid status over time and give useful information for the doctors to make 
sound clinical decision for each individual patient. Unfortunately we do not have such 
method that has been properly tested in our day-to-day patient care at present. 
Bioimpedance (BIA) is a clinical device that has been used extensively in research and 
some clinical settings to measure body fluid compartment. It is likely that it will become 
the standard tool to help doctors in assessing fluid status. It is simple to perform and non-
invasive. By doing this study, we hope to demonstrate that regular BIA measurement will 
give doctors added information regarding patient's fluid status so that subsequent clinical 
therapy can be tailored and applied to restore optimal fluid balance. We also want to 
investigate if blood pressure and heart function can be improved once we achieve better 
fluid status. 
 
Why have I been chosen? 
You have been chosen because you are treated with peritoneal dialysis.  
 
Do I have to take part? 
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No. If you are unable to take part for whatever reason (you do not have to give one), then 
this does not matter.  If you do decide not to take part in this study, your treatment shall not 
be affected in any way. 
 
What will happen to me if I take part? 
This study will last 12 months. During this time when you having your routine 
assessments, home visits or attending clinic you will undergo a BIA test to assess your 
fluid status.  This is a randomized study, which in this case means that the information 
from the BIA assessment will be available to the doctors to interpret on a random basis. If 
you are in the control group, decided by chance, the information is collected but not acted 
upon and your dialysis schedule will not be affected. If you are in the ‘active’ group, then 
your doctor may wish to adjust your target dry weight according to the additional 
information obtained from the BIA. 
 
Can I withdraw from the study at a later date? 
Yes. You are free to withdraw from the study at any stage even if you had agreed initially. 
This will not affect your treatment.  
 
What do I have to do? 
Once you have agreed to take part in the study you will be asked to continue your dialysis 
as usual and you will be assessed in the normal clinical way to decide if your fluid status is 
satisfactory.  If it is you will start the study which last 12 months. 
During this time, in addition to your routine assessments you will be asked to have the 
following done on a 3 monthly basis: 
- Assessment of fluid status by bioimpedance. You will have sticky pads on your hand 
and foot while lying down and connected to a device. A small electric current is 
passed through the body that you cannot feel and the measurements are used to 
calculate the amount of fluid present. You will feel no pain during the measurement 
and it takes about 5 minutes. It is very similar to having an ECG done. 
- Measurement of blood pressure. 
- Additional blood sample (approximately 10ml) taken along with your routine blood 
tests for research purpose. 
 
We will try to incorporate the visits into your regular clinical appointment as much as 
possible to reduce hospital attendance. 
Additional tests: We would like you to have these additional tests if you are able 
1. There is the option to undergo an echocardiogram to assess your heart function. 
This involves placing some jelly on your chest and looking at the heart with a probe 
on a small screen. As part of the test we would like to ask you to perform some 
very gentle exercise for about 5 minutes on a gym bicycle if you are able to. This is 
equivalent to walking on a flat surface at a moderate pace for a similar amount of 
time. This procedure will give important additional information about your heart 
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function. Your heart will be monitored closely throughout the procedure and if you 
do not feel well during the test you can stop at any time. The test will last for one 
hour and transport will be provided if required. If you do not want to participate in 
this additional test (heart scan) but agree for the rest of the study, it is acceptable. 
2. Total body water measurement by deuterium analysis. Deuterium is heavy water 
which can be found in small quantity in tap water and it is safe and not radioactive. 
Patients will be asked to drink a small amount of deuterium and the blood tests 
obtained before and after the ingestion will be used to determine the total amount of 
water in your body. 
 
What are the side effects or risks of taking part? 
We do not anticipate any side effects or risks during this study as BIA measurement is non-
invasive. There may be some discomfort when blood is being taken, so where possible we 
will take this when you are having blood taken for your usual clinical monitoring. 
 
What are the possible benefits of taking part? 
The results of this study are likely to help doctors improving their management of future 
PD patients. You are unlikely to receive any benefit of taking part. 
 
What if new information becomes available? 
If any new information comes to light to suggest any harm to you the study will be 
stopped.  
 
What about traveling costs? 
You will be re-imbursed any travelling costs incurred by travelling to the hospital for the 
purpose of the study.  
 
What happens when the research study stops? 
The result of the study will be analysed to see if BIA measurement is a useful clinical tool 
to monitor fluid status in PD patients. This would help doctors to refine their clinical care 
of the patients and facilitate design of future studies. 
 
What happens to the results of the research study? 
It will be presented at scientific meetings and published in international research journals.  
 
Who is organising the research and funding? 
This is a multi-centre study involving renal units in North Staffordshire, Leeds and 
Sheffield. It is designed and organized by your doctors, led by Professor Simon Davies 
who is based in North Staffordshire. The study will be funded from research grants 
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including from a pharmaceutical company that makes dialysis solutions. Your consultant 
will not be paid for doing this study. 
 
Will my taking part in this study be kept confidential? 
Yes. All data collected from this study will be kept anonymous (all patients will be given 
numbers and cannot be identified from this except by members of the research team). If 
you consent to take part in the research your medical records may be reviewed for the 
purpose of analysing results. They may also be looked at by the regulatory authority to 
ensure that the study is being carried out properly. Your name however will not be 
disclosed outside your own hospital.  
All the information identifying patients will be stored in the hospital in locked rooms if in 
paper form. Any data stored on computers will be protected by passwords known only to 
those directly involved in the research project. 
 
Who has reviewed the study? 
This study has been reviewed by experts in dialysis treatment who are independent of the 
study and has been approved by the local ethics committees.  
 
Contact for further information 
If you need independent advice regarding participating in research you can contact the 
PALS office of University Hospital of North Staffordshire on 01782 552814 or INVOLVE 
organization on 02380651088. This is a national advisory group that support and promote 
active public involvement in healthcare research. If at any stage you require more 
information regarding this particular study do contact your own named nurse. Alternatively 
you can contact the consultant supervising your care, Professor Simon Davies, either via 
the secretary on 01782 554164 or again via your PD nurse.  
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PATIENT CONSENT FORM 
 
Bioimpedance as a tool for fluid management in PD patients 
 
I have read the Patient Information Sheet (Version 2.0 dated 10th March 2009) and 
have had the opportunity to discuss any concerns. 
 
 
I agree to taking part in this study and that my participation is voluntary and  
that I am free to withdraw from the study at any time without my treatment 
being affected. 
 
 
I understand that relevant sections of my medical notes and data collected  
during the study may be looked at by individuals from the research teams, 
from regulatory authorities or from the NHS Trust, where it is relevant  
to my taking part in this research. I give permission for these individuals  
to have access to my records. 
 
I understand that I will not benefit financially if this research leads to the   
development of a new treatment or medical test.  
 
 
I agree to undergo the heart scans (Echocardiograms) at the hospital. 
   
 
 
 
Patient Name (PRINT)____________________     
Signature_______________________ 
 
 
Witness Name (PRINT)____________________     
Signature_______________________ 
 
Date: ___/___/_____ 
 
 (Version 2.0 dated 10th March 2009) 
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Appendix 6: BIA 101 Analyser user manual. 
IMPORTANT: All measurements must be performed on non-conductive surface 
BIA TESTING PROCEDURE 
• BIA 101 analyser should be calibrated using the dummy circuit provided. This should be 
performed at the beginning of each session of patient measurements. 
 
 
 
• The reference values of resistance and reactance are printed at the back of the circuit. 
Measurements within 1% precision of resistance value and 3% precision of reactance value 
are considered acceptable. All measurements should be recorded in record sheet provided. 
• Any abnormal result should be reported back to the study coordinator. 
 
RESEARCH PARTICIPANTS TESTING PROCEDURE 
• The participants should remove their right shoe and sock (generally the study is 
completed on the right side of the body). Whichever side is used should always be used 
subsequently. 
• The participants should lie supine with their arms 30 degrees from their body and legs not 
touching for about 5 minutes. Jewellery on the electrode side should be removed if 
possible. 
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• Attach the electrodes and cables as shown in the illustration. 
 
 
• Turn the analyzer on and make sure the participant refrains from moving. 
• When the measurements have stabilized, record the displayed Resistance (R) and 
Reactance (Xc). 
• Remove and dispose of the electrodes so as to not injure the participant’s skin. 
 
Maintenance 
• The analyser should be kept in the case provided when not in use. 
• It is recommended to charge the batteries fully at least once a week. This usually takes 
approximately 12 hours. 
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Appendix 7: Deuterium Oxide quality assurance report. 
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Appendix 8: Patient information leaflet and consent form for the study of 
breath analysis of deuterium abundance following IV D2O to estimate 
lung water volume. 
 
Error! Objects cannot be created from editing field codes. 
Patient Information leaflet (version 2.0 10th August 2008) 
Title of study: Evaluation of breath deuterium kinetics and the effects of posture 
following central injection of Deuterium Oxide as an estimate of total lung water 
(TLW) content in haemodialysis patients. 
Short title: Using breath test to measure lung water volume 
Invitation to participate 
We are inviting you to take part in a clinical study. Please take time to read and consider 
the following information carefully.  You can discuss this with whomever you wish. If you 
are unclear of any issues please feel free to contact your consultant or your named nurse. 
What is the purpose of the study? 
One of the purposes of haemodialysis treatment is to remove excess fluid. It is known that 
excess fluid in the body is associated with poorer outcome. While having 
accumulation of fluid in the legs may not cause much problem, too much fluid in the 
lungs can make patients breathless and cause harm to general health.  The challenge 
for the clinical staffs is to find out how much excess fluid is present in the lungs so 
that we can plan future treatment better for the patients. Currently we do not have 
any lung water measurement that is easy to use and acceptable to patients. However, 
we have developed a simple and acceptable breath test which allows us to measure 
total body water precisely and we are now trying to apply this to measure lung water 
volume. We want to find out how best to apply the breath test in order to obtain consistent 
and accurate results. We also want to make this as easy as possible for patients without 
causing too much inconvenience. 
Why have I been chosen? 
You have been chosen because you are treated with haemodialysis. 
 
Do I have to take part? 
  224 
No. It does not matter if you are unable to take part for whatever reason. Your usual 
treatment will not be affected 
What will happen to me if I take part and what do I have to do? 
You will be asked to sign a consent form. We will arrange a visit for you to come to 
hospital at your convenience. This can be before, after or in between your dialysis sessions. 
The visit will last approximately 1 hour. During that time you will have various tests to 
assess your fluid status. These include the following: 
-General measurements such as height and weight 
-Deuterium (heavy water) injection. This is a naturally occurring form of water present in 
tap water which is quite safe and not radioactive. We will use the vascular access that you 
normally use for your dialysis treatment. In the case of a fistula a small butterfly needle 
will be used for the purpose of injection. 
-Breath test before and after heavy water injection. You will be asked to breathe in and out 
normally into a flexible tube which connects to a machine. It will analyse the amount of 
heavy water present in your breath after the injection. You may be asked to perform this 
procedure several times in lying and sitting positions so that the results can be compared. 
-Bioelectrical impedance test. This test is similar to ECG recording where sticky pads are 
placed on your wrist and ankle and a very small electrical current is passed through the 
body for approximately 2 to 3 minutes. (You will not feel this) This is a very quick and 
easy way to calculate the amount of body fluid. 
You will be asked to repeat the tests at a later date. This is so that we can compare the 
results to ensure consistency. A separate consent form will be used for this purpose. 
Can I withdraw from the study at a later date? 
Yes. You are free to withdraw from the study at any stage even if you have agreed initially. 
What are the side effects or risks of taking part? 
We do not anticipate any significant side effects or risks of taking part in the study. In 
addition, we are doing everything we can to make the study as safe as possible such as 
using very small needle for injection to reduce the chance of bleeding and infection. The 
study will be carried out by a trained and qualified research doctor. 
 
What are the possible benefits of taking part? 
None 
What if new information becomes available? 
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If any new information comes to light to suggest any harm to patients the study will be 
stopped. 
What about travelling costs? 
Any travelling costs incurred by the study will be reimbursed. 
What happens when the research study stops? 
When the study is completed, we will analyse the results and use these to plan the next 
stage of our research. 
What happens to the results of the research study? 
It will be presented at scientific meetings and published in international research journals. 
These results will also help in designing future studies. 
Who is organising and funding the research? 
This research is organised by Professor Simon Davies, Professor of dialysis medicine of 
University Hospital North Staffordshire. The project is jointly funded by Renal 
Discovery Extramural Grant (Baxter), North Staffordshire Medical institute and the 
Wellcome trust. 
Will my taking part in this study be kept confidential? 
Yes. All data collected from this study will be kept anonymous. 
 Who has reviewed the study? 
This study has been reviewed by experts in dialysis treatment who are independent of the 
study and has been approved by the local peer review and the local ethics committees. 
Contact for further information 
If at any stage you require more information please do not hesitate to contact your own 
named nurse, or from Professor Simon Davies who is the consultant responsible for the 
study by calling his secretary at 01782554164 or Dr. Julie Wessels (01782554165), the 
consultant in charge of the haemodialysis treatment programme in your hospital. 
 
 
 
 
 
Error! Objects cannot be created from editing field codes. 
 
  226 
 
PATIENT CONSENT FORM 
 
Title of study: Evaluation of breath deuterium kinetics and the effects of posture following 
central injection of Deuterium Oxide as an estimate of total lung water (TLW) content in 
haemodialysis patients. 
 
Short title: Using breath test to measure lung water volume 
 
I have read the Patient Information Sheet (Version 1.0 dated 9 Feb 2008) and have 
had the opportunity to discuss any concerns. 
 
 
I agree to taking part in this study and that my participation is voluntary and  
that I am free to withdraw from the study at any time without my treatment 
being affected. 
 
 
I give permission for information to be taken, in confidence, from my medical 
records including  my date of birth, diagnosis, time on dialysis and the results 
of any tests done as part of the study. 
 
 
I understand  that  I will not benefit financially  if this research  leads to the   
development of a new treatment or medical test.  
 
Patient Name (PRINT)____________________     Signature_______________________ 
 
 
Witness Name (PRINT)____________________     Signature_______________________ 
 
Date: ___/___/_____ 
 
 (Version 1.0 dated 9 Feb 2008) 
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